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INTRODUCTION
Accurate and efficient genome editing is primarily dependent on the generation of 
a sequence-specific, genomic double-stranded DNA break (DSB) combined with the 
introduction of an exogenous DNA template into target cells. The exogenous template, 
called donor DNA, normally contains the foreign sequences flanked by DNA regions sharing 
sequence identity (“homologous”) to those bracketing the target site. The strategies for 
mediating the formation of DSBs at the predefined genomic loci, have been undergoing 
intense investigation since the introduction in the mid 90’s of sequence-customizable zinc-
finger nuclease (ZFN) technology [1]. More recently, prokaryotic protein-based transcription 
activator-like effector nucleases (TALENs) [2] and RNA-guided nucleases (RGNs) derived 
from clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 
(Cas9) complexes [3, 4] have substantially broadened the availability and applicability of 
designer nuclease-mediated genome editing. Methods for the introduction of designer 
nucleases into target cells range from the plasmid transfection of cell lines with transfection 
reagents (e.g. polycations and liposomes) to the electroporation of haematopoietic 
stem cells with messenger RNA [5]. In general, however, the most effective methods for 
introducing foreign DNA into target cells are those based on viral vectors. The availability 
of diverse viral vector systems each of which with their own target cell tropisms, permit 
transducing a broad range of cell types. Importantly, viral vector particle-mediated gene 
delivery hands researchers with the possibility of controlling in a precise manner the copy-
number of expression units reaching target cell nuclei and, as a result, the yields of encoded 
products. In this chapter, the main designer nuclease technologies are described along with 
the advantages and shortcomings associated with commonly used viral vector systems such 
as adeno-associated viral vectors (rAAV) [6], integrase-defective lentiviral vectors (IDLVs) [7] 
and adenoviral vectors (AdVs) [8]. 
Gene therapy
Correcting the phenotype associated with monogenetic disorders has been the focus of 
many researchers for many years. Historically, the first gene-therapy approaches were those 
based on the introduction of an exogenous correct copy of the mutated gene into target 
cells. Oncoretroviral vectors were generally used owing to their capacity of integrating its 
viral genome into host cell chromosomes. However, the strategy of random integration of 
an expression unit, flanked by unwarranted viral sequences, might prime serious adverse 
effects caused by insertional mutagenesis. Integration close to or within proto-oncogenes, 
might deregulate their expression in such a way as to induce monoclonal malignant cell 
expansion [9]. Next to this, the viral sequences flanking the expression unit are targets for 








































10  |  Chapter 1
Lastly, ectopic expression of gene products during early differentiation stages of stem cells 
can arrest these cells and eventually lead to cell death. Despite these major problems, a 
great deal of effort has been made into the design, optimisation and testing of viral vectors 
for the introduction of genetic payloads into target cells. In the first efficacious clinical 
trials, integration-proficient oncoretroviral vectors were used in order to integrate an 
expression unit in human long-term repopulating haematopoietic stem cells, relieving the 
X-linked severe combined immunodeficiency disorder (SCID-X1) in boys [11 - 13]. SCID-X1 
is characterised by a block in T-cell differentiation combined with an impairment in B-cell 
immunity and is lethal during the first years of life. X-linked SCID is linked to mutations in 
the interleukin 2 receptor gamma gene IL2-RG whose product is responsible for cytokine-
dependent signalling leading to the proliferation of T-cells. Adenosine deaminase (ADA)-
SCID has also been shown to be amenable to oncoretroviral vector-based gene therapy 
protocols. This monogenetic disorder originates from the lack of functional ADA, which leads 
to a reduced lymphocyte proliferation. The successes of some of these gene-therapy clinical 
trials were, however, clouded by the onset of leukaemia in several of SCID-X1 patients. [9, 
14]. Extensive characterisation of the vector integration profile in the patient cells revealed 
the underlying problems associated with these first-generation oncoretroviral vectors, 
namely, viral enhancer-driven proto-oncogene deregulation (e.g. LMO2) [15-18]. Following 
these clinical results, the design of these vectors has been improved by the removal of most 
of the viral promoter elements and cryptic splicing sequences combined with the use of less 
powerful cellular promoters to drive therapeutic transgene expression [19, 20]. In addition, 
new retroviral vectors based on lentiviruses (e.g. human immunodeficiency virus type 1), as 
opposed to murine oncoretroviral vectors, have also contributed to a further improvement 
in gene-therapy protocols. These developments, in combination with extensive monitoring 
of the treated patients, paved the way for several, so far mostly uneventful follow-up clinical 
trials. Taken together, these clinical trials have provided the medical field with a genetic 
approach for treating monogenetic disorders, which has been more recently expanded to 
other conditions like metachromatic leukodystrophy and Wiskott-Aldrich syndrome. [21, 
22]. 
 
Despite these steady improvements in clinical gene-therapy protocols, the preferred path 
to tackle monogenetic disorders would be to directly repair the disease-causing mutations 
without leaving a genetic “footprint” in the genome. Importantly, such genetic interventions 
should result in physiologically regulated gene expression without altering the expression of 
neighbouring genes. In order to introduce foreign DNA sequences into target cell genomes, 
the cellular DNA repair mechanisms can be exploited. Naturally, the most often used DNA 
repair pathway in mammalian cells is that of non-homologous end-joining (NHEJ) which, 
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1
at the newly formed junction so-called small insertions and deletions (indels) [23]. 
Homologous recombination (HR) is an alternative DNA repair pathway in which sequences 
from a homologous chromosome or sister chromatid serve as templates for restoring 
broken chromosomal DNA. In the presence of exogenous DNA templates, this pathway 
can be exploited for introducing in a precise manner foreign DNA into specific positions in 
the genome. However, the efficiency of “spontaneous” HR between a target chromosomal 
region and a corrective donor-DNA fragment is very low, often described as a ‘one-in-a-
million’ type of event, with efficiencies ranging from 10-8 to 10-6 [24, 25]. 
Importantly, these very low rates can be elevated substantially by actively triggering 
the endogenous DNA repair machineries. Pioneering experiments involving a homing 
endonuclease (HE) derived from the yeast Saccharomyces cerevisiae (I-SceI), provided 
a rationale for using site-specific nucleases as HR-mediated gene targeting triggers [26 - 
28]. Indeed, the I-SceI HE (also known as ‘meganuclease’) recognises a specific 18 bp-long 
sequence and, after binding, generates a DSB provoking the cell to repair the lesion and, in 
doing so, increase the rate of HR-mediated gene insertion by multiple orders of magnitude. 
The human genome does not contain the consensus I-SceI target site, nevertheless, there 
are multiple cryptic target sites leading to I-SceI mediated DNA cleavage [29]. As the location 
of these ambiguous binding sites are unclear, other methods were embraced to generate 
site-specific DSBs into the human genome, preferentially into genomic “safe-harbour” 
regions like the AAVS1 locus in the first intron of the PPP1R12C gene [30]. This region can be 
modified or used to integrate exogenous expression units without affecting the expression 
of neighbouring genes [31, 32]. Protein engineering of I-SceI and of other meganucleases 
did result in variations capable of identifying additional sequences occasionally existing in 
the human genome [33, 34]. Nonetheless, as the accuracy of sequence recognition of these 
proteins are not very strict as many “cleavable” pseudo-sites were identified by using rAAV 
DNA “trapping” [29]. Lastly, diverting these HRs to target other sequences than their natural 
target involves complex protein engineering which is a technique only available to a few 
research groups. Other type of protein engineering has been pushing the field of genome 
editing forward in the form of artificial site-specific nucleases based on zinc-finger motifs. 
Zinc-finger nucleases
ZFNs are chimeric proteins combining the sequence-specific protein-DNA interaction 
properties of arrayed zinc-finger motifs, with the cleaving activity of dimeric type IIS 
endonucleases [1, 35, 36]. Each zinc-finger motif can be designed to recognize a specific 
nucleotide triplet. Thus, a combination of 3 motifs in a tandem array can potentially 
generate a DNA-binding protein recognizing a 9 nucleotide-long target DNA sequence. The 
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most commonly, the type IIS restriction enzyme FokI. The catalytic activity of FokI nuclease 
domains is dependent on their dimerization in order to create an active nuclease complex 
capable of generating a DSB. To enable this dimerization process, a second ZFN is co-delivered 
to specifically bind a sequence on the opposite DNA strand located in the vicinity of that 
bound by its partner. Hence, these chimeric proteins assemble at their target sites to form 
a dimeric complex separated by 6- to 10-bp spacer sequences allowing for FokI nuclease 
domain dimerization and subsequent site-specific digestion of the DNA [1]. Although 
ZFN-mediated DNA cutting depends on binding to two properly spaced 9 bp half-target 
sites (conventionally described as “left-hand” and “right-hand”), and mismatches disturb 
the binding efficiency of the zinc finger motifs, off-target activity has been documented 
and studied by many research groups [37 - 40]. This off-target activity can be reduced by 
including a 4th zinc finger motif in each ZFN whereas extending it even further has the trade-
off of diminishing the overall activity [41]. Mutants of the FokI nuclease domain have been 
identified that, together, generate so-called forced heterodimeric FokI nuclease domains. 
These have been shown to reduce off-target DNA digestion owing to the fact that binding of 
the same ZFN pair member at off-target sites (i.e. homodimer assembly) is, to a large extent, 
prevented. 
ZFNs have been adopted by numerous investigators as valuable tools for the generation 
of site-specific DSBs for research purposes. This research resulted in a wide variety of insights 
into DNA repair mechanisms, donor DNA requirements and also led to the generation of 
various cell lines and animal models [42-45]. Currently, the success of ZFN technology is 
best illustrated by the initiation of the first human clinical trial involving the use of designer 
nucleases. This trial (coded: SB-728) consists of using adenoviral vector (AdV)-delivered ZFNs 
to knockout CCR5 alleles and, as consequence, generating HIV-resistant human CD4+ T-cells, 
to halt or perhaps reverse AIDS progression. On the other hand, the major drawbacks of the 
ZFN technology are their relatively low genomic target sequence coverage as well as the 
difficulty in designing and generating efficient ZFN pairs, which simultaneously, display low 
cytotoxicity. The relatively complex protein engineering platforms and extensive validation 
required for workable ZFN pair isolation continues to make it difficult the use of this 
technology by non-experts. In addition, the ZFN technology is comprehensively patented 
with only one ZFN scaffolding platform being commercially available for research purposes 
[46, 47]. 
Transcription activator-like effector nucleases 
The aforementioned limitations related to ZFN-based genome editing approaches were 
partially lifted after the introduction of a new class of chimeric nucleases whereby the 
DNA recognition is attained by transcription activator-like effector (TALE) protein elements 
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bacteria that, upon infection of host plant cells, act as virulence-enhancing transcriptional 
factor activators. Naturally, TALEs are organized into three distinct domains, the N-terminal 
region used for protein translocation to the nucleus, in order for binding to their DNA targets, 
the central DNA-binding domain containing a repeat array with repeat variable di-residues 
(RVDs) and a C-terminal region containing a nuclear localization signal sequence and the 
transcription activation domain. TALE proteins use a one-to-one protein-to-DNA code 
whereby the amino acids at positions 12 and 13 (i.e. RVDs) within each repeat of typically 
34 amino acids define binding to a specific nucleotide. Thus, RVD-containing TALE repeats 
can be placed in tandem creating a sequence-specific DNA binding motif, which in turn can 
be coupled to the FokI nuclease domain to generate a TALE-nuclease (TALEN) monomer 
[51, 52]. In common with ZFNs, these designer proteins work in tandem whereby a pair of 
TALENs assemble at their respective half-target sites on opposite DNA strands separated by 
an intervening spacer sequence. In the case of TALENs, however, the spacer sequences are 
larger than those of ZFNs, typically between 14- and 20-bp long. Importantly, the reported 
cytotoxicity profile of TALENs, presumably caused by off-target effects, is significantly lower 
than that of ZFNs, making TALENs a potentially safer artificial nuclease system [53]. Although 
it was initially reported that the affinity of the TALE repeat is restricted to the binding of the 
N-terminal domain to a thymidine, more recent findings indicate that this is far from being 
a strict requirement making the theoretical target-site coverage of TALENs to every two 
to three nucleotides. The robustness and simplicity of the TALEN technology is permitting 
the broad use of these nucleases for genome editing purposes. This is further aided by the 
development of ‘do-it-yourself’ TALEN assembly systems [54-57] and by the availability of 
various commercial services for the outsourcing of TALEN pair generation. 
RNA-guided nucleases
The two previously described nuclease systems depend on protein-DNA interactions for 
their target site selectivity. In contrast, RNA-guided nuclease (RGN) systems rely on the 
guiding of a non-specific nuclease by means of a single-stranded RNA corresponding to 
the target DNA sequence. RGNs are based on type II clustered regularly interspaced short 
palindromic repeats (CRISPR) innate immune systems found in bacteria and archaea. These 
innate immunity-related genetic systems evolved to counteract invading foreign DNA like 
that of plasmids and bacteriophages and are typically composed of a nuclease (Cas9) and 
short RNA moieties (CRISPR and trans-activating RNAs) The complex formed by Cas9, CRISPR 
RNA and trans-activating RNA scans the DNA for the presence of a so-called protospacer 
adjacent motif (PAM) of 3 bp (NGG) next to a CRISPR RNA-complementary sequence of 
approximately 20 bp. After binding to this target site, the tripartite complex cleaves the 
DNA strands leaving a blunt-ended DSB. The adaptation of this system to mammalian cells 
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[3, 4, 58]. Of note, by fusing the tracrRNA to the CRISPR RNA, a functional single-guide 
RNA (gRNA) module can be formed hence simplifying the system and making it possible 
to change the specificity of the RGN complex by merely changing the 20 bases responsible 
for the recognition of the target site. As a result RGNs are easy to be redirected to new 
single, or to multiple, chromosomal target sites. Transfection of gRNA oligoribonucleotides 
or gRNA-encoding RNA polymerase III-based expression units can be combined with Cas9 
delivery methods to the induced site-specific DSBs in target cells. Nevertheless, several 
publications reported the significant off-target cleaving activity of RGNs at DNA sequences 
containing up to 6 mismatches [59, 60]. Fu and co-workers searched in silico for the top 
20 off-target sites for 3 gRNAs and analysed these sites for the presence of CRISPR/Cas9-
dependent indels generated by NHEJ-mediated DNA repair. Independently of cell type or 
gRNA sequence, almost every predicted site contained T7 endonucleaseI (T7EI)-sensitive 
PCR products, indicative for indel formation at the predicted off-target sites [59 - 61]. Since 
these initial studies characterizing RGN off-target activity, considerable efforts have been 
undertaken to improve RGN specificity. These efforts included testing Cas9 proteins derived 
from different organisms, shortening the gRNA by 1 to 3 nucleotides (truncated-gRNA) 
to reportedly optimize thermodynamically related RNA-DNA hybridization parameters or 
by using pairs of Cas9 “nickase” mutants to induce single-stranded DNA breaks (nicks) in 
opposing DNA strands at the target site and, by doing so, generate a coordinated DSB [62, 
63]. However, although the use of the latter ‘double-nicking’ approach does reduce the 
generation of NHEJ-mediated chromosomal DNA disruptions at off-target sites, there is still 
the risk that off-target nicks can lead to DSBs, such as, by an advancing replisome [64].
More recently, it has been published that catalytically inactive forms of Cas9 can be 
fused to a FokI domain and, after dimerization, generate site-specific DSBs at the target site. 
This approach of using the multiplexing properties of RGNs combined with the dimerization 
requirement of FokI domains, reduced the off-target effect of RGNs dramatically albeit, at 
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Delivery of designer nucleases into target cells
Non-viral delivery systems 
Methods to introduce exogenous expression units into target cells are a key requirement for 
many research areas. These methodologies include transfecting plasmid DNA molecules into 
cells in culture by conjugating them to readily available cationic polymers or by encapsulating 
them in liposome vesicles [51, 52, 67]. These nucleic acid transfection protocols, however, 
are often not effective in primary cell cultures in part due to the slower division rates of 
these cells when compared to those of transformed cell lines. As the nuclease expression 
level is a key determinant for effective genome editing, improved methods to introduce 
these, often large, exogenous proteins into target cells are in demand. One way of delivering 
foreign genetic material into the cell nucleus is electroporation, whereby a short burst of 
current transiently opens the cell and nuclear membranes enabling the plasmid DNA or 
mRNA entry [68, 69]. This method, however, requires careful optimization on a per cell type 
basis and causes significant rates of cell-death. Considerable efforts have been made aiming 
at reducing the cell mortality and increasing the efficiency. These efforts resulted in protocols 
capable of transfecting human haematopoietic stem cells with ZFN mRNA displaying a 
measurable rate of gene disruption and the site-specific addition of an expression unit at the 
ZNF target sequences. Finally, zinc-finger motifs in ZFNs have a net positive charge and are 
therefore able to penetrate the cell surface of target cells [70]. TALENs lack this property, but 
were shown to be able to transduce target cells by fusing them to a poly-arginine protein 
transduction domain, also called cell-penetrating peptide (CPP). TALE repeats contain 18 
solvent-exposed cysteine residues that can be conjugated to a thiol-reactive nitropyridyl 
(Npys) Arg9 peptide(R9) enabling cellular membrane penetration. As this linkage is reversible 
under reducing conditions, the CPP moiety is released from the TALENs by disulphide bond 
reduction following their cytosolic entry. Albeit at low levels, the resulting TALENs were 
shown to induce site-specific DNA cleavage [71]. 
Viral vectors
In general, the most efficient methods for introducing genetic material into a broad variety 
of target cells are those based on viral vectors. Viral vector development harnesses the 
natural ability of viruses to deliver their genetic material into host cells. Indeed, viral vectors 
have been enabling scientists to introduce foreign genetic payloads into a wide range 
of target cells, including primary human cells in vitro and in vivo. By replacing essential 
gene sequences of the parental virus by exogenous expression units, viral vectors can 
be made replication-defective. In general, viral vectors can be divided in integrating and 
non-integrating systems whereby the former class ensures stable transduction of dividing 
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of specific proteins. Integration-competent murine oncoretroviral vector systems, such as 
that based on the murine Moloney leukaemia virus, have dominated the gene therapy 
research field for many years for the delivery of ectopic expression of transgenes. However, 
as aforementioned, the chromosomal DNA integration pattern of these oncoretroviral 
vectors is biased towards transcription start sites and CpG islands [72], increasing the risk of 
insertional mutagenesis by “landing” in or near a proto-oncogene like LMO2 [9]. Lentiviral 
vector systems, on the other hand, are biased to integrate their proviral DNA into the coding 
sequences of transcriptionally active genes in both dividing and non-dividing cells [73, 74]. 
These characteristics, combined with the removal of promoter/enhancer elements from the 
long terminal repeats, so-called self-inactivating (SIN) versions, leads to a much-reduced 
genotoxicity profile [74]. Lentiviral vectors can be used to deliver designer nucleases into 
target cells with high efficiency. Nevertheless, as the prolonged expression of a sequence-
targeting nuclease is not desired, the use of integration defective lentiviral vectors (IDLV) 
particles has been preferred. The main shortcoming of this non-integrating viral vector 
system is its very low expression level as a result of epigenetic silencing processes targeting 
episomal vector DNA [75, 76]. This silencing could, however, be ameliorated by using various 
histone deacetylase inhibitors [76, 77]. Importantly, lentiviral vectors deliver single-stranded 
positive-sense RNA molecules into target cells, which need first to be reverse transcribed 
into DNA by the vector particle-bound reverse transcriptase (RT). The low template affinity 
of RT combined with its RNaseH activity contributes to template switching events. This 
process is exacerbated when vector genomes contain regions sharing a high degree of 
sequence identity [78, 79]. For instance, the co-delivery of two ZFN ORFs in a single IDLV 
particle driven from a single promoter to yield an active nuclease complex from a single 
IDLV genome [77]. TALEN ORFs also suffer from this RT template switching phenomenon 
as shown by the precise deletion of several (up to 12) repeats from the TALE repeat region 
encoding the protein’s DNA-binding domain [80, 81, This thesis]. Recently, changing the 
DNA sequence corresponding to the various TALE repeats by removing as much as possible 
repetitive sequences, established the ability of lentiviral vectors to introduce intact TALEN 
proteins in target cells. [82]. In a study by Cai and colleagues, the use of lentiviral vector 
particles as protein transducing carriers of designer nucleases was described [83]. In this 
work, the ZFN and TALEN proteins were fused to the lentiviral Gag precursors and, during 
virion maturation, the nucleases were released from Gag in the virus particles in a protease-
dependent manner and found to be able to facilitate efficient DNA cleavage in transduced 
cells [83]. 
Recombinant AAV (rAAV) vectors contain a 4.7 kb single-stranded DNA genome which is 
flanked by two 145 bp inverted terminal repeats (ITRs). These palindromic, hairpin-forming, 
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1
them suitable for the delivery of ZFN ORFs and spacious enough to accommodate the 4.1-
kb Cas9 nuclease gene from S. pyogenes [84, 85]. The lifecycle of the wild-type virus is 
divided in lytic and latent phases as a result of the presence and absence of a helper virus 
(e.g. AdV), respectively. In the latter case, the virus integrates in cultured cells its genome 
preferentially in a defined region of the human chromosome 19 called AAV integration site 
1 (AAVS1). The integration reaction depends on the generation of a nick at a specific AAVS1 
target site that is mediated by the viral Rep78/68 proteins. In the absence of these proteins, 
such as following viral gene-deleted rAAV transductions, the genomes remain, for the most 
part, in an episomal state. In addition AAV transductions often result in a low expression of 
the transgene due, amongst other factors, to their single-stranded DNA nature [86, 87]. To 
counteract this low transgene expression, self-complementary rAAV (scAAV) systems have 
been developed. Following uncoating, the self-complementarity of scAAV genomes allows 
for the direct assembly of transcriptionally competent double-stranded DNA templates 
through intramolecular hybridization [88]. Indeed, the expression of transgenes delivered via 
scAAVs is higher when compared to that achieved by their conventional rAAVs counterparts. 
However, their halved cloning capacity (i.e. ~ 2.4 kb) makes them unsuitable for TALEN or 
Cas9 delivery. 
AdVs have linear double-stranded DNA genomes packaged in a non-enveloped icosahedral 
capsid. To date, 57 human serotypes have been isolated. These can be divided in 7 
species (A through G) and are found to cause a wide range of illnesses, ranging from mild 
respiratory diseases in children and the elderly, to life-threatening infections in people with 
a weakened immune system [89, 90]. AdVs are a commonly used vector platform whereby 
the deletion of several essential gene functions, usually, early (E) regions 1A (E1A) and 1B 
(E1B), often combined with the deletion of E3, creates space for the insertion of relatively 
large transgenes such as those encoding TALEN monomers and the S. pyogenes Cas9/
CRISPR nuclease. Importantly, the deletion of the E1 ORFs, renders these vectors replication 
incompetent in target cells and thus requires the use of E1A- and E1B-complementing cell 
lines like HEK293 [91], 911 [92] or PER.C6 [93] to provide in trans the missing functions during 
their production [8]. These E1-deleted or first-generation AdVs can be easily generated by 
using pAdEasy-based platforms [94, 95]. Although second-generation AdVs, combining the 
deletions of E1A and E1B with that of E2A or E4, can accommodate larger expression units, 
there are more constrains in their production since it requires the use of more specialised 
cell lines expressing the cytotoxic E2A or E4 gene products [96]. The latest generation of 
AdVs, the so-called “gutless” or high-capacity AdVs, can accommodate up to 37 kb of foreign 
DNA since, from the parental virus genome, these vectors only retain the cis-acting AdV 
TRs and packaging signal. The production of these vectors is executed in the presence of a 
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the co-replicating helper vector genomes from the packaged viral vector DNA fraction, 
the packaging signal of the helper is flanked by recombinase recognition sequences, for 
example loxP or FRT sites, and vector production takes place in complementing cell lines 
expressing the respective recombinase protein, Cre or FLP [97]. After several rounds of 
vector propagation, titers as high as 1×1012 vector particles per millilitre can be achieved. 
The availability of different AdV serotypes permits constructing AdVs with the capacity 
to transduce a wide variety of target cells independently of their cell division status. The AdV 
genome doesn’t integrate in the target cell genome, providing researchers with a vector 
system for the transient expression of designer nucleases. Owing to these properties, all 
the previously described classes of designer nucleases can be introduced into target cells by 
AdV systems in an efficient and controlled manner [80, 81, 99, This thesis].
Donor DNA templates
The activation of the cellular NHEJ DNA repair machinery in order to mutate genes via the 
introduction of a sequence-specific DSB is one of the approaches for editing the genome 
of a target cell. As aforementioned, the induction of a specific DNA repair mechanism 
depends, amongst other factors, on the cell-cycle status and on the presence of a donor 
DNA fragment to serve as a template to be inserted. The free-ended DNA end can, via 
strand-invasion, displace the target homologous sequence and, via base-pairing, use the 
complementary strand as template to copy the missing nucleotides. After completion, the 
generated DNA strand can flip back and be re-ligated to the broken strand completing this 
error-free DNA repair mechanism. Exogenously added DNA templates can be co-opted by 
the endogenous HR machinery to introduce in a targeted manner new genetic information 
into the target cell’s chromosomal DNA. Such exogenous DNA molecules (donor DNA) can 
harbour, for instance, an expression unit or sequences for the correction of genetic mutations 
flanked by sequences homologous to those framing a designer nuclease’s target site. Ideally, 
donor DNA templates are deprived of prokaryotic sequences and are on themselves non-
integrating entities, nonetheless, can be used by the HR DNA repair mechanism to serve as 
templates for site-specific chromosomal DNA insertion. To date, the introduction of various 
donor DNA molecules in target cells has been predominantly mediated by transfection 
protocols for single-stranded oligonucleotides and plasmid DNA or, more prevailing in hard-
to-transfect primary cell cultures, viral vectors like rAAVs and IDLVs. Despite the fact that 
short single-stranded DNA oligonucleotides have been shown to direct genetic correction 
per se, the combination of these molecules with the generation of a sequence-specific DSBs 
greatly enhances their use to fix the DNA lesion [100, 101]. Unquestionably, the use of these 
molecules greatly reduces the payload to be inserted impeding, for instance, the insertion 
of expression units. However, when used to correct single point mutations in open reading 
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1
can be adopted by the HR DNA repair machinery [102]. However, this methodology can, 
occasionally, co-integrate undesired flanking prokaryotic DNA sequences [103, This thesis]. 
Probably owing to the circular nature of plasmids, after copying the corrective nucleotides 
and likely due to the lack of downstream homologous sequences, the repair machinery 
presumably fails to switch back from the plasmid template to the endogenous genomic 
sequences, prompting the co-insertion of the plasmid backbone before completing the HR 
event. In vitro linearization of the plasmid DNA with restriction endonucleases can overcome 
this phenomenon, with the trade-off of reduced transfection efficiency in combination 
with the stimulation of exonuclease-mediated retention of the donor DNA sequences. 
Minicircle plasmids, deleted of prokaryotic sequences, prevent the integration of undesired 
methylation-prone prokaryotic elements, nevertheless their circular topology should not 
abolish the aforementioned “rolling-circle replication”-mediated type of insertions leading 
to undesired multiple copies [103, This thesis]. In principle, these illegitimate insertions pose 
no problems in gene-complementation protocols, albeit the insertions of multiple copies of 
the transgene can, in principle, yield deregulated transcriptional levels. 
IDLV-mediated delivery of donor sequences benefits from the wide tropism of this vector-
type, capable of transducing a wide variety of cells and has been successfully used as donor-
DNA templates in HR-mediated gene conversion experiments [104], even, in combination 
with electroporation of ZFN mRNA molecules, in clinically relevant human haematopoietic 
stem cells [5]. Nonetheless, IDLV vectors suffer from several limitations. First, lentiviral vector 
genomes have a limited cloning capacity, which constrains the introducing of large targeting 
expression units. Moreover, intronic regions within these expression units or cryptic splice 
sites should ideally be excluded, as to prevent IDLV-driven aberrant RNA splicing. Related 
to this, such integrated IDLV genomes could cause alternative splicing, generating aberrant 
transcripts [105]. Next to this, the high error rates resulting from reverse transcription 
can generate de novo mutations [106]. Finally, the DNA structure of a fraction of the IDLV 
genomes resembles plasmid DNA molecules in that they display a so-called 1-LTR or a 2-LTR 
circular topology [7]. The circular templates build-up, next to the free-ended linear cDNA 
forms, presumably via NHEJ-mediated intramolecular recombination. The circular structures 
can mediate concatemeric insertions of multiple expression units flanked by undesirable 
viral elements, whereas the linear form has the tendency to home to naturally occurring 
chromosomal DSBs and become trapped at off-target sites. Despite this, IDLVs are widely 
used to deliver DNA donor templates into target cells. This preference is largely explained by 
that fact that high levels of stably transduced cells can be achieved by using IDLV donor DNA 
after nuclease- induced HR. However, this comes with the trade-off that a significant subset 
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Conventional rAAVs and scAAVs are also used as donor DNA templates for site-specific 
integration, even in the context of gene targeting protocols that do not involve the generation 
of a DNA lesion [107]. Like IDLVs, rAAVs can be produced without any viral genes and have 
a wide range of tropisms making them good candidates for donor DNA template delivery. 
Their cloning capacity is, however, limited to approximately 4.7 kb. Next to this, off-target 
integrations in spontaneously occurring chromosomal DNA breaks generally dominate the 
overall integration profile of this vector type, often yielding 10 off-target integration events 
for each on-target integration [34].
The consequence of the use of sub-optimal donor DNA templates (i.e. templates with a 
promiscuous integration profile) for gene editing protocols led to the introduction of fail-
safe elements designed to either remove the unsolicited integrations or to directly select the 
cells containing correctly integrated donor DNA by means of drug-based selection schemes. 
In the former case, the placement of, for example, a herpes simplex virus thymidine kinase 
(HSV-TK) expression unit “outside” the homologous sequences enables a selection method 
based on ganciclovir, which becomes a toxic product in cells containing the HSV-TK unit 
[108, 109], due to illegitimate chromosomal DNA insertion. In the latter case, a neomycin 
expression unit, for instance, can be placed between the flanking homologous sequenced 
in a intronic region, forcing the insertion of the donor template and ablating cells lacking 
neomycin [110]. These procedures depend, next to the introduction of sizable gene-
expression cassettes, on very stringent selection protocols undesirable in most clinical 
genome modification protocols. An alternative method for the removal of unwanted donor 
template insertions, which does not depend on drug selections, is based on the excision 
of the exogenous integrated sequenced mediated by sequence-specific recombinases. The 
FLP and Cre recombinases can recognise their corresponding target-sites and if these are 
placed in a direct repeat orientation, mediate removal of the intervening DNA sequences 
[111-113]. This method will, however, leave a “footprint” in the genomic DNA in the form of 
one copy of the target site. Lastly, site-specific recombination events involving target-sites 
located on two different chromosomes might generate translocations, possibly prompting 
carcinogenesis [114, 115].
AdV vectors, as mentioned before, retain the ability to can transduce a wide variety of cell 
types and importantly, and accommodate relatively large genetic payloads. In the case of the 
previously described “gutless” AdV platform, this cloning capacity is as high as 37 kb. Still, up 
until recently, the use of this vector type as donor DNA delivery vehicles has been somewhat 
limited. In this regard, AdV-mediated donor DNA transfer has mostly involved gene targeting 
or gene repair strategies reliant on spontaneous HR and selection protocols. Nevertheless, 
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locations have been obtained [116, 117]. The target site-specificity and fidelity resulting 
from designer nuclease-induced AdV donor DNA insertion was only recently investigated 
[103, This thesis]. Experiments comparing this viral vector donor DNA type with that of IDLVs 
and plasmid DNA in the context of gene targeting models involving ZFNs, TALENs and RGNs 
revealed that, although the overall stable transduction efficiency of IDLV donor DNA was the 
highest among the different donor-DNA templates examined, the accuracy and specificity of 
the insertion of a transgene cassette at the desired locus was highest for the AdV donor DNA 
[103, This thesis]. The examined plasmid-based templates, similarly to IDLV donor DNA, 
showed a promiscuous integration pattern resulting in the integration of prokaryotic DNA 
sequences in addition to the off-target insertions and concatemeric forms of the exogenous 
DNA templates. By assessing different cell types and classes of designer nucleases, these gene 
targeting experiments established the unparalleled accuracy and specificity resulting from 
using AdV-delivered donor DNA templates into target cells. Validation of the hypothesis that 
the protein-capped DNA of AdV genomes formed the basis for this unsurpassed specificity 
and accuracy was achieved by a TALEN-induced in vivo digestion experiment, in which the 
release of the donor DNA template from the AdV genome readily led to illegitimate DNA 
integration. High-fidelity genetic modification of human cells, brought about by the delivery 
of both engineered nucleases and protein-capped donor DNA templates, has important 
implications to both fundamental and applied research protocols as it allows for accurate 
gene editing approaches without a strict requirement for using stringent selection regimes 
intended to remove donor DNA integrated at random genomic positions and/or as undefined 
concatemeric forms [103, This thesis].
To date, numerous efforts have been made to generate highly specific designer nucleases 
in order to mediate site-specific DNA lesions with a minimal off-target digestion profile. By 
fine-tuning ZFN target site selectivity, off-target effects can minimized, nevertheless, the 
cytotoxicity of these proteins still poses a problem. TALENs on the other hand are highly 
repetitive proteins exhibiting unsurpassed cleavage efficiency, combined with high sequence 
specificity and low cytotoxicity. The constant evolution in CRISPR protein and gRNA design, 
relieved the initially reported promiscuous properties of this popular genetic scissor. 
However, hitherto, the pursuit and optimization of high-fidelity donor DNA templates did 
not get the same emphasis as that devoted to improving the specificity of designer nuclease 
platforms. The finding that AdV-delivered protein-capped DNA donor templates results in 
highly specific and accurate genome modification following designer nuclease-induced DSBs 
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ABSTRACT
DNA repeats constitute potential sites for the nucleation of secondary structures such 
as hairpins and cruciforms. Studies performed mostly in bacteria and yeast showed 
that these non-canonical DNA structures are breakage-prone, making them candidate 
targets for cellular DNA repair pathways. Possible culprits for fragility at repetitive DNA 
sequences include replication and transcription as well as the action of structure-specific 
nucleases. Despite their patent biological relevance, the parameters governing DNA repeat-
associated chromosomal transactions remain ill-defined. Here, we established an episomal 
recombination system based on donor and acceptor complementary DNA templates to 
investigate the role of direct and inverted DNA repeats in homologous recombination in 
mammalian cells. This system allowed us also to ascertain in a stringent manner the impact 
of repetitive sequence replication on homology-directed gene repair. We found that non-
spaced DNA repeats can, per se, engage the homologous recombination pathway of the 
cell and that this process is primarily dependent on their spacing and relative arrangement 
(i.e. parallel or anti-parallel) rather than on their sequence. Indeed, our data demonstrate 
that contrary to direct and to spaced inverted repeats, non-spaced inverted repeats are 
intrinsically recombinogenic motifs in mammalian cells lending experimental support to 
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INTRODUCTION
The genomes of prokaryotes and eukaryotes harbor numerous and diverse types of repetitive 
DNA sequences many of which have been associated with genome evolution, regulation 
of gene expression and chromosomal rearrangements underlying a number of inherited 
disorders and certain translocation-bearing tumors. These motifs include single direct and 
inverted DNA repeats with or without internal spacers as well as high-copy-number tandem 
tracts (1-4). Accumulating evidence indicates that DNA repeats can adopt different non-
canonical (i.e. non-B) DNA conformations depending on a number of intrinsic parameters. 
These include the nucleotide composition, the length and the relative orientation of 
the constituent DNA units as well as their spacing and extent of sequence identity. 
Extrinsic factors such as the torsional strain associated with DNA metabolic processes, 
chromatinization and transcription are also thought to influence the likelihood that DNA 
repeats acquire higher-order conformations. DNA conformers have been implicated in both 
physiological and pathological processes including the regulation of DNA replication and 
expression, oncogenic chromosomal rearrangements and gene amplification (1-7). Related 
to this, palindromes (i.e. uninterrupted or non-spaced inverted DNA repeats) and inverted 
DNA repeats with relatively short central spacers, can, via local negative superhelical stress 
and ensuing intrastrand hybridization and branch migration, extrude into four-way Holliday 
junction-like DNA structures or cruciforms. Inverted DNA repeats in single-stranded form 
may also originate stem-loops or hairpins via intrastrand annealing. This may, for instance, 
occur when the unwinding of double-helical DNA during replication creates a lagging strand 
template.
The rearrangement of chromosomal DNA carrying non-canonical structures are likely 
preceded by and dependent on phosphodiester bond cleavage presumably via their 
resolution and processing by structure-specific nucleases. This might occur in concert with 
DNA replication-associated phenomena such as replisome stalling or slippage. In Escherichia 
coli, physical evidence was recently obtained for the emergence of double-stranded DNA 
breaks (DSBs) at a 246-base-pair (bp) palindrome via the combined effects of DNA replication 
and cleavage by the Mre11/Rad50 homolog SbcCD (8). Interestingly, studies carried out in 
a yeast model system revealed that inverted repeats of a 320-bp retrotransposon-derived 
human Alu sequence inserted into a LYS2 reporter allele were a target for the Mre11/
Rad50/Nbs1 complex suggesting evolutionary conservation of DNA structure-processing 
biochemical pathways (9). Moreover, in these prokaryotic and lower eukaryotic model 
systems, reporter gene expression rescue assays showed that long (i.e. >150 bp) inverted 
repeat-associated DNA breaks could engage the error-free homologous recombination (HR) 
pathway (3). Notwithstanding steady progress in this field, many questions remain with 
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ensuing higher-order DNA conformations and the recruitment of cellular pathways that 
regulate genetic recombination. This knowledge gap is particularly acute in cells of higher 
eukaryotes (2,3). In addition, hitherto, the vast majority of studies on the biological activity 
and fate of repetitive DNA in vivo focused on endogenous or exogenous test sequences 
embedded within the chromosomal DNA of dividing cells. With this type of experimental 
setups is difficult to assess a possible contribution of template DNA replication to repeat-
associated phenomena.
Here, we developed and deployed an extrachromosomal recombination system to 
specifically address the role of single DNA repeats of different sequence, arrangement 
(i.e. parallel or anti-parallel) and spacing in HR-mediated DNA repair in mammalian cells. 
Furthermore, the introduction of a eukaryotic origin of replication into the repetitive DNA-
containing episomes allowed us to also investigate the impact of target template DNA 
replication on the recombinogenic potential of the various motifs. We demonstrate that 
simple palindromes and composite inverted DNA repeats, but not direct or spaced inverted 
DNA repeats, serve as targets for the error-free HR repair pathway in mammalian cells and 
that this process is independent of ongoing DNA repeat-bearing molecule replication.
MATERIALS AND METHODS
Cells
HeLa cells (American Type Culture Collection [ATCC]), human embryonic kidney (HEK) 
293T cells (ATCC) and 911 cells (10) were cultured in Dulbecco’s modified Eagle’s medium 
(D-MEM; Invitrogen) supplemented with 5% fetal bovine serum (FBS; Invitrogen). PER.tTA.
Cre76 cells (11) and COS-7 cells (ATCC) were propagated in D-MEM supplemented with 10% 
FBS. All cells were cultured at 37°C in an atmosphere of 10% CO2 in humidified air.
Recombinant DNA. Plasmid pA1.GFP.A2 has been described previously (GenBank accession 
number: GQ380658 [12]). An XmaJI recognition sequence was introduced in pA1.GFP.
A2 at nucleotide positions 620 through 625 of the humanized Renilla reniformis green 
fluorescent protein (GFP) open reading frame (ORF) by PCR site-directed mutagenesis to 
generate the acceptor plasmid pR6K.GFP.STOP. Moreover, pR6K.GFP.STOP has the GFP 
ORF disrupted by an amber stop codon (Figure 1). The nucleotide sequences of the sense 
and antisense primers used for introducing the mutation that created the XmaJI site were 
5’-GAAGACCTAGGTGGAGGAC-3’ and 5’-GTCCTCCACCTAGGTCTTC-3’, respectively (point 
mutation is underlined) and the PCR was carried out with Phusion High-Fidelity DNA 
polymerase (Finnzymes) according to the instructions provided by the manufacturer. 
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IR.2), 5’-CTAGAGACGACGCAGCGAGCGAGCGAGCGCCACCGACGCACTAGT-3’ and 
5’-CTAGACTAGTGCGTCGGTGGCGCTCGCTCGCTCGCTGCGTCGTCT-3’ (DR/IR.3) and 
5’-CTAGGAAGGCGCGAGGGAGGGACCGCCGAGCAGGCACCGACGCACTAGT-3’ and 
5’-CTAGACTAGTGCGTCGGTGCCTGCTCGGCGGTCCCTCGCGCCTTC-3’ (DR/IR.4). 
Insertion of a recognition sequence for the meganuclease I-SceI into the XmaJI 
site of pR6K.GFP.STOP was accomplished using the oligodeoxyribonucleotides 
5’-CTAGGAAGTTACGCTAGGGATAACAGGGTAATATAGACTAGT-3’ and 
5’-CTAGACTAGTCTATATTACCCTGTTATCCCTAGCGTAACTTC-3’. To generate pR6K.GFP.STOP 
derivatives containing DNA repeats in a head-to-tail (direct repeat) or tail-to-tail (inverted 
repeat) configuration, the constructs carrying single copies of the oligodeoxyribonucleotide 
pairs corresponding to DR/IR.1, DR/IR.2, DR/IR.3 and DR/IR.4 were linearized with BcuI and 
subsequently subjected to a second round of oligodeoxyribonucleotide cloning. Restriction 
fragment size analysis was used to distinguish between recombinant plasmids carrying a 
direct or an inverted repeat of each oligodeoxyribonucleotide pair. To disrupt the palindrome 
in the IR.1-containing pR6K.GFP.STOP derivative acceptorIR.1 (Figure 1B and Figure 1C) at the 
center of symmetry, the plasmid was digested with BcuI and its backbone was combined 
with the oligodeoxyribonucleotide pair containing the I-SceI recognition sequence (ScR). 
The resulting construct was designated acceptorspIR.1. To create an acceptor plasmid, in which 
the GFP ORF is interrupted by the composite adeno-associated virus type 2 (AAV) inverted 
terminal repeat (ITR), AAV vector shuttle plasmid pDD2 (13) was digested with PvuII and 
BspLI. The resulting 127-bp AAV ITR-specific DNA fragment was inserted into the XmaJI site 
of pR6K.GFP.STOP following its blunt-ending with the Klenow fragment of Escherichia coli 
DNA polymerase I (Klenow, Fermentas) to produce acceptorITR. Plasmid pUC.hrGFPI.SV40pA 
was prepared by introducing the GFP ORF and the downstream bidirectional simian virus 40 
(SV40) polyadenylation signal (pA) derived from pA1.GFP.A2 into pUC19 using BamHI and 
XbaI. Next, the pA of the rabbit β-globin (βG) gene was inserted immediately upstream of 
the GFP-coding sequence in pUC.hrGFPI.SV40pA to inhibit possible spurious transcription 
of the GFP ORF due to the presence of cryptic promoters in the plasmid backbone. To this 
end, pAAV.hEF1a.DsRedT4.rbGpA, an AAV vector shuttle construct containing a DsRed.T4 
(14) expression unit controlled by the human eukaryotic translation elongation factor 1 
alpha 1 (EF1α) gene promoter and βG pA, was incubated with NotI and SmiI, the digestion 
products were blunt-ended using Klenow and the 587-bp βG pA-containing DNA fragment 
was purified from agarose gel. Subsequently, this fragment was inserted in the proper 
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to produce pUC.donor.rbGpA.hrGFPI.SV40pA. Deletion of the GFP start codon from pUC.
donor.rbGpA.hrGFPI.SV40pA was achieved by digesting the plasmid with SalI and SdaI, filling 
in the 3’ recessed ends with Klenow and self-ligation of the plasmid backbone to create the 
donor template pUC.donor.GFP.ΔATG (i.e. GFPΔATG; GenBank accession number: JF714898). 
Construct pUC.donor.rbGpA.DsRed.T4.SV40pA was made by replacing the GFP ORF in pUC.
donor.rbGpA.hrGFPI.SV40pA by the coding sequence of the red fluorescent protein (RFP) 
DsRed.T4. The DsRed.T4-coding sequence was excised from pAAV.hEF1a.DsRedT4.rbGpA 
using XbaI and NotI and subsequently combined with the 3.5-kb XbaI×NotI fragment of 
pUC.donor.rbGpA.hrGFPI.SV40pA. Disruption of the RFP ORF in pUC.donor.rbGpA.DsRed.
T4.SV40pA was accomplished by linearization with NcoI followed by Klenow treatment 
and self-ligation resulting in non-homologous donor plasmid pUC.donor.RFP.ΔATG (i.e. 
RFPΔATG; GenBank accession number: JF714899). The I-SceI expression construct pCAG.I-
SceI (GenBank accession number: JF714900) was made by inserting the 3.1-kb SalI×PstI 
fragment of pCbASce (15) into the polylinker of pUC19 after its digestion with SalI and PstI. 
The expression plasmid pCAG.I-SceI(Δ112-246) encoding a non-functional version of I-SceI 
was generated by digesting pCAG.I-SceI with BstBI followed by self-ligation of the resulting 
vector backbone. All DNA preparations were made by using the JetStar 2.0 DNA isolation 
system (Genomed).
Figure 1. Episomal recombination system to study the effects of repetitive DNA sequences on 
homology-directed gene repair in mammalian cells. (A) The bipartite system consists of acceptor 
and donor plasmids with differently disrupted GFP ORFs. In the acceptor plasmids, the GFP ORF is 
interrupted by an amber stop codon (asterisk) plus a test DNA sequence of choice (large red bar), 
whereas in the donor plasmid it is rendered non-functional by the deletion of its first 38 nts (short 
red bar). The interrupted GFP ORF in the various acceptor plasmids is framed by a constitutively 
active (broken arrow) human eukaryotic translation elongation factor 1 alpha 1 gene (EF1α) promoter 
and the SV40 pA (SV.pA), whereas that in the donor plasmid is preceded by the rabbit β-globin pA 
(βG.pA) and followed by the SV40 pA. The prokaryotic origins of replication R6K and ColE1 as well 
as the antibiotic resistance genes aminoglycoside 3’-phosphotransferase (KanR) and β-lactamase 
(AmpR) present in the acceptor and donor plasmid backbones, respectively, are also indicated. Once 
introduced into cells, donor and acceptor plasmids are candidate substrates for HR by virtue of the 
shared 339- and/or 584-bp DNA sequences. Reciprocal exchange of genetic information between 
acceptor and donor templates via cross-overs within these homologous regions is expected to give 
rise to transcription units with restored ORFs directing the synthesis of full-length GFP. (B) Three-step 
strategy to generate the various acceptor plasmids with test sequences 1 through 4 arranged in a 
direct or inverted repeat orientation (DR and IR series, respectively). Step 1: PCR-based site-directed 
mutagenesis of the C residue at position 624 of the GFP ORF into a G generates a premature stop 
codon and a XmaJI recognition site. Step 2: Insertion, at the XmaJI site, of test sequences 1, 2, 3 
or 4, which all contain a BcuI recognition sequence at their 3’ end. Step 3: Molecular clones with 
the BcuI sites in a position distal to the premature stop codon (orientation depicted) were used to 
duplicate test sequences 1, 2, 3 or 4. Acceptor plasmids with the meganuclease I-SceI recognition site 
or containing a single copy of target sequence 1 served as controls. (C) Schematic representation of 
directed and inverted repeats of DNA sequences 1 through 4, the I-SceI recognition site and a single 
copy of test sequence 1. The propensity of each DNA sequence to transit from lineform to cruciform 
by intrastrand Watson and Crick base pairing was estimated by calculating the Gibbs free energy (ΔG) 
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To provide acceptorScR, acceptorDR.1, acceptorIR.1 and acceptorspIR.1 with an SV40 origin of 
replication (ori), they were linearized with NdeI and blunt-ended using Klenow. Next, these 
linear DNA molecules were ligated to the SV40 ori-containing 323-bp PvuII×Eco147I fragment 
of pGL4.22 (GenBank accession number: DQ188842), yielding acceptorScR.ORI, acceptorDR.1.ORI, 
acceptorIR.1.ORI and acceptorspIR.1.ORI. All oligodeoxyribonucleotides were supplied by Eurofins 
MWG Operon, while the restriction and DNA modifying enzymes were from Fermentas.
Gibbs free energy calculations
The Gibbs free entry of the most stable secondary structure that could be folded by each of 
the DNA segments inserted into the XmaJI site of pR6K.GFP.STOP was calculated with the aid 
of the software program Mfold 3.2 (16) using energy rules for DNA (17) at http://mfold.rna.
albany.edu/?q=mfold/DNA-Folding-Form.
Extrachromosomal DNA extraction. Extrachromosomal DNA was extracted from the 
transfected cells essentially as described before (18) Briefly, at 72 hours post-transfection, 
cells were scraped from the surface of a 2-cm2 well with the plunger of a 1-ml Luer-Lok 
disposable syringe (BD Biosciences). The cell suspension was collected in a 15-ml screwcap 
tube with a conical bottom (Greiner Bio-One) and centrifuged for 5 minutes at 1,500×g. The 
supernatant was aspirated and the cells were washed once with 5 ml phosphate-buffered 
saline. After another round of centrifugation, the cell pellet was resuspended in 180 µl of 
solution I (10 mM Tris-HCl at pH 8.0; 10 mM EDTA; 100 µg/ml proteinase K [Fermentas]) and 
transferred to a 1.5-ml microtube (Eppendorf). Next, 180 µl of solution II (10 mM Tris-HCl at 
pH 8.0; 10 mM EDTA; 1.2% sodium dodecyl sulfate) was added. The microtube was inverted 
thrice to mix its content and incubated for 30 minutes at 37°C. Next, the sample was mixed 
with 90 µl of 5 M NaCl and stored overnight at 4°C. The following day, the chromosomal 
DNA was pelleted by centrifugation for 60 minutes at 16,100×g and the supernatant was 
removed to a new microtube. Subsequently, the supernatant was extracted twice with 
buffer-saturated phenol:chloroform:isoamyl alcohol (25:24:1) and once with chloroform and 
the episomal DNA was precipitated by addition of 2.5 volumes of ethanol and 0.5 volumes 
of 7.5 M ammonium acetate at pH 5.5. After washing with 70% ethanol, the DNA pellet was 
dried and dissolved in 100 µl of TE+ buffer (10 mM Tris-HCl at pH 8.0; 1 mM EDTA; 100 µg/
ml RNase A [Fermentas]). The purified DNA was used for PCR and Southern blot analyses.
Southern blot analysis. One fifth (i.e. 20 µl) of the extracted extrachromosomal DNA was 
incubated with XbaI and DpnI. XbaI releases the GFP ORF plus downstream SV40 pA from the 
acceptor plasmids for easy screening, whereas DpnI selectively digests the prokaryotic input 
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Next, the DNA was transferred by capillary action to an Amersham Hybond-XL membrane 
(GE Healthcare) using a standard Southern blot technique. The 744-bp GFP-specific probe 
was obtained by digestion of plasmid pA1.GFP.A2 with XbaI and XhoI (both from Fermentas) 
followed by preparative agarose gel electrophoresis. The DNA probe was labeled with 
EasyTide (α-32P) dCTP (3000 Ci/mmol; Perkin Elmer) using the DecaLabel DNA Labeling 
Kit (Fermentas). Prior to their application in hybridization experiments, the radiolabeled 
DNA fragments were separated from unincorporated dNTPs through size exclusion 
chromatography using Sephadex-50 (GE Healthcare) columns. A Storm 820 PhosphorImager 
(Amersham Biosciences) was used for the detection of labeled DNA. Images were acquired 
using the Storm scanner control 5.03 software and processed using ImageQuant Tools 3.0 
software (both from Amersham Biosciences).
In vivo assay to detect processing of inverted DNA repeats
Eighty-thousand HeLa cells were transfected essentially as described under “DNA 
transfections” with 266 ng of acceptorDR.1, acceptorIR.1 or acceptorScR each mixed with 133 
ng of pCAG.I-SceI or of pCAG.I-SceI(Δ112-246). Extrachromosomal DNA was isolated 72 
hours post-transfection as described elsewhere in this section and PCR was performed 
on 4 µl of DNA using 0.4 μM of primers 1 (5’-ATGGTGAGCAAGCAGATCCTGAAG-‘3) and 2 
(5’-CCGAGAAGGAAGTGCTCC-3’), 0.4 mM of each dNTP (New England Biolabs), 1×GoTaq 
reaction buffer, 1 mM MgCl2 and 2.5 U of GoTaq DNA polymerase (all from Promega) in 
a final volume of 50 μl. The PCR cycles were performed in a DNA Engine Tetrad 2 Peltier 
Thermal Cycler (Bio-Rad) using the following cycling conditions. A first denaturating step at 
95°C for 5 min, followed by 30 cycles of 60 sec at 95°C, 60 sec at 64°C and 120 sec at 72°C. 
Reactions were terminated by a final extension period of 5 min at 72°C. The synthesized 
DNA was purified using SureClean (Bioline) and dissolved in 30 µl of 10 mM Tris-Cl pH 8.0. 
The resulting PCR products were treated with DpnI alone or with DpnI plus I-SceI, XmaJI 
or BcuI and, subsequently, subjected to agarose gel electrophoresis. The inclusion of DpnI 
served to remove possible residual input prokaryotic plasmid DNA prior to Sourthern 
blot analysis. The procedures for Southern blotting and for DNA probe radiolabeling are 
described elsewhere in this section. The probe used is complementary to the hrGFP ORF 
and contiguous SV40 polyadenylation signal sequences. Undigested PCR products were 
cloned in the pCR4-TOPO cloning vector (invitrogen) using GT115 chemically-competent E. 
coli cells. Individual molecular clones corresponding to independent DNA processing events 
were sequenced using primer 1 or primer 6 (5’-CAGCTTCGAGGTGGTG-3’).
Statistical analysis
Statistical parameters were computed using Graph Pad Prism 4.03. Student’s t-test was 
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RESULTS
Design and construction of the episomal HR assay system
We established an extrachromosomal assay system to study the role of DNA repeats in 
homology-directed gene repair in vivo. This system is based on pairs of recombination 
substrates consisting of donor and acceptor (or target) DNA molecules containing GFP 
reporter genes that are rendered defective by different means (Figure 1A). The transcription 
unit in the donor plasmid was made non-functional by removing the first 38 nucleotides 
from the GFP ORF and lacks eukaryotic promoter/enhancer elements whereas the GFP ORF 
in the various acceptor constructs was disrupted by an internal stop codon preceding the test 
DNA sequences depicted in Figure 1B and Figure 1C. The donor and acceptor DNA templates 
share two regions of perfect sequence identity (Figure 1A, marked in grey), which in the 
acceptor plasmids are separated from each other by the test sequences. HR-dependent 
reciprocal exchange of genetic information through the common DNA segments of 584 and 
339 bp or via a single cross-over within the upstream, 584-bp, arm of homology are both 
expected to generate fully functional GFP transcription units. Thus, the capacity of different 
test DNA sequences to elicit homology-directed gene repair can be readily assessed by the 
analysis of GFP expression through direct fluorescence microscopy or flow cytometry.
The generation of site-specific DSBs by the Saccharomyces cerevisiae mitochondrial 
group I intron-encoded homing endonuclease I-SceI at its cognate 18-bp recognition 
sequence is a well-established method to trigger in a predictable manner DNA repair 
pathways in prokaryotic and eukaryotic systems (19) Therefore, in our experimental system, 
we used as positive control for HR-dependent rescue of GFP expression, cells exposed to 
a donor plasmid, an acceptor template containing the I-SceI recognition sequence (ScR) 
and an I-SceI expression construct. Cells that only received the first two plasmids served as 
negative control in the HR assay.
Using PCR-based site-directed mutagenesis, an XmaJI cleavage site was introduced 
into the GFP-coding sequence of the starting construct that served as basis to generate 
the acceptor plasmid panel (Figure 1B). This maneuver resulted also in the disruption of 
the GFP ORF by a stop codon contained within the XmaJI recognition sequence. Next, 
DNA fragments composed of hybridized synthetic oligodeoxyribonucleotides with XmaJI-
compatible cohesive termini encompassing the test sequences 1 through 4 (45-mers) or 
the recognition sequence for the I-SceI meganuclease (42-mers; Figure 1B, orange) were 
individually inserted at the PCR-created XmaJI site (Figure 1B). The four test sequences 
consisted of two different DNA segments of 25 bp (Figure 1B, red and cyan) extended at 
the 3’ end with two different 9-bp DNA sequences (Figure 1B, green and violet) and a BcuI 
recognition sequence (Figure 1B, grey). Subsequently, another copy of each of the four test 
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interrupted by the direct repeats DR.1, DR.2, DR.3 or DR.4 or the inverted repeats IR.1, IR.2, 
IR.3 or IR.4 (Figure 1C). Due to their identical GC content, the four different test sequences 
were predicted to possess very similar and low folding free energies when in a tandem 
antiparallel orientation while those corresponding to their arrangement in a direct repeat 
configuration were calculated to be rather high (Figure 1C). Thus, on theoretical grounds the 
inverted repeats of the four test sequences have a higher likelihood to originate secondary 
structures via intrastrand hybridization than their isogenic counterparts displaying a direct 
repeat arrangement (Figure 1C).
Experimental evidence for inverted repeat-dependent formation of DNA secondary 
structures in acceptor plasmids
The bacteriophage T7 endonuclease I is a commonly used tool to probe for the presence 
of cruciform- or Holliday-like secondary structures in DNA. This resolvase recognizes 
preferentially the four-way junctions characteristic of these types of DNA conformers and, 
in its dimeric form, introduces paired nicks close to the branch points leading to subsequent 
DNA cleavage. On the other hand, negative superhelical torsional stress, such as present 
in the supercoiled fraction of plasmid DNA (SC), is a major driving force in the nucleation 
and extrusion of cruciform-like structures at DNA repeats. Thus, the E. coli enzyme DNA 
topoisomerase I by catalyzing the relaxation of negatively supercoiled DNA should, to a 
great extent, inhibit the generation of cruciforms as scored in in vitro assays based on the 
accumulation of T7 endonuclease I-resolved plasmid DNA molecules (i.e. linear form). The 
results presented in Figure 2A correspond to an experiment in which the validated cruciform-
forming plasmid pUC(AT) was used to confirm that the time-dependent accumulation of the 
linear T7 endonuclease I-derived DNA product does indeed depend on SC DNA. In fact, in 
the presence of the DNA topoisomerase I, virtually all the pUC(AT) plasmid transited from 
the SC to the OC form resulting in a concomitant stringent inhibition of cruciform resolution. 
Importantly, an equivalent experimental outcome was observed when the DNA substrate 
harboring the test IR.1 sequence was deployed, suggesting that this plasmid is prone to the 
acquisition of cruciform-like structures as well (Figure 2B).
Next, to investigate the ability of the different tandem arrangements of the test DNA 
sequences to induce the nucleation and extrusion of cruciform-like structures in plasmid 
substrates, the ScR-, IR.1- or DR.1-containing acceptor constructs were treated or mock-
treated with T7 endonuclease I. For the sake of clarity, hereinafter these acceptor plasmids 
will be named after the test sequences that they contain (e.g. acceptorScR, acceptorIR.1, and 
so forth). Because acceptorScR purposely possesses a test DNA sequence with an intrinsically 
low intrastrand folding capacity (ΔG = -0.35 kcal/mol) it served to establish the background of 
the assay. To provide for a test DNA sequence known to give rise to four-way DNA structures 
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derived from the AAV ITR inserted at GFP nucleotide position 624. This DNA segment, which 
contains three self-complementary regions (i.e. A/A’, B/B’ and C/C’), has a high propensity 
to fold into a T-shaped hairpin structure by intrastrand hybridization (20,21). Thus, the 
acceptorITR plasmid was also subjected to T7 endonuclease I treatment. Furthermore, to 
generate internal references, each acceptor plasmid was linearized in parallel with the 
restriction enzyme ApaLI.
Agarose gel electrophoresis of T7 endonuclease I- or ApaLI-treated acceptor plasmids 
revealed that fragments with sizes consistent with DNA cleavage (i.e. linearized DNA forms) 
were clearly more prominent in the samples of acceptorIR.1 and acceptorITR than in those 
corresponding to acceptorScR and acceptorDR.1 (Figure 2C). Indeed, there was no noticeable 
difference in the accumulation of linear DNA between the non-repeat-containing acceptorScR 
and the direct repeat-containing acceptorDR.1. As expected, agarose gel electrophoresis 
of acceptor plasmids not exposed to T7 endonuclease I resulted in the detection of only 
supercoiled and open circular (i.e. nicked) DNA topologies (Figure 2C). 
Figure 2. In vitro assay to probe for the formation of cruciform-like secondary structures in DNA repeat-
containing acceptor plasmids. (A) Testing the effect of the negative supercoiling-relaxing enzyme DNA 
topoisomerase I on the yields of T7 endonuclease I-resolved DNA (solid arrowhead) using the validated 
cruciform-forming plasmid pUC(AT). pUC(AT) treated or not treated with DNA topoisomerase I (+Topo 
and -Topo, respectively) was exposed to T7 endonuclease I for 10, 20, 30 or 60 min or underwent 
a 60-min mock treatment (0). Following agarose gel electrophoresis, the resulting DNA forms were 
visualized through ethidium bromide staining. OC and SC, open circular and supercoiled DNA forms, 
respectively. (B) Testing the impact of the negative supercoiling-relaxing enzyme DNA topoisomerase 
I on the yields of T7 endonuclease I-resolved DNA (solid arrowhead) using the acceptor substrate 
containing the test non-spaced inverted repeat sequence IR.1. AcceptorIR.1 treated or not treated with 
DNA topoisomerase I (+Topo and –Topo, respectively) was exposed to T7 endonuclease I for 10, 20, 30 
or 60 min or was subjected to a 60-min mock treatment (0). C and SC, open circular and supercoiled 
DNA forms, respectively. (C) Target DNA plasmids acceptorScR (ScR), acceptorIR.1 (IR.1), acceptorDR.1 
(DR.1) and acceptorITR (ITR) were incubated in the presence (+) or absence (-) of T7 endonuclease I 
(T7) for 10 min. The resulting DNA products were resolved by agarose gel electrophoresis and stained 
with ethidium bromide. OC and SC, open circular and supercoiled DNA forms, respectively. L, Acceptor 
plasmid linearized with ApaLI. (D) Target DNA plasmids acceptorIR.1, acceptorDR.1 and acceptorITR 
were either incubated with T7 endonuclease I for 10, 20, 30 or 60 min or underwent a 60-min mock 
treatment (0). The resulting DNA products were analyzed by agarose gel electrophoresis and ethidium 
bromide staining. L, Acceptor plasmid linearized with ApaLI. (E) The test plasmids harboring the non-
spaced inverted repeat sequences IR.1 through IR.4 (left panels) as well as those containing their 
respective direct repeat counterparts (right panels) were treated with T7 endonuclease I for 20, 30 or 
60 min prior and resolved through agarose gel electrophoresis. SC, supercoiled DNA; solid arrowheads 
point to the resolved linear molecules. (F) The plasmids acceptorDR.1, acceptorspIR.1, acceptorIR.1 and 
acceptorITR were incubated with T7 endonuclease I for 10, 20, 30 and 60 min and analyzed by agarose 
gel electrophoresis. (G) In vitro mapping of the T7 endonuclease I cleavage site in acceptor molecules. 
Upper panel, diagram of the expected digestion patterns resulting from the combined activities of 
SalI and T7 endonuclease I or of HincII and T7 endonuclease I. The numerals correspond to the sizes 
(in bp) of the different DNA fragments each of which drawn in relation to the parental acceptor DNA 
template containing the ITR sequence embedded within the hrGFP ORF. Lower left and right panels, 
agarose gel electrophoresis of ITR-containing acceptor molecules treated only with SalI or with SalI 
and T7 endonuclease I or exposed to HincII or to HincII plus T7 endonuclease I, respectively. Lanes M 
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In another set of experiments, we investigated the T7 endonuclease I-dependent 
accumulation of linear acceptor DNA species as a function of time. To this end, constructs 








































42  |  Chapter 2
min or left untreated. Analysis of the resulting DNA products by agarose gel electrophoresis 
showed that for each period of T7 endonuclease I treatment, the inverted repeat-containing 
plasmids acceptorIR.1 and acceptorITR yielded higher amounts of linear DNA than the direct 
repeat-containing construct acceptorDR.1 (Figure 2D). In fact, exposure of acceptorDR.1 for 60 
min to T7 endonuclease I generated less linear DNA molecules than a 10-min incubation of 
acceptorITR and acceptorIR.1 with the same enzyme (Figure 2D). However, linear acceptorITR 
molecules accumulated with faster kinetics than linear acceptorIR.1 DNA (Figure 2D). These 
data, in agreement with the calculated folding free energy values (Figure 1C), indicate that 
T7 endonuclease I-susceptible secondary DNA structures (e.g. DNA cruciforms) can be 
formed after insertion of the test DNA sequences as inverted repeats in acceptor plasmid 
substrates (Figure 1C). These experimental results further suggest that the AAV ITR has a 
higher propensity to acquire a T7 endonuclease I-sensitive DNA conformation than IR.1. 
Similar experiments were also carried out with not only the acceptor substrates harboring 
IR.1, DR.1 and ITR but also with those containing each of the other 6 non-spaced repeat 
sequences (i.e. DR.2, DR.3, DR.4, IR.2, IR.3 and IR.4) as well as that with the spaced inverted 
repeat sequence spIR.1. Results from these experiments established that for each of the 
IR/DR acceptor pairs those substrates containing the non-spaced inverted repeat led, at 
very time point analyzed, to a higher accumulation of T7 endonuclease I-resolved linear 
forms than that resulting from those harboring the non-spaced direct repeat (Figure 2E, 
compare each left panel with the corresponding right panel). Of note, acceptorspIR.1 with 
its spaced inverted repeat was clearly less prone to T7 endonuclease I digestion than its 
acceptorIR.1counterpart (Figure 2F, compare second with third panel from the top). Once 
again, acceptorITR with its multi-palindromic AAV ITR sequence displayed a somewhat higher 
susceptibility to the T7 endonuclease I when compared to that of acceptorIR.1 (Figure 2F, 
compare the two lowest panels). Finally, to identify the position corresponding to the major 
T7 endonuclease I cleavage site in acceptor DNA backbones with secondary structure-
forming test sequences, we incubated an ITR-containing construct (Figure 2G, upper panel) 
exclusively with SalI or with SalI and T7 endonuclease I or exposed it to HincII or to HincII 
and T7 endonuclease I. Agarose gel electrophoresis of the resulting DNA fragments revealed 
digestion patterns fully consistent with T7 endonuclease I-dependent cleavage of the 
acceptor templates at the location of the inverted repeat (Figure 2G, lower panels). 
Inverted repeats stimulate DNA exchange through homologous recombination in 
mammalian cells
Next, we deployed the aforementioned episomal HR assay system (Figure 1) to ask 
whether DNA templates containing direct or inverted DNA repeats can serve as substrates 
for homology-directed gene repair in mammalian cells. In these experiments, HeLa cells 
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four days post-transfection, HR-dependent GFP repair was measured by flow cytometry. 
Transfection of the donor construct GFPΔATG, acceptorDR.1 or acceptorIR.1 alone did not give 
rise to measurable GFP-specific signals showing that the mutations introduced in these 
plasmids did functionally disrupt the GFP ORF (Figure 3A). Co-transfection of both GFPΔATG 
and acceptorScR resulted in a low percentage of GFP-positive cells (i.e. 0.3 ± 0.2 % [n=8]; 
Figure 3A, donor + ScR), establishing the background of the assay in the presence of both 
donor and acceptor templates. To validate the extrachromosomal recombination system, we 
relied on I-SceI-mediated site-specific DSB formation, which is a well-established method to 
induce HR in a controlled and predictable manner (see e.g. [19]). For this purpose, HeLa cells 
were co-transfected with GFPΔATG, acceptorScR and the I-SceI-encoding expression plasmid 
pCAG.I-SceI. The inclusion of pCAG.I-SceI resulted in a large increase in the frequency of 
GFP-positive cells (i.e. 2.5 ± 0.4 % [n=11]; Figure 3A, donor + ScR + I-SceI). Interestingly, 
while co-transfection of GFPΔATG and acceptorDR.1 yielded background levels of GFP-positive 
cells (Figure 3A, compare donor + ScR with donor + DR.1), co-delivery of the donor construct 
together with acceptorIR.1 gave rise to a significantly higher percentage of GFP-positive cells 
(i.e. 1.9 ± 0.5 % [n=11]; Figure 3A, compare donor + ScR and donor + DR.1 with donor + IR.1). 
These data imply that a tandem of test sequence 1 when arranged in an inverted repeat 
orientation serves as an effective target for homology-directed gene repair.
To further investigate the relationship between the relative orientation of repetitive 
DNA sequences and HR-mediated gene repair, HeLa cells were co-transfected with GFPΔATG 
and with an acceptor plasmid containing a tandem of test sequences 2, 3 or 4 arranged 
in either a direct or in an inverted repeat configuration. Consistent with the previous 
results (Figure 3A), acceptor plasmids endowed with the various inverted repeats yielded 
significantly higher numbers of GFP-positive cells than their isogenic direct repeat-containing 
counterparts, which gave rise to frequencies of GFP-positive cells not significantly above 
background level (i.e. GFPΔATG + acceptorScR; Figure 3B). Thus, at least for the four different 
test DNA sequences investigated, which possess the same GC content, induction of HR is 
primarily dependent on the arrangement of the repetitive DNA unit as opposed to their 
specific nucleotide sequence. 
Central spacing abolishes inverted DNA repeat-dependent homology-directed gene repair
To study the impact of repetitive DNA spacing in inverted repeat-induced HR, we generated 
acceptorspIR.1. This plasmid was made by inserting at the axis of symmetry of IR.1, a 42-bp 
sequence encompassing the ScR to effectively separate test sequence 1 from its reverse 
complement copy. In these experiments, HeLa cells were transfected with a mixture of 
the donor plasmid GFPΔATG, acceptorScR, acceptorIR.1 or acceptorspIR.1 and, where indicated, 
pCAG.I-SceI. As previously observed, co-transfection of GFPΔATG and acceptorIR.1 resulted in 
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by acceptorspIR.1, yielded GFP expression rescue activity levels that were not above those 
detected in cell cultures exposed to GFPΔATG and acceptorScR (Figure 3C). Possibly, physical 
separation of the repetitive DNA unit as in acceptorspIR.1 inhibits the in vivo formation of 
cruciform-like structures as suggested by our in vitro assay results (Figure 2F) as well as 
those of others (22-24), which renders the transfected DNA templates no longer a target 
for the HR machinery. Addition of pCAG.I-SceI to the transfection mixtures consisting of 
GFPΔATG and either acceptorScR or acceptorspIR.1 rescued high-level GFP expression (Figure 
3C). The latter outcome shows that acceptorspIR.1 does not contain an intrinsically defective 
GFP target template. Taken together, these data indicate that perfect palindromes or non-
spaced inverted DNA repeats are preferred over spaced inverted DNA repeats as targets for 
homology-directed gene repair in vivo presumably due to their capacity to form secondary 
structures in vivo that can subsequently serve as direct targets for cellular structure-specific 
nucleases. 
Figure 3. Effect of repetitive DNA sequences in a direct or inverted repeat configuration on homology-
directed gene repair in HeLa cells. (A) HeLa cells were transfected with acceptorDR.1 or acceptorIR.1 
alone (DR.1 and IR.1, respectively) or with either of these two acceptor plasmids in combination 
with the donor construct GFPΔATG (donor + DR.1 and donor + IR.1, respectively). Mock-transfected 
HeLa cells (mock) and HeLa cells transfected with GFPΔATG alone (donor) or together with acceptorScR 
(donor + ScR) served as negative controls. The positive control for the rescue of GFP expression by HR 
was provided by co-transfecting HeLa cells with acceptorScR, GFPΔATG and the I-SceI-encoding plasmid 
pCAG.I-SceI (donor + ScR + I-SceI). Quantification of the number of GFP-positive cells was carried out 
by flow cytometry at 4 days post-transfection. A minimum of 5 and a maximum of 11 independent 
experiments were performed with 10,000 events corresponding to viable cells being measured 
per sample. (B) HeLa cells were co-transfected with GFPΔATG plus either acceptorIR.2, acceptorDR.2, 
acceptorIR.3, acceptorDR.3, acceptorIR.4 or acceptorDR.4. To facilitate comparison, data sets corresponding 
to HeLa cells co-transfected with GFPΔATG and acceptorScR or with GFPΔATG, acceptorScR and pCAG.I-SceI 
as well as those corresponding to HeLa cells co-transfected with GFPΔATG and either acceptorIR.1 or 
acceptorDR.1 presented in Figure 3A are repeated in Figure 3B (open and grey bars, respectively). 
Quantification of GFP expression rescue was carried out by flow cytometry at 4 days post-transfection. 
Cumulative data from 4 different experiments (solid bars) are expressed as mean ± standard deviation. 
*p=0.002; **p=0.009. (C) Flow cytometric analysis of HeLa cells that, in addition to being exposed to 
the donor plasmid GFPΔATG also received acceptorScR, acceptorIR.1 or acceptorspIR.1. In the latter construct, 
the inverted repeat of test sequence 1 is interrupted at its axis of symmetry by an I-SceI recognition 
site (see diagram below the graph). HeLa cells co-transfected with GFPΔATG, the I-SceI encoding plasmid 
pCAG.I-SceI and either acceptorScR or acceptorspIR.1 served as positive controls for HR-mediated GFP 
repair. Data corresponding to a minimum of 3 different experiments are shown as mean ± standard 
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Experimental evidence for in vivo nuclease-mediated processing of non-spaced inverted 
DNA repeats
In the search of evidence for nuclease-mediated processing of palindromic test sequences 
in vivo, we set-up the assay system illustrated in Figure 4A. In this assay, HeLa cells are 
transfected with acceptorIR.1, acceptorDR.1 or with acceptorScR mixed with pCAG.I-SceI or 
with pCAG.I-SceI(Δ112-246). Expression plasmid pCAG.I-SceI(Δ112-246) encodes a non-
functional I-SceI protein. Cells co-transfected with acceptorScR and pCAG.I-SceI constitute a 
positive control for in vivo site-specific DSB formation at acceptor templates. A key feature 
of this assay is the fact that a discriminating marker in the form of a BcuI recognition site 
lies at the axis of symmetry of the test non-spaced inverted repeat sequence (Figure 1B 
and Figure 4A, upper panel). Generation of cruciforms at this sequence followed by its 
recognition and processing by cellular structure-specific nuclease(s) should result in DNA 
breaks. The resulting DNA can subsequently serve as a substrate for error-prone DNA repair 
processes in the cell, such as non-homologous end-joining (NHEJ), eventually leading to 
the emergence of a population of BcuI-resistant acceptor molecules (Figure 4A). Likewise, 
processing of I-SceI-mediated DSBs by a cellular error-prone DNA repair pathway should 
yield templates that are knocked-out in the I-SceI cognate target site. Thus, DNA processing/
repair at specific test sequences should lead to a mixture of hrGFP templates that can be 
PCR-amplified and discriminated on the basis of sequence-specific enzymatic digestions 
combined with Southern blot and nucleotide sequence analysis. Southern blotting of 
amplicons made with the aid of primer set 1/2 (Figure 4A), showed the presence of I-SceI-
undigested templates in extrachromosomal DNA isolated from HeLa cells co-transfected 
with acceptorScR and pCAG.I-SceI (+I-SceI; Figure 4B) but not in those co-transfected with 
acceptorScR and pCAG.I-SceI(Δ112-246) (-I-SceI; Figure 4B). Importantly, the same analysis 
applied to episomal DNA extracted from HeLa cells transfected with acceptorIR.1 or with 
acceptorDR.1 revealed the presence of BcuI-undigested templates in cells exposed to the 
former construct (Figure 4B, lower-left panel). The fact that PCR products amplified from 
acceptorScR or from acceptorIR.1 and treated with XmaJI did not yield discernable undigested 
material suggests that the majority of the DNA sequence modifications took place in the 
vicinity of the respective I-SceI site or of the IR.1 axis of symmetry. Next, amplicons isolated 
from the BcuI-undigested fraction were cloned into pCR4-TOPO and subjected to restriction 
fragment length analysis using BcuI. This analysis confirmed the disruption of the BcuI 
restriction site in several of the analyzed clones (Figure 4C, lanes 1, 2, 4, 5 and 6). Moreover, 
the apparently different molecular weights of the restriction fragments migrating slower 
than 1.2 kb-sized linear DNA suggest that the BcuI-refractory clones do harbor sequences 
representing the end-product of independent DNA processing/repair events. To confirm this, 
and to identify the breakpoints in acceptorIR.1 templates at the nucleotide level, we carried 
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also sequenced a pCR4-TOPO-based clone corresponding to PCR-amplified DNA from HeLa 
cells co-transfected with acceptorScR and pCAG.I-SceI (Supplementary Figure S1). 
Figure 4. In vivo processing and repair of non-spaced inverted DNA repeats. (A) Diagrammatic 
representation of the experimental set-up deployed to study the processing and repair of non-spaced 
inverted DNA repeats in cells (see text for details and legend of Figure 1A for an explanation of the 
symbols). (B) Southern blotting analysis using an hrGFP ORF- and SV40 pA-specific probe of PCR 
products derived from extrachromosomal DNA isolated from HeLa cells co-transfected with acceptorScR 
and pCAG-I.SceI (+I-SceI), acceptorScR and pCAG-I.SceI(pCAG.I-SceI(Δ112-246) (-I-SceI), acceptorIR.1 or 
acceptorDR.1. Prior to electrophoresis, the DNA samples were treated with DpnI alone (-) or with DpnI 
together with I-SceI, XmaJI or BcuI. Sizes corresponding to undigested amplicons (solid arrowhead) 
expected for the primer pair 1/2 are indicated on the right of the autoradiograms. (C) Upper panel, 
Diagram of a pCR4-TOPO molecular clone containing a PCR product amplified from extrachromosomal 
DNA isolated from HeLa cells transfected with acceptorIR.1 and treated with BcuI. Vertical arrow points 
to the original position of the BcuI recognition site. Lower panel, Agarose gel electrophoresis of BcuI-
treated pCR4-TOPO clones harboring PCR products amplified from episomal DNA extracted from 
HeLa cells transfected with acceptorIR.1 and exposed to BcuI digestion (lanes 1 through 6). Lane M, 
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Inverted DNA repeat-dependent homology-directed gene repair occurs in a variety of 
mammalian cell types
Subsequently, we exposed cultures of HEK 293T cells, human fetal retinoblasts (911 and 
PER.tTA.Cre76 cells) and African green monkey kidney fibroblasts (COS-7 cells) to GFPΔATG 
and either acceptorDR.1 or acceptorIR.1. Again, negative and positive controls were provided 
by co-transfecting cultures of each of these cell types with a mixture of the donor plasmid 
GFPΔATG and acceptorScR alone or together with pCAG.I-SceI, respectively. Data depicted in 
Figure 5A, show distinct levels of HR-dependent GFP repair in the various cell types tested. 
This might be the result of different transfection efficiencies and/or of intrinsic cell type-
specific differences in the ability to recognize and process, via HR, DNA secondary structures. 
Importantly, however, like in HeLa cells, appreciable HR-mediated GFP repair was only 
observed after co-transfection of GFPΔATG and acceptorIR.1 (Figure 5A). This IR.1-mediated HR 
stimulatory effect was independent of the amount of p53 present in the disparate cell types 
tested (Supplementary Figure S2). Some representative flow cytometry dot plots and direct 
fluorescence microscopy micrographs corresponding to these experiments are depicted in 
Figure 5B and Figure 5C, respectively. Collectively, these experiments suggest that inverted 
DNA repeat-induced HR is a mammalian cell type-independent phenomenon.
 
Figure 5. Effect of repetitive DNA sequences in a direct or inverted repeat configuration on homology-
directed gene repair in mammalian cells. (A) Flow cytometric analysis of human embryonic kidney 
293T cells (HEK), human fetal retinoblasts (911 and PER.tTA.Cre76 [PER]) and African green monkey 
kidney fibroblasts (COS-7) co-transfected with GFPΔATG and either acceptorDR.1 or acceptorIR.1. Negative 
and positive controls for HR-mediated GFP repair in each of the tested cell types were provided by cells 
containing GFPΔATG and acceptorScR (-) or these two plasmids as well as pCAG.I-SceI (+), respectively. (B) 
Dot plot representation of GFP expression in human embryonic kidney 293T cells (HEK) transfected 
with GFPΔATG alone (donor) or with a mixture of GFPΔATG and either acceptorDR.1 or acceptorIR.1. Cultures 
co-transfected with GFPΔATG, acceptorScR and the I-SceI expression plasmid pCAG.I-SceI served as 
positive control. Flow cytometry was carried out 3 days post-transfection with 10,000 viable cells 
being analyzed per sample. (C) Live-cell imaging by phase-contrast and fluorescence microscopy of 
monolayers of African green monkey kidney fibroblasts (COS-7) co-transfected with GFPΔATG and either 
acceptorIR.1 or acceptorDR.1. Parallel cultures exposed to GFPΔATG, acceptorScR and pCAG.I-SceI served 
as positive control for HR-dependent GFP reconstitution. Microscopic analysis was performed 3 days 
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Composite inverted DNA repeats are equally effective at stimulating homology-directed 
gene repair as simple palindromes
To investigate the capacity of a structurally more “complex” or composite inverted DNA 
repeat to stimulate HR, we deployed acceptorITR. Contrary to HeLa cell cultures that 
were transfected with donor GFPΔATG or acceptorITR alone, those exposed simultaneously 
to GFPΔATG and acceptorITR readily revealed the presence of GFP-positive cells (Figure 6A). 
The percentages of these cells were similar to those observed in HeLa cell cultures upon 
co-transfection of GFPΔATG and acceptorIR.1 (Figure 3). To rule out the possibility that DNA 
sequences prone to secondary structure formation, such as the AAV ITR, alter plasmid DNA 
transfection efficiency, we transfected HeLa cells with pDsRed or with pDsRed2X.ITR. The 
former construct contains an expression unit based on the human elongation factor 1α 
promoter, the DsRed.T4 reporter and the rabbit β-globin polyadenylation signal, whereas 
the latter has this transcription unit flanked by AAV ITRs. Flow cytometric analysis at 72 hours 
post-transfection showed that cultures exposed to pDsRed2X.ITR had a frequency of reporter-
positive cells as well as an amount of DsRed.T4 protein very similar to those measured in 
cultures transfected with pDsRed. We conclude that the ITR sequences do not significantly 
affect the transfection efficiency of plasmid DNA (Supplementary Figure S3).
To confirm, at the molecular level, the accurate repair of GFP ORFs following inverted 
repeat-mediated HR, we performed PCR analysis on extrachromosomal DNA isolated from 
HeLa cells transfected with GFPΔATG alone or together with acceptorITR. Extrachromosomal DNA 
extracted from HeLa cells exposed to acceptorITR in combination with the non-homologous 
donor construct RFPΔATG served as an extra negative control. The PCR assay shown in Figure 
6B is based on primer pairs 1/2 and 1/3 to amplify PCR products that are diagnostic for 
the generation of GFP templates corrected by two-sided and one-sided HR, respectively. 
Although primers 1 and 2 also bind to the acceptor plasmid, their use did not yield any PCR 
products (Figure 6C) most likely due to the inability of the thermostable polymerase to the 
read through the AAV ITR. As shown in Figure 6C (upper and middle panels), PCR fragments 
corresponding to reconstituted GFP ORFs were exclusively detected in the DNA sample 
from the cells that were co-transfected with donor GFPΔATG and acceptorITR. Moreover, the 
results demonstrate that gene repair was brought about by two-sided as well as by one-
sided HR (Figure 6C, lane 1 of upper panel and lane 1 of middle panel, respectively). Of 
note, amplification reactions carried out on an in vitro mixture of GFPΔATG and acceptorITR 
plasmids did not yield any product, showing that the detection of specific amplicons in the 
DNA sample derived from HeLa cells co-transfected with GFPΔATG and acceptorITR was not an 
artifact but the result of genetic information exchange in vivo (not shown). Internal control 
PCR amplifications using primers 4 and 5 showed the presence of the homologous and the 
non-homologous donor templates GFPΔATG and RFPΔATG, respectively, confirming the integrity 








































Non-spaced inverted DNA repeats are preferential targets for homology-directed gene repair  |  51
2
Next, we performed an independent transfection experiment in HeLa cells followed by the 
same DNA isolation procedure and PCR assay. In this new experiment, however, an extra 
control was included. This consisted in using extrachromosomal DNA from cells transfected 
with acceptorITR mixed, prior to PCR, with extrachromosomal DNA from cells transfected 
with donor GFPΔATG. Data depicted in Supplementary Figure S4 shows, once again, the 
presence of the specific 1.2-kb amplicon exclusively in the sample corresponding to cells 
co-transfected with donorΔATG and acceptorITR.
The PCR products obtained with the aid of primer pair 1/2 were inserted into a plasmid 
vector after which, nucleotide sequence analysis of twenty randomly selected DNA clones 
was carried out. From this analysis resulted that nineteen of these clones contained GFP 
ORFs without any mutations linking them to error-free HR events (Figure 6D, 5 uppermost 
nucleotide sequences). The remaining clone had the GFP ORF disrupted at the initially 
engineered premature stop codon and AAV ITR-derived, heterologous, DNA (Figure 
6D; lowest nucleotide sequence) suggesting that it was the product of inverted repeat 
microhomology-directed recombination (25) or of error-prone non-homologous end-
joining (NHEJ), possibly following center-break palindrome revision or cruciform resolution 
(2,3,26,27). Additionally, we studied the kinetics of homology-directed gene repair involving 
acceptorITR and acceptorIR.1 and directly compared it to that of conventional DSB-induced 
HR. To this end, HeLa cells were transfected with donor GFPΔATG alone or together with 
acceptorIR.1, acceptorITR or a mixture of acceptorScR and pCAG.I-SceI. Results shown in Figure 
6E, reveal a time-dependent increase in the number of GFP-positive cells (Figure 6E, upper 
graph) as well as in the amount of reporter protein per GFP-positive cell (Figure 6E, lower 
graph) in all cultures co-transfected with acceptor plasmids and the donor GFP∆ATG construct. 
Interestingly, the time-dependent increase in the frequency and fluorescence intensity of 
GFP-positive cells was faster in cultures exposed to acceptorScR and pCAG.I-SceI than in those 
incubated with acceptorITR or with acceptorIR.1. Moreover, no significant differences in both 
of the GFP-specific parameters were found at all time points tested in cell cultures exposed 
to GFP∆ATG and either acceptorITR or acceptorIR.1 (Figure 6). We postulate that the lower HR-
inducing activity of the inverted DNA repeat sequences as compared to DSBs may relate 
to their transient nature. Perhaps, secondary structures formed in vivo by certain inverted 
repeats and palindromes constitute “facultative” or “intermittent” DNA lesions leading to a 
sporadic engagement of the HR machinery. Another contributing factor may be the larger 
number of biochemical reactions necessary to process cruciform-like structures by HR than 
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Figure 6. Comparison of the ability of simple and composite inverted DNA repeats to trigger homology-
directed gene repair in mammalian cells. (A) HeLa cells were transfected with GFPΔATG (donor) or with 
acceptorITR (ITR) or were co-transfected with GFPΔATG plus acceptorITR (donor + ITR). Analysis of GFP 
expression by flow cytometry was carried out 4 days post-transfection on 10,000 viable cells per sample. 
Horizontal lines representing means were derived form 9 independent experiments. (B) Schematic 
representation of the PCR-based assay deployed to detect GFP ORFs repaired via homology-directed 
gene targeting. Primers 1 and 2 were designed to amplify templates resulting from two-sided HR whilst 
oligodeoxyribonucleotides 1 and 3 were used to specifically detect products of one-sided HR. Primer 
1 recognizes the first 24 nts of the GFP ORF. Oligodeoxyribonucleotides 2 and 3 target sequences 
exclusively present in the acceptor and donor plasmid backbones, respectively. The PCR products of 
primers 4 and 5, which bind to the rabbit β-globin pA (βG.pA) and SV40 pA (SV.pA), respectively, served 
as internal control for extrachromosomal DNA quality and quantity. Amplicon size (in bp) expected for 
each primer pair is indicated. For an explanation of the other symbols see the legend of Figure 1A. 
(C) PCR analysis using primer pairs 1/2, 1/3 and 4/5 (upper, middle and lower panels, respectively) of 
extrachromosomal DNA isolated from HeLa cells co-transfected with acceptorITR and the homologous 
donor plasmid GFPΔATG (lane 1) or with acceptorITR and the non-homologous donor plasmid RFPΔATG 
(lane 2) or from HeLa cells transfected with GFPΔATG alone (lane 3). Lane M, GeneRuler DNA Ladder 
Mix molecular weight marker. (D) Nucleotide sequence data of individual clones corresponding to 
PCR products obtained with primers 1 and 2. Clones #5, #9, #14, #16 and #18 represent products of 
HR containing a repaired GFP ORF. The encircled ORF-correcting cytosine is derived from the donor 
plasmid. Clone #4 corresponds to a rearranged acceptor template featuring 38 bp of the originally 
introduced AAV ITR (purple line above graph) and retaining the engineered stop codon. The G marked 
with the asterisk is derived from the original acceptor template. (E) Flow cytometric analysis at the 
indicated time points of HeLa cells transfected with the donor construct GFPΔATG alone or together with 
either acceptorIR.1, acceptorITR or a mixture of acceptorScR and the I-SceI-encoding plasmid pCAG.I-SceI. 
Both the frequencies of GFP-positive cells (upper graph) as well as their average mean fluorescence 
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Replication of DNA repeat-containing acceptor molecules does not significantly affect 
homology-directed gene repair
SV40 is a mammalian double-stranded DNA virus with a circular genome whose replication 
has been extensively studied as a model for chromosomal nuclear DNA replication in higher 
eukaryotes (28). The only viral cis-acting element and trans-acting factor required for 
SV40-dependent DNA replication are the ori and the large T antigen protein, respectively. 
Thus, to investigate the impact of target template replication on DNA repeat-induced HR 
in mammalian cells, the SV40 ori was introduced at equivalent positions in acceptorScR, 
acceptorDR.1, acceptorIR.1 and acceptorspIR.1 to generate the constructs acceptorScR.ORI, 
acceptorDR.1.ORI, acceptorIR.1.ORI and acceptorspIR.1.ORI, respectively. Next, each of these plasmids 
was individually transfected into the SV40 large T-expressing COS-7 cells together with 
the homologous donor construct GFPΔATG or the non-homologous donor plasmid RFPΔATG. 
Extrachromosomal DNA isolated from these cells was treated with DpnI to selectively 
digest the input prokaryotic DNA and with XbaI to linearize de novo synthesized acceptor 
DNA molecules and HR products. Southern blot analysis of the digestion products using a 
GFP-specific probe revealed SV40 ori-dependent accumulation of de novo generated DNA 
molecules, demonstrating the replication proficiency of the SV40 ori-containing acceptor 
plasmids in COS-7 cells (Figure 7A). Interestingly, acceptor DNA replication did not lead to 
a significant increase in homology-directed gene repair levels in any of the experimental 
set-ups tested (Figure 7B). Taken together, these data indicate that under the prevailing 
experimental conditions, replication of acceptor DNA molecules carrying a palindrome, a 
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Figure 7. Testing the impact of target DNA synthesis on DNA repeat-mediated homology-directed gene 
repair. (A) SV40 ori-dependent DNA replication of acceptor constructs. Acceptor plasmids containing 
the test sequences ScR, IR.1, DR.1 or spIR.1 and with or without SV40 ori were transfected into COS-7 
cells together with the homologous donor construct GFPΔATG or the non-homologous donor plasmid 
RFPΔATG. At 3 days post-transfection, extrachromosomal DNA was extracted and treated with XbaI 
and the prokaryotic DNA methylation pattern-sensitive restriction enzyme DpnI. After agarose gel 
electrophoresis, the resolved DNA was subjected to Southern blot analysis using a GFP-specific probe. 
DpnI-resistant, de novo replicated DNA, was detected only in samples of cells transfected with SV40 
ori-positive acceptor plasmids (right-hand side upper panel). (B) Relative homology-directed gene 
repair frequencies in COS-7 cells transfected with GFPΔATG, the indicated acceptor plasmids with (+) or 
without (-) SV40 ori and in one case also pCAG.I-SceI.
DISCUSSION
Repetitive DNA sequences include not only single, direct and inverted repeats (2-4), like 
the ones investigated in this study, but also high-copy-number repetitive DNA tracts such as 
those corresponding to 1-4 bp microsatellites and 6-64 bp minisatellites (1). Microsatellites 
include the expandable trinucleotide repeats associated with neurodegenerative and 
neuromuscular disorders such as Huntington’s and oculopharyngeal muscular dystrophy. 
Despite their diversity, diverse lines of evidence point to the acquisition of non-B 
conformations by DNA at these motifs (e.g. hairpins, cruciforms, G-quadruplex, Z-DNA and 
H-DNA) as a common culprit through which they exert their biological effects possibly in 
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number of experiments mainly carried out in bacterial and yeast model systems indicates 
that long single DNA repeats (i.e. >150 bp; [3]) with the potential to form secondary 
structures (e.g. hairpins and cruciforms) can serve as targets for the shuffling and exchange 
of genetic information (2,3).
The knowledge about the biological activity of different types of DNA repeats in 
relation to gene repair pathways (especially single repeats in the size range <150 bp) and 
the putative role played in these processes by DNA replication is scant. This knowledge 
gap is particularly acute in cells of higher eukaryotes (2,3). In this study, we have devised 
an extrachromosomal functional read-out system based on pairs of complementary 
DNA templates carrying defective GFP-encoding sequences that can serve as substrates 
for intermolecular HR-dependent gene repair. This experimental system allowed us to 
investigate in a quantitative manner the effect of various types of single DNA repeats on the 
HR process in mammalian cells. Furthermore, by endowing acceptor DNA molecules with 
a eukaryotic origin of replication, we could probe in a strict manner the role of template 
DNA synthesis on repeat-induced homology-directed gene repair. We found that, contrary 
to direct and to spaced inverted repeats, both simple palindromes as well as composite 
inverted DNA repeats constitute targets for the HR pathway in mammalian cells. Induction 
of homology-directed gene repair was dependent on the arrangement and spacing of 
the repetitive DNA unit rather than on its nucleotide sequence. We also found that the 
presence of inverted DNA repeat sequences in target molecules rendered them susceptible 
to coordinated nicking by T7 endonuclease I, a bona fide four-way DNA branch resolving 
enzyme (29). These results are consistent with other in vitro data showing that lineform-
to-cruciform transition in double-stranded DNA molecules relies on the presence of an 
inverted repeat and is negatively affected by intervening spacer sequences in a length-
dependent manner (22-24). We thus demonstrate that non-spaced inverted DNA repeats 
per se can stimulate homology-directed gene repair in mammalian cells presumably due 
to their capacity to form secondary structures in vivo that can subsequently serve as direct 
targets for cellular structure-specific nucleases. These processes may eventually lead to the 
formation of DSBs that constitute canonical substrates for, amongst others, NHEJ- and HR-
based allelic and non-allelic recombination. Indeed, Inagaki and co-workers have recently 
shown in 293 cells by using a two-plasmid system together with a PCR-based assay that 
large secondary structure-forming palindromic AT-rich repeats (PATRRs), often associated 
with translocations in the human germ line, stimulate intermolecular rearrangements via a 
pathway likely to involve NHEJ (27). The impact of template DNA replication on the PATRR-
specific rearrangements was, however, not investigated.
Resolution of cruciform-like structures is thought to start with the introduction of single-
strand breaks on opposite sites of the branch point followed by a ligation step resulting 
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generate “open” ends. Candidate resolving and processing enzymatic activities are those 
of the first isolated bona fide mammalian Holliday junction resolvase Gen1 (30) and Mre11 
(31), respectively. Other candidate resolvase is that corresponding to the SLX4 complex 
(32). Possibly outcomes of such ectopic recombination processes include chromosomal 
translocations and loss-of-heterozigosity. Related to this, in silico analysis of the human 
genome as well as experiments in yeast suggest that, during evolution, palindromes and 
inverted repeats with short spacers are counter selected compared to direct repeats and 
inverted repeats with long spacers (9). Indeed, without implying causality, more recent 
computer-aided phylogenetic sequence analyses revealed a correlation between DNA 
repeat pairs, NHEJ and non-allelic HR in the shaping of mammalian genome evolution (33). 
Finally, we also showed that, at least under conditions that do not disrupt processivity 
of DNA synthesis, replication of molecules harboring the direct or the inverted DNA repeats 
did not significantly increase the frequencies of HR-dependent gene repair events when 
compared to those measured in the absence of acceptor DNA replication. This finding on 
single DNA repeats adds to recent results indicating that, at least in the case of the high-
copy-number trinucleotide repeat associated with Friedreich’s ataxia GAA×TTC, DNA 
rearrangements can ensue in the absence of replication (34). Other processes like DNA 
transcription and certain repair pathways such as the herein examined HR can provide for 
alternative mechanisms underlying DNA repeat-associated rearrangements as proposed 
elsewhere (1,35). Indeed, the fact that repeat-associated DNA instability can occur 
independently of a replication-based mechanism (e.g. replication stalling or slippage) can 
also be circumstantially inferred from the significant age-dependent expansion of secondary 
structure-forming trinucleotide repeats in post-mitotic neurons of patients afflicted by 
certain neurodegenerative disorders (1). 
Current models of inverted repeat-driven secondary structure formation in vivo posit 
that palindromes or quasi-palindromes can, under torsional strain, transit from lineform 
to cruciform in double-stranded DNA via intrastrand annealing. On the other hand, 
spaced inverted repeats, albeit being also self-complementary, can only hybridize in the 
single-stranded form such as when a DNA replication fork advances through them and 
concomitantly gives rise to the Okazaki initiation zone (OIZ) in the lagging strand. Possibly, 
under these conditions, and depending on the length of the repeat/spacer sequences relative 
to that of the OIZ, lagging strand self-annealing becomes thermodynamically favorable 
resulting in the formation of hairpins that can stall DNA replication (2,36) Interestingly, we 
showed that replication of DNA molecules containing the spaced inverted repeat spIR.1 
could not overcome their inability to promote homology-directed gene repair. Related 
to this, Voineagu and colleagues (36) have recently deployed a SV40 ori-based plasmid 
system and 2D agarose gel electrophoresis to demonstrate that Alu-derived 320-bp-long 
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stalling in COS-1 cells, whereas the same inverted repeat with a 52-bp spacer did not. 
The authors interpreted these results as a consequence of the OIZ size limit not allowing 
effective stem-loop hairpin formation by inverted DNA repeats with the larger spacer. Thus, 
on the basis of our results and those of Voineagu and co-workers and towards dissecting 
the inverted repeat parameters allowing hairpin assembly through the postulated lagging 
strand displacement-dependent mechanism, it will be interesting to evaluate different-sized 
repeat/spacer sequences and their relationship with replication fork stalling on one hand 
(36) and homology-directed gene repair on the other (this study). These experiments might 
help to define the rules underlying secondary structure formation, replisome stalling and 
the HR-inducing activity of inverted DNA repeats in mammalian cells. Finally, the functional 
genetic assay described herein might also be helpful in evaluating the effect of other types 
of DNA motifs/parameters on HR in higher eukaryotes and the contribution of cellular 
factors to this process.
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ABSTRACT
The array of genome editing strategies based on targeted double-stranded DNA break (DSB) 
formation have recently been enriched through the introduction of transcription activator-
like type III effector nucleases (TALENs). To advance the testing of TALE-based approaches, 
it will be crucial to deliver these custom-designed proteins not only into transformed cell 
types but also into more relevant, chromosomally stable, primary cells. Viral vectors are 
among the most effective gene transfer vehicles. Here, we investigated the capacity of 
lentiviral and adenoviral vectors to package and deliver functional TALEN genes into various 
human cell types. To this end, we attempted at assembling particles of these two vector 
classes, each of which encoding a monomer of a TALEN pair targeted to a bipartite sequence 
within the AAVS1 “safe harbor” locus. Vector DNA analyses revealed that adenoviral vectors 
transferred intact TALEN genes, whilst lentiviral vectors failed to do so, as shown by their 
heterogeneously sized proviruses in target cells. Importantly, adenoviral vector-mediated 
TALEN gene delivery resulted in site-specific DSB formation at the intended AAVS1 target 
site at similarly high levels in both transformed and nontransformed cells. In conclusion, we 
demonstrate that adenoviral, but not lentiviral, vectors constitute a valuable TALEN gene 
delivery platform. 
Key words: Viral vectors, TALE nuclease, double-stranded DNA breaks, genome editing. 
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INTRODUCTION
The ability to design DNA-binding motifs that recognize pre-defined sequences of choice 
within complex eukaryotic genomes is opening a wide range of basic and applied research 
possibilities that involves the modulation of endogenous gene expression and chromosomal 
DNA editing. The latter aim has been mostly pursued by designing zinc-finger nucleases 
(ZFNs) comprising a sequence-specific array of synthetic zinc-finger motifs fused to the 
nuclease domain of the type IIS restriction endonuclease FokI (1,2). In addition, the recoding 
of natural homing endonucleases for heritable genome modification purposes has also been 
undergoing intense investigation (3,4). These artificial enzymes are tailored to generate 
double-stranded DNA breaks (DSBs) at pre-defined genomic sequences. As a consequence 
of their activity, targeted gene knock-out or chromosomal insertion of exogenous DNA can 
ensue following the activation and engagement of the error-prone non-homologous end-
joining (NHEJ) or the error-free homologous recombination (HR) DNA repair pathways, 
respectively. 
The recent discovery of the rules governing the recognition of specific DNA sequences 
by bacterial transcription activator-like type III effectors (TALEs) (5,6) has translated in a 
novel and straightforward methodology to construct proteins with customized DNA binding 
specificities. TALEs are proteins found in phytopathogenic bacteria of the genus Xanthomonas, 
whose main well-established function is to induce expression of specific host plant genes 
that enhance virulence. TALEs comprise an N-terminal translocation domain, a central region 
of tandem direct repeats that confers DNA binding specificity and a nuclear localization 
motif preceding a C-terminal transcriptional activation domain (7). The DNA binding domain 
of TALEs displays a unique architecture composed of a tandem array of typically 15.5 to 19.5 
repeat units with circa 34 residues each (7). Often, the only distinguishing feature among 
the different repeats is a 2-amino acid hypervariable polymorphism at positions 12 and 
13 dubbed “repeat-variable di-residue” (RVD). Crucially, it has been discovered that each 
individual RVD dictates the binding of the repeat in which it is embedded to a single nucleotide 
(5,6). Therefore, this one repeat to one nucleotide code directly establishes a simple rule 
governing TALE-DNA interactions. This insight combined with the modular nature of the 
DNA binding domain, is permitting researchers to harness TALE-derived repeats as custom-
made scaffolds on which to assemble functional heterologous domains. Hitherto, designer 
TALEs tested in vitro and in cellula have included those with transcriptional activation or 
FokI nuclease domains (8,9). The latter, called TALE nucleases (TALENs) operate similarly to 
ZFNs in that a pair is assembled at a given DNA sequence consisting of two half-target sites 
separated by a spacer sequence (10). The directional binding of each TALEN monomer to its 
respective half-target site induces dimerization of the FokI portions resulting in site-specific 
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indications that binding of an individual TALE repeat to its cognate base pair is altered by 
neighboring sequences. This context-independent feature combined with the simple DNA 
binding code suggests that, when compared to ZFNs, TALENs can bind a wider range of DNA 
sequences and be programmed in an easier and more predictable manner. Moreover, the 
ability to construct functionally viable TALEN pairs with relatively large arrays of repeats has 
the potential to render them more specific than ZFNs. 
Thus far, nucleic acids encoding TALENs have been introduced into cells by nucleic acid 
microinjection or by transfection methods based on chemical agents or electroporation 
(8,9,12-14). Unfortunately, these methods suffer from low throughput or are too cytotoxic or 
too inefficient in populations of non-transformed cells. Notably, the therapeutic application 
and the thorough assessment of the genome-wide TALEN specificity, for instance, will be 
dependent on highly efficient TALEN delivery systems into relevant karyotypically stable 
cells. In the realm of biomedical research this will include tissue-specific stem and progenitor 
cells. From the broad variety of methods to introduce foreign nucleic acids into cells, viral 
vectors have proven to be the most effective thus far. In particular, vectors derived from the 
double-stranded linear DNA human adenovirus serotype 5 and from the single-stranded 
positive-sense RNA lentivirus human immunodeficiency type 1 (HIV-1) have become broadly 
used (15,16). Due to the infection mechanisms evolved by their parental viruses (17,18), 
adenoviral and lentiviral vectors are particularly fit for the in vitro and in vivo transduction 
of dividing and non-dividing cells. In the current study, we investigated the suitability of 
these two major vector classes as delivery vehicles of TALEN sequences. We report that, in 
contrast to lentiviral vectors, adenoviral vectors can package and deliver functional TALEN-
encoding expression units into transformed, immortalized and primary human cells. 
MATERIALS AND METHODS
Cells
The 293T and HeLa cells (American Type Culture Collection) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM; Invitrogen). The medium used for the culturing of the 
former and latter cell types was supplemented with 10% and 5% fetal bovine serum (FBS; 
Invitrogen), respectively. The adenoviral vector packaging cell lines PER.C6 (19) and PER.
E2A (20) were maintained in DMEM containing 10% FBS, 10 mM MgCl2 (Sigma-Aldrich) 
without and with 250 μg/ml Geneticin (Invitrogen), respectively. These cells were kept in a 
humidified-air 10% CO2 atmosphere. The human myoblasts were obtained from a Duchenne 
muscular dystrophy patient and were immortalized through constitutive expression of 
Bmi-1 and TERT. The generation of and culture conditions for these immortalized human 
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fetal mesenchymal stem cells (hMSCs) were cultured as previously specified (22). The human 
myoblasts and hMSCs were kept in a humidified-air 5% CO2 atmosphere.
Recombinant DNA
A TALEN pair (Supplementary Figure S1) targeting intron 1 of the PPP1R12C locus (AAVS1 
target site: 5’-TCTGTCCCCTCCACCCCAC-spacer-GACAGGATTGGTGACAGAA-3’) were 
generated by Golden Gate cloning, as previously described (9). To generate pAdShu.TALEN-
LS1.IRES.RFP and pAdShu.TALEN-RS1.IRES.RFP, plasmids 1383.pVAX.AAVS1.TALEN.L-94 and 
1384.pVAX.AAVS1.TALEN.R-95 were digested with Eco32I (Fermentas) and PmeI (New 
England Biolabs) and the resulting 3.0-kb TALEN open reading frame (ORF) fragment were 
isolated and ligated into the Eco32I-linearized 8.8-kb plasmid vector backbone pShuttle.
IRES.DsRedEx2.1. Cells transduced with vectors based on this construct can be traced 
and quantified via the encoded red fluorescent protein reporter DsRedEx2.1 (RFP). The 
firstgeneration (i.e. early region 1 [E1]-deleted) fiber-modified adenoviral vector molecular 
clones pAd.ΔE1.TALEN-LS1.F50 and pAd.ΔE1.TALEN-LS1.F50 (Figure 2A) were assembled by HR 
following transformation of E. coli cells BJ5183pAdEasy-1.50 (23) with shuttle plasmids pAdShu.
TALEN-LS1.IRES.RFP and pAdShu.TALEN-RS1.IRES.RFP, respectively, whilst the second-
generation adenoviral vector molecular clones pAd.ΔE1ΔE2A.TALEN-LS1.F50 and pAd.
ΔE1ΔE2A.TALEN-RS1.F50 (Figure 2A) were assembled by HR following transformation of E. 
coli cells BJ5183pAdEasy-2.50 (23) with shuttle plasmids pAdShu.TALEN-LS1.IRES.RFP and pAdShu.
TALEN-RS1.IRES.RFP, respectively. Prior to transformation all shuttle plasmids were digested 
to completion with MssI. The structure and composition of lentiviral vector constructs pLV.
TALEN-LS1.i.RFP, pLV.TALEN-RS1.i.RFP, pLV.TALEN-LS1 and pLV.TALEN-RS1 are described in Figure 
1A. The plasmid CMVPRES (24; herein referred to as pLV.CMV.eGFP) served as a negative 
control in the PCR amplifications of TALEN sequences.
Viral Vectors
The production of adenoviral vectors Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 took 
place in PER.C6 cells, whereas that of adenoviral vectors Ad.ΔE1ΔE2A.TALEN-LS1.F50 and 
Ad.ΔE1ΔE2A.TALEN-RS1.F50 occurred in PER.E2A cells. The rescue of vector particles was 
initiated by transfecting each of the PacI-linearized adenoviral vector molecular clones 
into their respective packaging cells by using a polyethyleneimine-based protocol (23). The 
procedures to propagate and purify the resulting viral vectors have been described elsewhere 
(23). Vector titers were determined through limiting dilutions on HeLa indicator cells 
seeded at a density of 0.8×105 cells per well of 24-well plates (Greiner). At three days post-
transduction, frequencies of RFP-positive cells were determined through flow cytometry by 
using a BD LSR II FACS (Becton Dickinson). As a result, the titers are expressed in terms of 
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glycoprotein-G (VSV-G)-pseudotyped lentiviral vectors were generated by transfecting 293T 
cells essentially as specified elsewhere (25) except for the use of 7.5×106 cells in T75-cm2 
flasks instead of 1.75×107 cells in T175-cm2 flasks. A total amount of 12.85 μg of DNA was 
transfected corresponding to 2:1:1 mixtures of lentiviral vector transfer plasmid, packaging 
construct psPAX2 (Addgene plasmid 12260) or psPAX2D116N (25) and VSV-G pseudotyping 
construct pLP/VSVG (Invitrogen). Lentiviral vector titers were determined by using HIV-1 
p24gag immunocapture (Perkin Elmer). 
Immunofluorescence microscopy
Fifty-thousand HeLa cells were seeded in wells of 24-well plates and, after an overnight 
incubation period, they were either mock-transduced or were transduced with Ad.ΔE1.
TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50 at 3 HTU/cell. Three days post-transduction, the 
cells were subjected to immunostaining essentially as described elsewhere (26) except for 
the use of an influenza hemagglutinin (HA)-specific mouse monoclonal IgG1 antibody (HA.11 
clone 16B12; Covance) together with a goat anti-mouse IgG (H+L) Alexa 488-conjugated 
secondary antibody (A-11001; Molecular Probes).
Western blot analysis
HeLa cells seeded at a density of 1×105 cells per well of 24-well plates (Greiner) were 
transduced with different amounts of Ad.ΔE1.TALEN-LS1.F50 or Ad.ΔE1.TALEN-RS1.F50. At 72 
hours post-transduction, the cell monolayers were rinsed with ice-cold phosphate-buffered 
saline (pH 7.4) and lysed in 100 μl of ice-cold RIPA buffer composed of 50 mM Tris-HCl (pH 
7.5), 150 mM NaCl, 0.1% sodium dodecyl sulphate (SDS), 0.5% sodium deoxycholate and 1% 
Nonidet P-40 plus a cocktail of protease inhibitors (Complete Mini, Roche Applied Science). 
Next, the cell lysates were spun at 4°C for 8 min at 16,400×g. The proteins were subjected to 
electrophoresis through an SDS-7.5% polyacrylamide gel after which they were transferred 
onto an Immobilon-P membrane (Millipore) by electroblotting overnight. After incubation 
with TBST blocking solution consisting of 10 mM Tris-HCl (pH 8.0), 150 mM NaCl and 0.2% 
Tween-20 supplemented with 10% non-fat dry milk powder (Elk, Campina), the membranes 
were incubated overnight at 4°C with the HA-specific monoclonal antibody F-7 (SC-7392, 
Santa Cruz Biotechnology) diluted 1:1000. Subsequently, the membranes were washed 
once with TBST at room temperature and subjected to a 3-hour incubation period with a 
horseradish peroxidase conjugated goat anti-mouse secondary antibody (SC-2005; Santa 
Cruz Biotechnology) diluted 1:5000 in blocking solution. Finally, the membranes were rinsed 
and processed for protein detection by chemiluminescence as described elsewhere (27). 
The Western blot analysis to detect TALEN expression following lentiviral vector 
transduction was performed as follows. Hundred-thousand HeLa cells were seeded in wells 
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of IDLV.TALEN-LS1 in the presence of polybrene (8 μg/ml). Forty-eight hours after transduction, 
the cells were harvested and total protein lysates were prepared as aforementioned. Fifty 
micrograms of protein were subjected to electrophoresis through a NuPAGE 4-12% Bis-Tris Gel 
(Invitrogen) and were transferred onto a nitrocellulose membrane (Hybond-ECL, Amersham) 
that was subsequently exposed overnight at 4°C to a mouse monoclonal antibody against 
the HA-tag (clone 12CA5 a gift from Valeria Marigo). A horseradish peroxidase-conjugated 
goat anti-mouse secondary antibody (Amersham) was diluted 1:2000 in blocking solution. 
The proteins were detected by using a chemiluminescence labelling detection reagent 
(ECL; GE Healthcare Life Sciences). For protein loading normalization, the same membrane 
was stripped and incubated with a 2000-fold diluted mouse monoclonal antibody directed 
against β-actin (sc-81178, Santa Cruz Biotechnology). 
Isolation and structural analysis of adenoviral vector DNA
DNA was isolated from purified adenoviral vector particles as follows. To a 50-μl vector 
preparation aliquot it was added 12 μl of DNaseI buffer (130 mM Tris-HCl [pH 7.5], 1.2 mM 
CaCl2 and 50 mM MgCl2), 8 µl of DNaseI (10 mg/ml; Fermentas) and 50 µl of Milli-Q water 
(Millipore). This mixture was incubated for 30 min at 37°C, after which, the DNaseI was 
inactivated for 1 hour at 55°C after the addition of 2.4 μl of 0.5M EDTA (pH 8.0), 6 μl of 
10% SDS and 1.5 μl of a Proteinase K (21.4 mg/ml; Fermentas). Next, the vector DNA was 
purified by using the QIAEX II Gel Extraction Kit (Qiagen) and was eluted in 30 μl of 10 mM 
Tris-HCl (pH 7.8). After measuring its concentration with the aid of a Nanodrop (Thermo 
Scientific), the recovered DNA was subjected to BcuI (Fermentas) digestion and agarose gel 
electrophoreses (200 ng) and to PCR analyses (1 ng). The PCR amplifications were carried 
out with primers TALEN-Seq-F (5’-CCAGCTGCTGAAGATCGCCAAGC-3’) and TALEN-Seq-R 
(5’-CTATCCTGAGTGGAATTTCTGGC-3’) whose target sequences flank the TALEN DNAbinding 
motifs. The DNA samples were subjected to PCR with 0.4 μM of these primers (Eurofins 
MWG Operon), 0.1 mM of each dNTP (New England Biolabs), 1× Colorless GoTaq Flexi 
buffer, 1 mM MgCl2 and 2.5 units of GoTaq DNA polymerase (all from Promega). The PCR 
cycles were performed in a DNA Engine Tetrad 2 Peltier Thermal Cycler (Bio-Rad) using the 
following cycling parameters. After a 3-min denaturation step at 95°C, the samples were 
subjected to 30 cycles consisting of 30 s at 95°C, 30 s at 60°C and 4 min at 72°C. The reactions 
were terminated by a final elongation period of 3 min at 72°C. One-fifth of these reactions 
were subjected to electrophoresis through 1% agarose gels in 1× TAE buffer. Moreover, to 
establish the integrity of TALEN sequences in adenoviral vector particles at the nucleotide 
level, the 2.4-kb BcuI fragments from Ad.ΔE1.TALEN-LS1.F50 or from Ad.ΔE1.TALEN-RS1.F50 DNA 
were inserted into a XbaI-linearized pUC19 backbone and were sequenced by using M13-F 
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Surveyor nuclease S mutation detection assay
Genomic DNA was extracted from mock-transduced or adenoviral vector-transduced target 
cells as described before (28). Briefly, at 72 hours post-infection, the cells were collected by 
trypsinization and incubated overnight at 55°C in 500 µl of lysis buffer (100 mM Tris-HCl [pH 
8.5], 5 mM EDTA, 0.2% SDS, 200 mM NaCl) supplemented with freshly-added Proteinase 
K at a final concentration of 100 ng/ml. Next, the cell lysates were extracted twice with 
a buffersaturated phenol:chloroform:isoamyl alcohol mixture (25:24:1) and once with 
chloroform. The DNA in the aqueous phase was precipitated by the addition of 2.5 volumes 
of absolute ethanol and 0.5 volumes of 7.5 M ammonium acetate (pH 5.5). After washing 
with 70% ethanol, the DNA pellet was mildly dried and dissolved in 100 μl of TE buffer (10 
mM Tris-HCl [pH 8.0] and 1mM EDTA) supplemented with RNase A (Fermentas) at a final 
concentration of 100 μg/ml.
The recovered DNA was used for PCR analyses. The extent of AAVS1 processing by the 
error-prone NHEJ DNA repair pathway was evaluated by using the Surveyor assay (SURVEYOR 
Mutation Detection Kit, Transgenomics) according to the manufacturer’s instructions. In brief, 
genomic DNA purified from mock-transduced or adenoviral vectortransduced cells was used 
as a template to PCR amplify a 469-bp AAVS1 sequence flanking the TALEN pair target site. 
PCR mixtures contained 0.4 μM of primers AAVS1-CEL1-F (5’-TTCGGGTCACCTCTCACTCC-3’) 
and AAVS1-CEL1-R (5’-GGCTCCATCGTAAGCAAACC-3’), 0.1 mM of each dNTP, 1× Colorless 
GoTaq Flexi buffer, 1mM MgCl2 and 2.5 units of GoTaq DNA polymerase. The PCR cycles were 
performed using the following cycling conditions. An initial denaturation step at 95°C for 5 
min was followed by 40 cycles of 30 s at 95°C, 30 s at 61°C and 30 s at 72°C. The reactions 
were terminated by a final elongation period of 5 min at 72°C. The PCR products, after 
being heat-denaturated and re-annealed according to the manufacturer’s specifications, 
were treated with the nucleotide mismatch-sensitive Surveyor nuclease S (SNS) enzyme 
in order to detect small insertions and deletions (indels) caused by NHEJ-dependent DNA 
repair. Samples were loaded on a 1.7% agarose gel and electrophoresis was performed in 
1× TAE buffer. The DNA was visualized by in-gel staining with 2 µg/ml of ethidium bromide 
(Sigma-Aldrich) in 1× TAE buffer followed by stain removal in Milli-Q water. The frequencies 
of target DNA cleavage were determined by using the ImageJ software (National Institutes 
of Health, USA). Genomic DNA derived from hMSC cells co-transduced with a 1:1 mixture 
of Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 at a total multiplicity of infection (MOI) of 
24 HTU/cell, served as template to PCR amplify the AAVS1 target site region. The pGEM-T 
Easy TA cloning vector (Promega) was ligated to the resulting 469-bp amplicons and was 
transformed into E. coli strain DH5α. Plasmid DNA from 20 randomly selected colonies was 
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PCR analyses of TALEN sequences following lentiviral vector-mediated gene transfer
Total cellular DNA from HeLa cells incubated with integration-competent or integrase-
defective lentiviral vectors (IDLVs) was isolated as specified elsewhere (28). The recovered 
DNA was subjected to three different PCR protocols. To determine the integrity of the cellular 
DNA, a PCR targeting the human housekeeping gene hypoxanthine phosphoribosyltransferase 
1 (HPRT1) was performed. To this end, reactions containing 0.4 μM of primers hHPRT.1 and 
hHPRT.2 (29), 0.1 mM of each dNTP, 1× Colorless GoTaq Flexi buffer, 1mM MgCl2 and 2.5 
U of GoTaq DNA polymerase, were assembled. The PCR cycles were performed using the 
following cycling conditions. An initial denaturating step at 95°C for 5 min was followed by 
30 cycles of 30 s at 95°C, 30 s at 60°C and 120 s at 72°C.
A second set of PCR mixtures were assembled to amplify a 458-bp TALEN sequence 
corresponding to the N-terminal, non-repetitive region, of each nuclease. These 
consisted of 0.4 μM of primers TAL-N.s (5’-CCTTACGACGTGCCTGACTACG-3’) and TAL-N.
as (5’-CGCTTGGCGATCTTCAGC-3’), 0.1 mM of each dNTP, 1× Colorless GoTaq Flexi buffer, 
1mM MgCl2 and 2.5 U of GoTaq DNA polymerase. The PCR cycles were performed using the 
following cycling conditions. An initial denaturating step at 95°C for 5 min was followed by 
30 cycles of 30 s at 95°C, 30 s at 62°C and 30 s at 72°C. 
Finally, the third PCR set was designed to amplify a 2.5-kb TALEN sequence encompassing 
the region encoding the repetitive DNA-binding domain of each nuclease. To this end, 
reactions containing 0.4 μM of primers CMV-prom.F (5’-AATGGGCGGTAGGCGTGTA-3’) and 
TALE.as.Pr2 (5’-GTCGGGTCTGCTCAGCTG-3’), 0.1 mM of each dNTP, 1× Colorless GoTaq Flexi 
buffer, 1mM MgCl2 and 2.5 U of GoTaq DNA polymerase, were assembled. The PCR cycling 
parameters consisted of an initial denaturating step at 95°C for 5 min followed by 40 cycles 
of 30 s at 95°C, 30 s at 60°C and 180 s at 72°C. In all three protocols, the PCR amplifications 
were terminated by a final elongation period of 5 min at 72°C. Control samples subjected 
to the same PCR conditions were carried out in parallel. These controls consisted of using, 
in place of DNA from lentiviral vector-transduced HeLa cells, DNA from mocktransduced 
HeLa cells, DNA from Ad.ΔE1.TALEN-RS1.F50 -transduced HeLa cells, pAd.ΔE1.TALEN-LS1.F50, 
pLV.CMV.eGFP or MilliQ water. Additional controls were provided by PCR amplifications on 
DNA isolated from HeLa cells exposed to an LV.TALEN-RS1 preparation made with the aid of 
pUC19 instead of the lentiviral vector packaging construct psPAX2 (Addgene plasmid 12260) 
or on DNA extracted from cells transfected with pLV.TALEN-RS1 transfer plasmid mixed or not 
mixed with ExGen500 (Fermentas).
Southern blot analysis
Total cellular DNA from 4×105 hMSCs exposed to three different MOIs of Ad.ΔE1.TALEN-
LS1.F50 or of Ad.ΔE1.TALEN-RS1.F50 was extracted 72 hours post-transduction and purified 
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DNA per sample was resolved in a 1% agarose gel in 1× TAE buffer. Next, the DNA was 
transferred by capillary action onto an Amersham Hybond-XL membrane (GE Healthcare Life 
Sciences) using a standard Southern blot technique. A 397-bp probe specific for TALEN DNA 
corresponding to the N-terminal region of the nucleases was isolated by digestion of 1383.
pVAX.AAVS1.TALEN.L-94 with XbaI and PstI (both from Fermentas) and was purified with 
the aid of the QIAEX II gel extraction kit (Qiagen). This DNA probe was radiolabelled with 
EasyTide (α-32P) dCTP (3000 Ci/mmol; Perkin Elmer) by using the DecaLabel DNA labelling 
system (Fermentas). Prior to its addition onto the membrane, the radiolabeled fragment 
was separated from unincorporated dNTPs through size-exclusion chromatography with the 
aid of Sephadex-50 columns (GE Healthcare Life Sciences). A Storm 820 PhosphorImager 
(Amersham) as used for the detection of the probe-hybridizing DNA. Finally, images were 
acquired and processed by using the Storm scanner control 5.03 and the ImageQuant Tools 
3.0 software, respectively (both from Amersham). 
HeLa cell clones were derived from an LV.TALEN-LS1-transduced population by limiting 
dilution using a seeding density of 0.3 cells per well in 96-well plates. Southern blot analysis 
of genomic DNA extracted from various HeLa cell clones was performed as follows. Genomic 
DNA was extracted from 5×106 cells from each clone using a QIAamp DNA Mini Kit according 
to the manufacturer’s instructions (Qiagen). Ten micrograms of genomic DNA was digested 
overnight with AflII (New England Biolabs), subjected to electrophoresis through a 0.8% 
agarose gel and was transferred onto a Hybond-XL nylon membrane. Prior to DNA detection, 
this membrane was incubated with a (α-32P)-labelled 814-bp probe corresponding to the 
lentiviral vector LTR elements R and U5, the packaging signal and part of the Rev-responsive 
element (RRE).
RESULTS
Lentiviral vectors introduce rearranged TALEN genes into human cells
We started by investigating the feasibility of generating lentiviral vectors to deliver 
TALENencoding expression units into human cells. Although the long-term presence of 
artificial nucleases in cells is, clearly, undesirable in most experimental settings, lentiviral 
vectors can be made with in-built stringent drug-controllable transgene expression 
systems (30) or class I integrase mutant moieties (31,32). These integrase mutations are 
non-pleiotropic as they confer an integration-defective phenotype to the vectors by 
specifically disabling the chromosomal insertion step of their DNA. IDLVs are, therefore, 
being increasingly exploited to deliver transgenes whose expression is only required during 
a short timeframe in populations of cycling cells. Examples include IDLV-mediated delivery 
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Therefore, we constructed the transfer plasmids pLV.TALEN-LS1 and pLV.TALEN-RS1 to 
package the lentiviral vector pairs LV.TALEN-LS1/IDLV.TALEN-LS1 and LV.TALEN-RS1/IDLV.TALEN-
RS1, respectively. These constructs encode a TALEN enzyme (i.e., TALEN-LS1 or TALEN-RS1) 
specific for the AAVS1 locus at the human chromosome 19 (19q13.42-qter). Moreover, 
we also constructed pLV.TALEN-LS1.i.RFP and pLV.TALEN-RS1.i.RFP to make lentiviral vector 
particles carrying bicistronic cassettes encoding TALEN-LS1 and TALEN-RS1, respectively, and 
through an IRES, the RFP reporter. To investigate the integrity of vector genomes in target 
cells we carried out transduction experiments on HeLa cells deploying the lentiviral vector 
set harboring the TALEN-RS1 ORF. Following DNA extraction from vectortransduced cells, we 
set-up a PCR assay (Figure 1A) based on the use of primer pairs framing the repeats of the 
TALEN ORF and its upstream region encoding the nuclease’s N-terminus (CMVprom. F/TALE.
as.Pr2) or targeting exclusively the latter segment (TAL-N.s/TAL-N.as). PCR amplifications 
with primers CMV-prom.F and TALE.as.Pr2 on DNA extracted from HeLa cells transduced 
with LV.TALEN-RS1, IDLV.TALEN-RS1 or LV.TALEN-RS1.i.RFP did not yield detectable levels of 2.5-
kb amplicons diagnostic for full-length TALEN-RS1 sequences (Figure 1B, upper panels, lanes 
5, 6 and 11, respectively). In fact, in these samples, the only PCR products that could be 
discerned were those consistent with heterogeneously sized sub-genomic templates whose 
molecular-weight range spanned from about 0.8 to 1.5 kb. Significantly, PCR amplifications 
carried out on the same DNA templates with primers TAL-N.s and TAL-N.as, gave rise to 
properly-sized 0.46 kb PCR products indicating that the non-repetitive upstream portion 
of the TALEN-RS1 ORF did not suffer major rearrangements in transduced cells (Figure 4B, 
middle panels). Of note, equivalent results were obtained in complementary transduction 
experiments that made use of the lentiviral vector set carrying the TALEN-LS1 ORF (not 
shown). To validate these data, PCR amplifications were done in parallel on control samples. 
These negative and positive controls consisted of water (Figure 1B, lane 4) or DNA extracted 
from mock-transduced HeLa cells (Figure 1B, lane 1), Ad.ΔE1.TALEN-RS1.F50-transduced HeLa 
cells (Figure 1B, lane 10), plasmid pAd.ΔE1.TALEN-LS1.F50 (Figure 1B, lane 2) or plasmid pLV.
CMV.eGFP (Figure 1B, lane 3). Additional controls consisted of PCR amplifications on DNA 
isolated from HeLa cells exposed to an LV.TALEN-RS1 preparation made with pUC19 instead 
of the lentiviral vector packaging construct psPAX2 (Figure 1B, lane 7) or incubated with 
plasmid pLV.TALEN-RS1 mixed or not mixed with the DNA transfection agent ExGen500 (Figure 
1B, lanes 8 and 9, respectively). PCR amplifications targeting HPRT1 served as a control for 
DNA template integrity (Figure 1B, lower panels). 
To complement these PCR results on whole target cell populations, we carried out 
Southern blot analysis on genomic DNA from individual HeLa cell clones derived from a bulk 
population transduced with LV.TALEN-LS1. To this end, the chromosomal DNA from 15 clones 
was digested with AflII, Southern blotted and incubated with the probe depicted in Figure 
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was subjected to the same procedures. Results depicted in Figure 1C demonstrate that none 
of the tested clones yielded the AflII 6.4-kb fragment diagnostic for full-length LV.TALEN-LS1 
proviruses. 
Finally, we investigated through HA tag-directed Western blot analysis, TALEN-LS1 
expression following addition of 200 ng of p24gag of LV.TALEN-LS1 or 400 ng of IDLV.TALEN-LS1 
onto HeLa cultures. These experiments failed to show detectable levels of HA-specific signals 
in protein lysates corresponding to vector-transduced cells, whilst HA-specific signals at a 
molecular-weight consistent with full-length TALEN-LS1 proteins could be readily detected 
in control lysates derived from pLV.TALEN-LS1-transfected HeLa cells or 293T producer cells 
(Figure 1D). To serve as controls for assembly of LV.TALEN-LS1 or IDLV.TALEN-LS1 particles, 
we produced in parallel LV and IDLV vector preparations carrying a human PGK1 promoter-
driven eGFP reporter (LV.PGK.eGFP and IDLV.PGK.eGFP, respectively). Exposure of HeLa 
cell cultures to 200 ng of p24gag of LV.PGK.eGFP or to 400 ng of IDLV.PGK.eGFP led to the 
transduction of 97% and 83% of the target cells, respectively (not shown). 
Taken together, these data indicate that TALEN sequences introduced into human cells 
through lentiviral vectors are prone to extensive rearrangements resulting presumably from 
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Figure 1. Structural analyses of lentiviral vectors harboring TALEN sequences in transduced cells. (A) 
Genetic organization of lentiviral vector constructs. Diagram of bicistronic pLV.TALEN-LS1.i.RFP and 
pLV.TALEN-RS1.i.RFP and of monocistronic pLV.TALEN-LS1 and pLV.TALEN-RS1 lentiviral vector transfer 
plasmids. The bicistronic constructs code for the AAVS1-specific custom-made nucleases TALEN-LS1 
or TALEN-RS1 and, through an IRES sequence, a RFP reporter, whereas the monocistronic plasmids 
encode exclusively the AAVS1-specific designer nucleases. Each of the TALEN proteins are tagged by 
an HA antigen located close to their N-termini (not drawn). Gray boxes with broken arrow, hybrid 5’ 
long-terminal repeat (LTR) containing CMV and HIV-1 sequences; gray boxes without broken arrow, 
selfinactivating (SIN) 3’ LTR; Ψ, HIV-1 packaging signal; RRE, Rev-responsive element; cPPT, central 
polypurine tract; WPRE, Woodchuck hepatitis virus posttranscriptional regulatory element. In pLV.
TALEN-LS1.i.RFP and pLV.TALEN-RS1.i.RFP the ORFs are under the transcriptional control of the CMV 
promoter and the polyadenylation signal present within the SIN 3’ LTR, whilst the ORFs in pLV.TALEN-
LS1 and pLV.TALEN-RS1 are under the control of the CMV promoter and the bovine growth hormone 
polyadenylation signal (bGH). Primers, PCR products and Southern blot probe used are depicted as 
half-arrows, black bars and gray bar, respectively, and are drawn in relation to their respective vector 
DNA sequences. For the sake of simplicity, plasmid backbone sequences are not show. The sizes of the 
PCR products expected from the amplification of full-length lentiviral vector genomes are indicated. 
The 6.4-kb AflII restriction fragment corresponding to intact DNA from LV.TALEN-LS1 or LV.TALEN-RS1 
is also indicated. (B) Expression analysis. PCR analyses of TALEN-encoding lentiviral vector genomes 
following transduction of HeLa cells. PCR amplifications with the aid of the primers shown in Figure 1A 
were carried out using, as template, total cellular DNA from mocktransduced HeLa cells, plasmid pAd.
ΔE1.TALEN-LS1.F50, plasmid pLV.CMV.eGFP or nuclease-free H20 (lanes 1, 2, 3 and 4, respectively). PCR 
amplifications using the same primer pairs were performed in parallel on DNA extracted from HeLa 
cells transduced with integrationcompetent LV.TALEN-RS1 (lane 5), integrase-defective IDLV.TALEN-RS1 
(lane 6), Ad.ΔE1.TALEN-RS1.F50 (lane 10) or integration-competent LV.TALEN-RS1.i.RFP (lane 11). Extra 
PCR controls supplementing those corresponding to lanes 1 through 4, were provided by using DNA 
isolated from HeLa cells exposed to an LV.TALEN-RS1 preparation made in parallel but deploying pUC19 
instead of lentiviral vector packaging construct psPAX2 (lane 7) or incubated with pLV.TALEN-RS1 mixed 
or not mixed with the DNA transfection agent ExGen500 (lanes 8 and 9, respectively). Lane M, Gene 
Ruler DNA Ladder Mix. A primer pair targeting the human HPRT1 served to control the integrity of the 
cellular DNA. (C) Clonal analysis. Southern blot analysis of AflII-digested genomic DNA from HeLa cell 
clones 1 through 15 stably transduced with LV.TALEN-LS1. The vector-specific probe that was used is 
shown in Figure 1A (horizontal gray bar). Lane M, 1 Kb molecular-weight marker. The parental transfer 
plasmid pLV.TALEN-LS1 treated with AflII served as an internal control for intact vector DNA. (D) TALEN 
protein detection. HA tag-directed Western blot analysis of full-length TALEN-LS1 expression in 293T 
producer cells (lane 1), IDLV.TALEN-LS1- and LV.TALEN-LS1-transduced HeLa cells (lane 2 and lane 4, 
respectively) and in pLV.TALEN-LS1-transfected 293T cells used to generate these IDLV.TALEN-LS1 and 
LV.TALEN-LS1 vector preparations (lanes 3 and 5, respectively). Lane 6, HeLa cells transfected with pLV.
TALEN-LS1. The β-actin served as loading control.

Adenoviral vectors deliver full-length TALEN genes into human cells inducing high-level 
DSB formation at an endogenous chromosomal target locus
In light of the previous results, we sought to investigate the feasibility of using adenoviral 
vectors as an alternative delivery platform for the introduction of intact TALEN genes into 
human cells. To this end, the full-length adenoviral vector molecular clones pAd.ΔE1.TALEN-
LS1.F50 and pAd.ΔE1.TALEN-RS1.F50 were assembled through HR in E. coli to produce the 
E1-deleted adenoviral vectors Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50, respectively 
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5, a bicistronic expression unit encoding a monomer of the AAVS1-specific TALEN pair and, 
for tracing and quantification purposes, the RFP reporter (Figure 2A). In addition, their 
adenoviral genomic sequences harbor an ORF coding for a vector retargeting chimeric fiber 
composed of serotype 5 basal shaft domains fused to apical shaft and knob domains derived 
from the species B adenovirus serotype 50 (F50). The latter CD46-interacting motif allows 
for entry of vectors displaying species B fiber domains into human cells lacking on their 
surface the Coxsackie B virus and adenovirus receptor, CAR. Of note, among these cells 
there are various therapeutically relevant tissue-specific normal and malignant stem and 
progenitor cell types (37-41). In addition, plasmids pAd.ΔE1ΔE2A.TALEN-LS1.F50 and pAd.
ΔE1ΔE2A.TALEN-RS1.F50 were also constructed to assemble fiber-modified E1- plus E2A-
deleted particles Ad.ΔE1ΔE2A.TALEN-LS1. F50 and Ad.ΔE1ΔE2A.TALEN-RS1.F50, respectively 
(Figure 2A). By virtue of their lack of E2A, these so-called second-generation adenoviral 
vectors have been shown to display a muchreduced de novo replication and “leaky” viral 
gene expression profile in target cells when compared to their E1-deleted, first-generation, 
counterparts (see, for instance, ref. 20).
We started by testing whether TALEN sequences are stably maintained in first- and 
second-generation adenoviral vectors following their rescue and subsequent propagation 
on their respective packaging cell lines. Thus, these producer cells were transfected with 
PacI-treated plasmids pAd.ΔE1.TALEN-LS1.F50, pAd.ΔE1.TALEN-RS1.F50, pAd.ΔE1ΔE2A.TALEN-
LS1.F50 or pAd.ΔE1ΔE2A.TALEN-RS1.F50 to assemble the corresponding adenoviral vector 
particles (Figure 2A). The rescued particles were subsequently amplified following serial 
propagation on increasing amounts of packaging cells. The frequency of RFP-positive 
producer cells, as monitored by direct fluorescence microscopy, revealed a clear propagation 
round-dependent increase in vector yields (not shown). The Ad.ΔE1.TALEN-LS1.F50 and 
Ad.ΔE1.TALEN-RS1.F50 vectors, corresponding to two independent batches, were purified 
through CsCl buoyant density gradient ultracentrifugation, after which, the integrity of their 
genomes was probed by BcuI restriction fragment length analysis. To serve as an additional 
molecular-weight reference, the parental plasmids pAd.ΔE1.TALEN-LS1.F50 and pAd.ΔE1.
TALEN-RS1.F50 were taken along in this analysis. Results depicted in Figure 2B show that 
the overall DNA restriction pattern is consistent with that expected from linear full-length 
adenoviral vector genomes (Figure 2A). Thus, importantly, the internal TALE-encompassing 
restriction fragments derived from Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 DNA 
did co-migrate with those corresponding to their respective 2.4-kb parental plasmid 
counterparts (Figure 2B, arrowheads). Results equivalent to these were obtained following 
the structural analyses of DNA isolated from Ad.ΔE1ΔE2A.TALEN-LS1.F50 and Ad.ΔE1ΔE2A.
TALEN-RS1.F50 (Supplementary Figure S2). Next, we performed a more sensitive PCR-based 
assay using primers bracketing the 17.5 repeats of TALEN-LS1 and TALEN-RS1 to search for 
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pAd.ΔE1.TALEN-LS1.F50 and pAd.ΔE1.TALEN-RS1.F50 served as control DNA templates. This 
assay led to the detection of 2.1-kb amplicons whose size is diagnostic for vector DNA 
genomes harboring intact TALEN-encoding genes (Figure 2C). Moreover, Southern blot 
analysis of extrachromosomal DNA isolated from hMSCs exposed to different amounts of 
Ad.ΔE1.TALEN-LS1.F50 or Ad.ΔE1.TALEN-RS1.F50 also led to the sole detection of full-length 
TALEN sequences in the transduced cells (Figure 2D). Finally, we cloned into pUC19 the 
2.4-kb DNA species from BcuI-treated Ad.ΔE1.TALEN-LS1.F50 or BcuI-treated Ad.ΔE1.TALEN-
RS1.F50 and sequenced the inserts from six individual clones. DNA sequence information 
corresponding to the 7 most downstream and to the 3 to 4 most upstream TALEN repeats 
could be retrieved (Supplementary Figure S3). The nucleotide sequences analyzed revealed 
to be isogenic to that in the parental constructs with no evidence for point mutations, local 
rearrangements and/or deletions. 
Transduction experiments deploying Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 
alone or mixed together were carried out on CAR-positive human cervix carcinoma HeLa cells 
(42) and on two CAR-negative cell types, namely, immortalized myoblasts from a Duchenne 
muscular dystrophy (DMD) patient and hMSCs (42,43). The use of relatively modest MOIs 
was sufficient to transduce most target cells in the various cultures (Figure 3A). Importantly, 
HA tag-specific immunofluorescence microscopy and Western blot analyses (Figure 3B and 
3C, respectively) demonstrated the expression of TALEN-LS1 and TALEN-RS1 genes in target 
HeLa cells following their transduction with Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.
F50, respectively. Taken together, we conclude that first-generation adenoviral vectors can 
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Figure 2. Structural analysis of TALEN-encoding adenoviral vector genomes. (A) DNA structures of 
the first-generation adenoviral vectors Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 and of the 
second-generation adenoviral vectors Ad.ΔE1ΔE2A.TALEN-LS1.F50 and Ad.ΔE1ΔE2A.TALEN-RS1.F50 drawn 
in relation to those of their respective plasmid clones. The adenoviral vector and shuttle plasmid 
DNA templates are depicted as BcuI physical maps with numerals specifying the different restriction 
fragment sizes in kilobases (kb). These DNA molecules harbor a bi-cistronic expression unit coding 
for the AAVS1-specific artificial nucleases TALEN-LS1 or TALEN-RS1 and, through an IRES sequence, a 
RFP reporter. The open reading frames are under the transcriptional control of the cytomegalovirus 
immediate-early gene promoter (CMV) and the simian virus 40 (SV40) polyadenylation signal. The 
central region of TALEN-LS1 and TALEN-RS1 encode a tandem of 17.5 TALE repeats that define specificity 
to the AAVS1 target sequence at the human chromosome 19 (19q13.42-qter). C-terminally both 
TALENs contain the non-specific cleavage domain of FokI, whose catalytic activity is contingent upon 
DNA binding-dependent dimerization. Each of the TALEN proteins are tagged by an HA antigen located 
close to their Ntermini (not drawn). The thick and thin lines represent adenoviral vector and plasmid 
backbone sequences, respectively. Ψ, human adenovirus serotype 5 packaging signal; Ad L-ITR and Ad 
RITR, “left” and “right”, respectively, adenoviral inverted terminal repeat. F50, ORF encoding chimeric 
fiber composed of basal shaft domains from adenovirus serotype 5 fused to apical shaft and knob 
motifs from adenovirus serotype 50. The kanamycin-resistance gene (KanR) and the prokaryotic origin 
of replication (ori) are also indicated. (B) Restriction fragment length analysis of Ad.ΔE1.TALEN-LS1.
F50 and Ad.ΔE1.TALEN-RS1.F50 genomes treated with BcuI. Plasmids pAd.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.
TALEN-RS1.F50 served as a reference. The sizes (in kb) of the DNA restriction fragments resulting from 
the BcuI treatment are indicated on the left. The arrowhead points to the 2.4 kb DNA fragments 
diagnostic for intact, non-rearranged, TALE-derived DNA sequences within TALEN-encoding genes. 
Marker, molecular-weight marker Gene Ruler DNA Ladder Mix. (C) PCR analysis on DNA isolated 
from Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 particles using primers TALEN-Seq-F and TALEN-
Seq-R (F and R half arrows, respectively). These primers, drawn in relation to their respective target 
sequences, amplify most of the TALEN-LS1 and TALEN-RS1 DNA including the seventeen 102-bp tandem 
DNA repeats. The position (arrowheads) and size (in kb) of the 2.1-kb amplicon diagnostic for intact 
TALEN transgenes are indicated at the right. Marker, Gene Ruler DNA Ladder Mix. H20, PCR performed 
with nuclease-free water instead of vector DNA template. (D) Autoradiogram of MunI-treated 
extrachromosomal DNA isolated from HeLa cells transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.
TALEN-RS1.F50 at MOIs of 10, 5 and 1 HTU/cell. The DNA, extracted at three days post-transduction, was 
subjected to Southern blot analysis using a 397-bp probe hybridizing to a sequence encoding the NH2 

























































































































Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer  |  81
3
Finally, to investigate the functionality of TALENs introduced into human cells through 
adenoviral vector-mediated gene transfer, we deployed the Surveyor mutation detection 
assay (Figure 4A). PCR amplification of AAVS1 target DNA from mock-transduced cells or from 
cells transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50 yielded amplicons 
that, upon denaturation and reannealing, were not susceptible to site-specific cleavage by 
the mismatch-sensitive SNS enzyme (Figure 4B, solid arrowhead in the upper panel). This 
data validated the read-out system by demonstrating the absence of indels at the AAVS1 
locus under these experimental control conditions. However, co-transduction of HeLa cells 
and DMD myoblasts with Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 resulted in efficient 
cleavage of the endogenous chromosomal target sequence, as evidenced by the detection 
of large amounts of SNS-digested products (Figure 4B, open arrowheads in the lower 
panels). This conclusion was substantiated through vector dose-response experiments on 
HeLa cells, human myoblasts and hMSCs (Figure 4C). Additional transduction experiments 
on hMSCs that made use of the second-generation adenoviral vectors Ad.ΔE1E2A.TALEN-
LS1.F50 and Ad.ΔE1E2A.TALEN-RS1.F50 produced results similar to those shown in Figure 4C 
(Supplementary Figure S4). Finally, we sought to confirm the involvement of the NHEJ 
pathway in the repair of the TALEN-induced DSBs. To this end, we cloned the AAVS1-specific 
PCR products resulting from genomic DNA of hMSCs exposed to Ad.ΔE1.TALEN-LS1.F50 and 
Ad.ΔE1.TALEN-RS1.F50 at an MOI of 12 HTU/cell each. DNA sequencing of twenty randomly 
selected clones revealed that 12 of these harbored indels characteristic of NHEJ-mediated 
repair of DSBs (Figure 4D). 
We conclude that delivery of TALENs by first- and second-generation adenoviral vectors 
is a highly effective approach to generate in a cell type-independent manner site-specific 
DSBs at an endogenous human target locus. 
Figure 3. Adenoviral vector-mediated delivery of TALEN genes into transformed and nontransformed 
human cells. (A) Gene transfer efficiency. Upper panel, phase-contrast and live-cell RFP direct 
fluorescence microscopy on HeLa cells transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-
RS1.F50 at an MOI of 6 HTU/cell or with a mixture of the two adenoviral vectors at an MOI of 6 HTU/
cell each. Lower panel, RFP direct fluorescence microscopy on immortalized DMD myoblasts and on 
primary hMSCs transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50 at an MOI of 12 
HTU/cell or co-transduced with a 1:1 mixture of Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 at 
a total MOI of 24 HTU/cell. The fluorescence microscopy images were acquired at 48 hours post-
infection. (B) HA tag-specific immunofluorescence microscopy on HeLa cells mock-transduced or 
transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50 at an MOI of 3 HTU/cell. The direct 
fluorescence microscopy and the immunofluorescence microscopy were carried out at 48 and 72 
hours post-infection, respectively. (C) HA tag-directed Western blot analysis of protein lysates derived 
from HeLa cell cultures incubated for 72 hours with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50. 
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Figure 4. Targeted disruption of the chromosomal AAVS1 locus. (A) Schematic representation of the 
Surveyor mutation detection assay used to probe TALEN activity in human cells. Assembly of the 
TALEN pair at the bipartite target sequence results in local DSB formation. The errorprone NHEJ DNA 
repair pathway links the broken chromosomal ends introducing in the process small insertions and 
deletions (indels) at the junction (grey boxes). PCR on chromosomal DNA with primers framing the 
target site yields a mixture of amplicons representing the heterogeneous population of mutated 
sequences and non-modified alleles. Denaturation and re-annealing of this mixture results in DNA 
species with internal base pairs that are mismatched. The Surveyor nuclease S (SNS) enzyme, by 
preferentially recognizing and cleaving at DNA sequences with such mismatched base pairs, yields 
low-molecular-weight DNA fragments (open arrowheads) that can be resolved from undigested DNA 
(solid arrowheads) through conventional agarose gel electrophoreses. Parallel samples not treated 
with SNS (-) served as a negative control. (B) TALEN activity at AAVS1. Upper panel, Surveyor assay 
on chromosomal DNA isolated from HeLa cells not exposed (mock) or exposed to Ad.ΔE1.TALEN-LS1.
F50 or to Ad.ΔE1.TALEN-RS1.F50 at a high and a low dose (i.e. 6 and 2 HTU/cell, respectively). Lower 
panels, Surveyor assay on chromosomal DNA extracted from HeLa cells and DMD myoblasts (left and 
right panels, respectively). HeLa cells were mock-transduced (-) or were co-transduced with 6 HTU/
cell of Ad.ΔE1.TALEN-LS1.F50 and 6 HTU/cell of Ad.ΔE1.TALEN-RS1.F50 (+). Human myoblasts were mock-
transduced (-) or were co-transduced with 12 HTU/cell of Ad.ΔE1.TALEN-LS1.F50 and 12 HTU/cell of 
Ad.ΔE1.TALEN-RS1.F50 (+). Solid and open arrowheads indicate the positions of undigested and SNS-
digested DNA molecules, respectively. White numerals correspond to the percentage of target site 
cleavage. (C) Dose-response of TALEN activity. Surveyor assay on cellular DNA from HeLa cells, DMD 
myoblasts and hMSCs untreated or treated with different doses of 1:1 mixtures of Ad.ΔE1.TALEN-LS1.
F50 and Ad.ΔE1.TALEN-RS1.F50. In these dose-response co-transduction experiments the total amounts 
of vector applied on HeLa cells were 12, 4, 1.3, 0.4 and 0.15 HTU/cell, whereas on DMD myoblasts 
and hMSCs HTU/cell were 24, 8, 2.7, 1.0 and 0.3. Solid and open arrowheads indicate the positions 
of undigested and SNS-digested DNA molecules, respectively. White numerals correspond to the 
percentage of target site cleavage. (D) Sequence analysis. DNA sequencing of cloned AAVS1-specific 
amplicons resulting from PCR amplifications on genomic DNA isolated from hMSCs co-transduced with 
Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 at 12 HTU/cell each. The presence of indels in 12 out of 
20 clones, “footprint” for NHEJ processing of DSBs, demonstrates at the nucleotide level the TALEN-
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DISCUSSION
The approaches aiming at editing or modulating the expression of specific endogenous 
genes and targeting chromosomal insertion of exogenous DNA, have recently been enriched 
with the introduction of sequence-specific designer TALEs. To broaden the use of TALE-
based proteins and to most optimally screen and evaluate their performance in many 
settings, it will be crucial to expand the range of cellular delivery tools for these molecules. 
Despite their promise and favorable set of attributes when compared to other custom-made 
sequence-specific proteins, TALEs are relatively large proteins whose DNA binding specificity 
is governed by an extensive tract of repetitive sequences. However, DNA repeats are known 
to be particularly unstable motifs. Indeed, examples of both physiological and function-
impairing processes associated with instability of tandem repeats are copious and cover 
virtually all biological systems from viruses and prokaryotes to eukaryotes (44-46). Also 
in the context of gene delivery vehicles, such as those based on adenoviral and lentiviral 
vectors, examples exist pointing to certain repetitive sequence arrangements as the culprits 
behind DNA instability (47-50). Bearing this in mind, in the present study we sought to 
investigate the suitability of adenoviral and lentiviral vectors, two of the most commonly 
used viral vector systems, to serve as TALEN gene delivery platforms. 
We report that lentiviral vector genomes bearing TALEN sequences are prone to 
rearrangements in target cells. In this regard, the structural analyses of these genomes in 
HeLa cell populations and in individual HeLa cell clones by PCR and Southern blot analyses, 
respectively, suggest that most of the rearrangements occurred through recombination 
events involving the TALE repeat array ultimately leading to deletions with various sizes. 
Conversely, we found that TALEN sequences are stably maintained in first- and second-
generation adenoviral vectors following their serial propagation in producer cells. 
Indeed, the TALEN transgenes in the adenoviral vector genomes presented neither large 
rearrangements nor small-scale mutations as revealed by restriction fragment length analysis 
and DNA sequencing, respectively. Importantly, transduction experiments with the TALEN-
encoding adenoviral vectors led to DSB formation at the intended target chromosomal locus 
in transformed and non-transformed human cells at similarly high frequencies. 
Clearly, viruses from the Adenoviridae and Retroviridae families display diametrically 
different structural features, life cycles and replication strategies (15,51,52). The latter aspect 
in particular is likely to contribute to the disparate stability of TALEN ORFs in adenoviral versus 
lentiviral vectors. Adenoviruses replicate via a DNA strand-displacement mechanism using 
a virus-encoded high-fidelity DNA polymerase and a single-stranded DNA-binding protein 
that, by cooperatively coating the displaced single-stranded replicative intermediates, 
presumably inhibits spurious intramolecular hybridization (52,53). Retroviruses, on the 
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copy RNA genomes into linear double-stranded DNA templates that serve as substrates for 
proviral chromosomal insertion (51). The RTs of simple and complex retroviruses also display 
a RNase H activity responsible for the digestion of the RNA component of hybrid RNA:DNA 
duplex intermediates. Moreover, they share a low template affinity and processivity. These 
features seem to have evolved to allow RT to undergo at least two obligate template switching 
events (i.e. minus-strand and plus-strand DNA transfer) in order to complete full-length viral 
DNA synthesis and, as “byproduct”, generate genotypic diversity through recombination. It 
is known, however, that the presence of direct repeats in retroviral genomes increases the 
likelihood for additional inter- and intra-molecular template switching events, often resulting 
in the deletion of one of the repeats plus intervening sequences (47,48,54,55). In fact, the 
insertion of direct repeats in retroviral genomes provides for an elegant model system to 
study the RT template switching process in vivo or to induce precise rearrangements of cis- 
and trans-acting elements in retroviral vectors (54,56). Of note, the frequency of template 
switching increases with the size of and the distance between the direct repeat units. The 
latter finding suggests that spacing favors template “looping” which, in turn, aids in the 
intra-strand alignment of direct repeats, RT template switching and ensuing intra-molecular 
deletions (55). The models for these direct repeat-induced deletions (48,54,55) postulate 
that during reverse transcription, RT and the nascent DNA strand dissociates from the RNA 
template due to the aforementioned RNaseH activity and intrinsic low template affinity. 
Segments and, eventually, all nascent DNA strand hybridizes to the RNA template at the 
distal “acceptor” repeat serving as a novel “ectopic” initiation point for RNA-dependent 
DNA synthesis. The net result of these processes is often homogenously sized deletions of 
the retroviral genome. In contrast to simple direct repeat pairs, TALE sequences present a 
tract of numerous and contiguous repeats. Thus, each of these arrayed repeat units provide 
for multiple potential positions at which RT template switching may occur. This corollary is 
consistent with the heterogeneous and sub-genomic sized population of TALENcontaining 
lentiviral vector proviruses that were detected in stably transduced clones. 
Notwithstanding these findings, one can envision strategies that might minimize or 
overcome the instability of TALEN sequences in lentiviral vectors. For instance, by exploiting 
the degeneracy of the genetic code, the individual TALE motifs within the array could be 
reengineered by the introduction of judiciously chosen silent substitutions to increase 
sequence divergence among repeats. Regarding this issue, it has been shown via a lentiviral 
vector direct repeat deletion assay that deletion frequencies can decrease steeply with 
incremental repeat sequence divergence (57). 
In conclusion, TALEN sequences are prone to rearrangements following their introduction 
into human cells by lentiviral vectors. As a result, effective lentiviral vectormediated 
TALEN gene transfer will be dependent upon new optimization strategies. Conversely, we 
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transfer of full-length TALEN genes into human cells. Importantly, the resulting TALEN 
protein yields suffice to induce high-level DSB formation at an endogenous chromosomal 
target locus. 
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ABSTRACT
Transcription activator-like effector nucleases (TALENs) are designed to cut the genomic DNA 
at specific chromosomal positions. The resulting DNA double strand break activates cellular 
repair pathways that can be harnessed for targeted genome modifications. TALENs thus 
constitute a powerful tool to interrogate the function of DNA sequences within complex 
genomes. Moreover, their high DNA cleavage activity combined with a low cytotoxicity 
make them excellent candidates for applications in human gene therapy. Full exploitation 
of these large and repeat-bearing nucleases in human cell types will benefit largely from 
using the adenoviral vector (AdV) technology. The genetic stability and the episomal nature 
of AdV genomes in conjunction with the availability of a large number of AdV serotypes 
able to transduce various human cell types make it possible to achieve high-level and 
transient expression of TALENs in numerous target cells, regardless of their mitotic state. 
Here, we describe a set of protocols detailing the rescue, propagation and purification of 
TALEN-encoding AdVs. Moreover, we describe procedures for the characterization and 
quantification of recombinant viral DNA present in the resulting AdV preparations. The 
protocols are preceded by information about their underlying principles and applied in 
the context of second-generation capsid-modified AdVs expressing TALENs targeted to the 
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INTRODUCTION
Targeted genome engineering is based on the creation of double-stranded DNA breaks 
(DSBs) at predefined chromosomal positions, which activate DNA repair pathways such as 
non-homologous end-joining (NHEJ) or the homologous recombination (HR) machinery (1). 
The potential sphere of action of genome engineering is broad and includes the development 
of new molecular medicine modalities based on the addition of therapeutic genes at so-
called “safe harbor” loci or the correction of endogenous defective genes. Ultimately, such 
“genome surgery” should constitute a departure from conventional gene therapy, in which 
exogenous DNA is inserted at unpredictable chromosomal positions (2). 
Generically, genome editing strategies depend on the introduction of designer nucleases 
into target cells for inducing the site-specific DSBs (3). Designer nuclease technologies are 
evolving at a rapid pace and include zinc-finger nucleases (ZFNs), transcription activator-
like effector nucleases (TALENs) and, more recently, RNA-guided nucleases (RGNs) based on 
the prokaryotic CRISPR/Cas9 adaptive immune systems (4). While each of these platforms 
have their pros and cons, assessment of the specificities of ZFNs and RGNs revealed a 
considerable degree of off-target DNA cleavage (5-9). On the other hand, currently available 
data suggest that TALENs seem to be better tolerated in mammalian cells than ZFNs (10,11), 
although it is not clear yet whether “better tolerability” correlates with higher target site 
specificity, a key parameter in future therapeutic applications of genome editing protocols 
in patient-derived cells.
TALENs are easy to engineer heterodimeric designer nucleases that combine high 
cleavage activity with low cytotoxicity (12). The modularly structured DNA binding domain 
of transcription activator-like effectors (TALEs) was originally discovered in pathogenic 
bacteria of the genus Xanthomonas (13,14). Each repeat module within the DNA recognition 
domain consists of a conserved stretch of about 34 residues. The interaction with a single 
nucleotide of the DNA target site is mediated via two variable residues in positions 12 and 
13. Repeat modules with different specificities can be fused into tailored arrays to direct the 
non-specific FokI endonuclease domain to a predetermined target site (15,16).
Adenoviral vectors (AdVs) based on human adenoviruses (HAdVs) are widespread and 
versatile vehicles for introducing recombinant genes into human cells (17). Among these, 
those encoding immunomodulatory proteins or antigens are often selected as therapeutic 
payloads for anticancer and vaccination purposes (18). The broad use and adaptability 
of AdVs stem from several key features of their parental viruses as well as the extensive 
knowledge gathered on their biology since they were discovered in 1953 (19). 
Presently, over 50 human adenovirus serotypes have been identified and classified in 
various sub-groups or species (A to G). They are mildly pathogenic viruses consisting of 
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icosahedral capsid with fiber proteins protruding from each of its twelve vertices (17,18). 
The structural proteins are involved in host cell attachment by binding to specific cell surface 
receptors and can differ substantially among the various serotypes (20). As a result, the cell 
tropism of Adenoviridae family members can vary profoundly, owing in large part to their 
particular fiber-receptor interactions. For instance, under regular cell culture conditions, the 
prototypic species C serotypes 2 and 5 utilize the Coxsackievirus B and Adenovirus receptor 
(CAR) as primary cell surface attachment moiety (21), whereas CD46 is engaged by, amongst 
others, the species B serotypes 35 and 50 (22). An important feature of human adenoviruses 
is the similarity with which they infect diving and non-dividing cells. Indeed, the entry of 
viral genomes into host cell nuclei is independent of nuclear envelope integrity owing to the 
active process by which endosome-remodeled virions dock at the nuclear pore complex, 
disassemble and release their genomes into the nucleoplasm after having been transported 
in complex with dynein along the cytoplasmic microtubule network (23). Once in the 
nucleus, the orchestrated activation of the “early” (E) and “late” (L) viral gene expression 
programs yields large amounts of newly assembled mature particles. At the completion of 
the lytic viral life cycle, 103 to 104 virions are typically found within each host cell nucleus. 
The most common AdVs are based on the CAR-interacting prototypic HAdV serotype 
5 and are deleted in E regions whose products participate in viral DNA replication and/
or activate the viral gene expression program (17). In addition to disrupting the regular 
replication cycle in target cells, these deletions create space for the insertion of exogenous 
DNA. As a result, for their production, these vectors require packaging cell lines, expressing 
in trans the viral genes, which have been deleted in the AdV backbone. These types of AdVs 
are called helper-independent as they can be amplified autonomously in such specialized 
packaging cell lines. The simplest helper-independent AdV type lacks the viral early region 1 
(E1) and are thus called E1-deleted or first-generation AdVs. Notwithstanding the attributes 
of first-generation AdVs and their suitability for many different applications, it was shown 
that at high multiplicities of infection (MOI), the removal of E1 does not fully block expression 
of viral open reading frames (ORFs), presumably due to partially complementing E1A-like 
cellular functions (24). Albeit at low-levels, the ensuing de novo viral protein synthesis can 
hamper the optimal deployment of these AdVs in certain experimental settings, such as 
those involving the transduction of therapeutically relevant cell types. This has prompted 
the development of second-generation AdVs combining deletions in E1 with those in other 
E region(s), namely, early region 2A (E2A) and/or early region 4 (E4) (17). Of note, because 
the functions encoded in early region 3 (E3) are dispensable for vector propagation in cells 
cultured in vitro, first- and second-generation AdVs are often also deleted in E3. In addition 
to curtailing the phenomenon of “leaky” viral gene expression in target cells, propagation 
of second-generation AdVs is less likely to yield contaminating replication-competent AdVs 
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and commonly used producer-cell genomes (25). Clearly, the issue of RCA contamination 
is particularly relevant whenever AdV preparations are produced for therapeutic gene 
transfer protocols (26). For this reason, AdV packaging cell lines, such as PER.C6 and N52.E6, 
were designed without DNA sequence overlap between the recombinant portions of their 
genomes and AdV DNA (27,28).
The available in-depth knowledge about adenovirus capsid structure and gene regulation 
allows constructing AdVs with genomic modifications not only in E but also in L ORFs. For 
instance, genetic manipulation of the fiber-encoding L transcription unit 5 (L5) permits 
retargeting AdV particles to cells with low or no CAR on their surface. These transductional 
targeting strategies can be based on engineering capsids with heterologous ligands (29) 
or on tapping the natural diversity of HAdVs to create chimeric fibers displaying receptor-
interacting motifs derived from a serotype with a selected tropism of choice (29,30). This 
“fiber swapping” approach is based on exchanging the apical fiber motifs of serotype 5 
for those of another serotype, such as serotype 35 or serotype 50, and has proven to be 
very valuable for the transduction of therapeutically relevant CAR-negative cells. These cells 
include normal and malignant hematopoietic cells as well as myocytes and mesenchymal 
stromal cells (20,29,30).
We postulate that AdV technologies, besides their utility in established biomedical 
research areas such as oncology and vaccinology, will start playing an increasing role in 
the emerging field of genome engineering as well. In fact, AdV-mediated introduction of 
ZFNs into CD4+ T cells to knockout the HIV co-receptor gene CCR5, represents the first 
testing of a designer nuclease-based therapeutic strategy in humans (31). Related to 
this, our laboratories together with collaborators have recently demonstrated that AdVs 
can introduce functional TALEN ORFs into human cells (32). Importantly, the frequencies 
of targeted mutagenesis achieved by AdV-mediated TALEN expression were similar in 
transformed and non-transformed cells (32). In contrast, the same TALEN ORFs delivered 
in the context of conventional and integration-defective lentiviral vectors suffered from 
extensive function-impairing rearrangements within their repeat arrays, presumably due 
to frequent template switching of the reverse transcriptase (32). Yang and colleagues have 
subsequently confirmed these results by demonstrating that lentiviral vector-mediated 
delivery of intact TALEN ORFs requires substantial sequence optimization to reduce the 
length and frequency of repetitive sequences (33). These optimized TALENs were dubbed re-
coded TALENs. However, because there are precedents for the importance in achieving high 
yields of sequence-specific nucleases in target cells for robust site-specific DSB formation 
(34,35), AdVs might ultimately be preferable over silencing-prone IDLVs (36) for transient 
TALEN expression.
In the current article, we provide a set of protocols detailing the production and 
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procedures for the characterization and quantification of AdV genomes. These protocols 
are applied in the context of producing and validating a pair of second-generation fiber-
modified AdVs containing TALEN ORFs under the control of the house-keeping PGK1 gene 
promoter (PGK). The resulting TALEN proteins are addressed to target sequences within the 
so-called AAVS1 “safe harbor” locus, located in the long arm of the human chromosome 
19 at position 19q13.42-qter. Of note, the herein described methodologies can be directly 
applied to the generation and characterization of AdV particles harboring other transgenes 
of interest, including those encoding other types of sequence-tailored nucleases or genome-
modifying enzymes.
CONSTRUCTION OF ADV MOLECULAR CLONES
Materials
1. Electro-competent E. coli strain BJ5183 (Addgene bacterial strain 16398) containing 
the pAdEasy-1 “backbone” plasmid or derivatives (here BJ5183pAdEasy-2.50)
2. E. coli strain DH5α (Life Technologies)
3. pAdShuttle expression plasmids (e.g. pAdSh.PGK.SV40)
4. TALEN-encoding plasmids (e.g. 1383.pVAX.AAVS1.TALEN.L-94 and 1384.pVAX.
AAVS1.TALEN.R-95)
5. 10 mg/ml transfer RNA (tRNA) carrier (Sigma-Aldrich)
6. Luria-Bertani broth (LB; Life Technologies) medium and agar plates
7. 500 µg/ml kanamycin sulfate (Sigma-Aldrich)
8. PmeI (New England BioLabs) or MssI (Thermo Scientific)
9. Absolute ethanol (J.T. Baker)
10. Table-top Eppendorf centrifuge
11.  Electroporator (here Gene Pulser electroporator [Bio-Rad])
12. Agarose gel electrophoresis reagents and apparatus
13. Plasmid DNA purification system e.g. JETSTAR 2.0 Plasmid Maxiprep Kit (Genomed)
14. Spectrophotometer (here NanoDrop ND-1000 [Thermo Scientific]) 
Methods
The methods for constructing helper-independent AdV genomes are numerous. Among the 
first were those based on assembling full-length AdV DNA in producer human cells by HR 
between co-transfected “shuttle” and “backbone” constructs. Alternative methods based 
on AdV genome assembly in yeast or bacteria cells were subsequently developed due to the 
inefficiency and unpredictability of DNA recombination in human cells (17). Among these 
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dependency on enzymatic manipulations and reproducibility in recovering plasmids 
containing whole AdV DNA (37). From the onset these reagents correspond to individual 
molecular clones that can be directly applied for rescuing and propagating AdV particles in 
producer cells. This feature obviates the need for time-consuming plaque assays to isolate, 
screen and select viral clones prior to large-scale AdV propagation and purification. Recently, 
the versatility of this method was increased by the development of an AdEasy-based system 
to produce first- and second-generation AdVs with tropism for CAR- or CD46-positive cells 
(38). In this chapter, we exploit this new AdV assembly system for detailing the construction 
and characterization of second-generation fiber-modified AdVs containing TALEN expression 
units. The same methods can be applied to generate AdVs with other genotypes.
1- Insert each TALEN ORF into an AdEasy-compatible pAdShuttle expression plasmid by 
using conventional recombinant DNA procedures (Fig. 1) (39). In the present work, the 
TALEN ORFs in 1383.pVAX.AAVS1.TALEN.L-94 and 1384.pVAX.AAVS1.TALEN.R-95 (32) were 
inserted into pAdSh.PGK.SV40 yielding expression plasmids pAdSh.PGK.TALEN-LS1 and 
pAdSh.PGK.TALEN-RS1, respectively. Of note, the decision on which promoter to use is an 
important one and should be done having in sight which cell type(s) are intended as target 
cells. For instance, it is known that the ubiquitously used cytomegalovirus immediate-early 
gene promoter, albeit strong in many cell types, underperforms or suffers from silencing 
phenomena in others. Among the latter are those with substantial scientific and therapeutic 
relevance such as muscle cells and embryonic stems cells. Therefore, to broaden the use 
of transient AdV-mediated TALEN expression in human cells, it might be advisable to select 
cellular gene regulatory elements. Generally, valuable candidates are represented by the 
promoter/enhancer elements derived from the human genes EEF1A1, UBC and PGK1 (a.k.a. 
EF1α, ubiquin C and PGK, respectively). 
2- Digest 4 µg of TALEN-encoding pAdShuttle plasmids (e.g. pAdSh.PGK.TALEN-LS1 and 
pAdSh.PGK.TALEN-RS1) with the restriction enzyme PmeI (or MssI isoschizomer) in a total 
volume of 40 µl. Check the completeness of the digestion by subjecting a 10-µl sample to 
agarose gel electrophoreses. 
3- Precipitate the digested DNA by adding 20 µl of demineralized water, 25 µg of tRNA 
“carrier” molecules plus 2.5 volumes of ice-cold absolute ethanol, homogenize and 
centrifuge the mixtures at 20,000 ×g for 30 minutes at 4ºC. 
4- Dissolve the recovered dried DNA pellet in 30 µl of demineralized water and use 10 µl to 
transform, in an ice-cold 1-mm cuvette, a 90-µl suspension of electro-competent BJ5183 
cells containing the pAdEasy “backbone” of choice. In this chapter, to package the TALEN 
expression units in second-generation fiber-modified AdV particles, we used BJ5183pAdEasy-2.50 
cells (38). BioRad Gene Pulser electroporation settings: 1.25 V, 200 Ω and 25 µFD with a time 
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Figure 1. Outline of the AdV-based TALEN 
packaging and delivery system. The ORFs 
coding for a functional heterodimeric 
TALEN pair (TALEN-L/TALEN-R) are 
individually cloned into the multiple 
cloning site of an AdEasy “shuttle” plasmid 
(pAdShuttle) containing the transcriptional 
regulatory elements of choice (e.g. the 
human PGK1 gene promoter [PGK] and 
the simian virus 40 polyadenylation signal 
[SV40]). L-ITR and R-ITR, HAdV “left” 
and “right” inverted terminal repeats, 
respectively; Ψ, HAdV packaging signal; 
TALE repeats, transcription activator-like 
effector region coding for the sequence-
specific DNA binding domain; TALEN-L and 
TALEN-R, “left” and “right” TALE nuclease, 
respectively; FokI, DNA portion encoding 
the non-specific nuclease domain of the 
homodimer-forming type IIS restriction 
enzyme FokI; KanR, kanamycin-resistance 
gene; ori, prokaryotic origin of replication. 
The resulting constructs are treated 
with PmeI and are transformed into 
recombinogenic E. coli strain BJ5183pAdEasy+ 
harboring a pAdEasy-derived “backbone” 
construct of choice. In the current work 
we deployed BJ5183pAdEasy-2.50 cells to 
generate E1- and E2A-deleted (i.e. second-
generation) AdVs displaying particle-
retargeting fiber motifs from HAdV 
serotype 50. HR at DNA sequences common 
to “shuttle” and “backbone” constructs 
(labeled in the red) results in the assembly 
of full-length AdV molecular clones. 
These plasmids are isolated by screening 
individual colonies grown in agar plates 
containing kanamycin. Transfection of AdV 
packaging cell lines with PacI-digested AdV 
molecular clones leads to the assembly of 
AdV particles containing TALEN-encoding 
expression units. The rescued vector 
particles can subsequently be propagated 
to high-titers in producer cells and purified 
from cellular components. The resulting 
stocks of AdV particles are then subjected 
to assays to establishing the quantity and 
integrity of their packaged recombinant 
genomes. After this final characterization, 
AdV preparations are ready for genome 
editing experiments based on transducing 
and expressing the functional TALEN pair 
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5- Add 400 µl of LB broth medium without antibiotics, transfer the bacteria to a sterilized 
Eppendorf tube and shake for 45-60 minutes at 30ºC. 
6- Plate the transformed cells onto two LB agar plates containing 50 µg/ml of kanamycin 
sulfate and, after an overnight incubation period at 30ºC, select and grow small-sized 
colonies for 16-20 hours at 30ºC in the presence of 50 µg/ml of kanamycin sulfate.
7- Isolate the plasmids by using a conventional alkaline lysis DNA extraction protocol and, on 
the basis of restriction enzyme analyses, select clones containing full-length AdV genomes 
for large-scale plasmid DNA purification. To this end, any commercially available DNA 
extraction procedure based on ion-exchange chromatography columns can be deployed. 
Optional extra step: transform into and purify from a non-recombinogenic E. coli strain (e.g. 
DH5α) the full-length AdV molecular clones. 
8- Determine the concentration and purity (A260/A280) of the resulting large-scale DNA 
preparations by spectrophotometry and confirm their integrity by restriction enzyme 
fragment length analyses. If warranted, complement these data through transgene-directed 
DNA sequencing analyses. 
RESCUE AND PROPAGATION OF ADVS
Materials
1. Full-length AdV molecular clones (here pAdVΔ2P.TALEN-LS1.F50 and pAdVΔ2P.TALEN-
RS1.F50).
2. PacI restriction enzyme (New England Biolabs)
3. 1 mg/ml 25-kDa linear polyethylenimine (PEI; Polysciences) in H2O
4. 0.5 M NaCl (Merck)
5. 5 ml Polystyrene Round-Bottom tubes (BD Falcon)
6. E1- and E2A-complementing AdV packaging cell line (here PER.E2A cells) 
7. Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies)
8. Non-heat inactivated fetal bovine serum (FBS; Life Technologies)
9. 1M MgCl2 (Sigma-Aldrich)
10. 50 ml blue screw cap conical bottom tubes (Greiner Bio-One)
11. 0.05% trypsin-ethylenediaminetetraacetic (EDTA) solution (Life Technologies)
12. Phosphate-buffered saline (PBS) pH=7.4
13. 6-well plates, 75- and 175-cm2 cell culture flasks (all from Greiner Bio-One)
14. 0.45 µm pore-sized filters (Pall Life Sciences)
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Method
In brief, full-length AdV molecular clones (e.g. pAdVΔ2P.TALEN-LS1.F50 and pAdVΔ2P.TALEN-RS1.
F50) are first linearized with PacI (Fig. 2A). Next, the PacI-treated DNA is introduced into AdV 
packaging cells by a polycation-based DNA transfection protocol. The restriction enzyme 
treatment removes the prokaryotic DNA sequences and positions the ITR-embedded HAdV 
origins of replication close to DNA termini necessary for the initiation of HAdV-dependent 
replication. The rescued genome-containing AdV particles are subsequently amplified to 
high-titers by serial propagation on increasing numbers of producer cells. 
1- Digest 6.25 µg of each full-length AdV molecular clone with PacI in a total volume of 30 
µl, after which heat-inactivate the restriction enzyme by a 20-minute incubation period at 
65ºC.
2- Seed PER.E2A cells (40) or any another E1- and E2A-complementing cell line in wells of 
6-well plates. In the case of PER.E2A cells, seed 1.25×106 cells in DMEM containing 10% 
FBS and 10 mM MgCl2. Incubate overnight at 39ºC in a 10% CO2 atmosphere. The mutant 
E2A gene in PER.E2A cells confers a thermo-sensitive phenotype to the encoded DNA-
binding protein (DBP). Therefore, these cells are normally cultured at 39ºC (non-permissive 
temperature) to avoid DBP’s cytotoxicity, whereas at the time of vector production, they are 
shifted to 34ºC (permissive temperature) to allow proper folding of the protein. Clearly, to 
rescue first-generation AdVs with conventional or retargeting fibers, E1-complementing cell 
lines such as 293 (41), 911 (42), or PER.C6 (27) suffice. 
3- Add the 30-µl PacI digestion mixture to 190 µl of 150 mM NaCl in a 5 ml polystyrene 
round-bottom tube. In parallel, dilute 18.8 µl of a 1 mg/ml PEI solution in 150 mM NaCl to 
a final volume of 220 µl.
4- Add the PEI to the DNA solution, vortex vigorously for approximately 10 seconds 
and incubate for 20 minutes at room temperature to let the DNA-polycation complexes 
form. Next, dispense dropwise the colloidal suspension into the wells containing the AdV 
packaging cells.
5- After overnight incubation at 39ºC in a 10% CO2 atmosphere, remove the transfection 
mixtures, add regular culture medium and incubate the cells at the permissive temperature 
of 34ºC in a 10% CO2 atmosphere. Monitor the monolayers for the appearance of viral 
plaques and, ultimately, complete cytopathic effect (CPE) as defined by over 90% detached 
producer cells. Of note, in case the transfected cells become over-confluent stalling the 
development of full CPE, sub-culture them into a 75-cm2 flask taking care to beforehand 
remove the trypsin by pelleting and re-suspending the produced cells in regular fresh 
medium. 
6- Release the rescued AdV particles from the producer cells by subjecting the collected cell 
suspension in medium to three cycles of freezing and thawing. To this end, liquid N2 and 
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7- Remove the cellular debris by centrifugation at 1,000 ×g for 10 minutes in a swing-
out rotor and add supernatant fractions to 75-cm2 culture flasks containing newly seeded 
producer cells at about 70-80% confluence. Of note, for optimal AdV propagation, it is 
advisable adjusting the inocula fractions to result in complete CPE of the producer cells 
within 2 to 3 days post-infection. As an optional extra step, the recovered supernatants can 
be further clarified by filtration through 0.45 µm pore-sized filters. To generate a research-
scale AdV preparation, a minimum of 1 and a maximum of 3 propagation rounds are 
normally sufficient to yield enough clarified AdV supernatant material (“master virus seed 
stock”) to use in at least one large-scale infection round comprising 18-20 175-cm2 culture 
flasks containing producer cells at 70-80% confluence (~2×107 cells/flask).
8- Collect the producer cells in sterile 50 ml blue screw cap conical bottom tubes and 
centrifuge them at 2,000 ×g for 10 minutes in a swing-out rotor. Discard the supernatants, 
resuspend the producer cells in 40 ml of PBS and divide the cell suspensions in two sterile 50 
ml blue screw cap conical bottom tubes. Move forward to the concentration and purification 
of the AdV particles or store the material at -80ºC. 
CONCENTRATION AND PURIFICATION OF ADV PARTICLES
Materials
1. Ultracentrifuge (here Beckman Coulter LE-80K)
2. SW28 rotor (Beckman Coulter) or similar
3. VTI65.1 rotor (Beckman Coulter) or similar
4. Open-top polyallomer centrifuge tubes, 25×89 mm (Beckman Coulter)
5. Quick-Seal® polyallomer centrifuge tubes, 16×76 mm (Beckman Coulter)
6. Tube Sealer 342420 (Beckman Coulter) or similar apparatus
7. Amicon Ultra-15 Centrifugal Filter Devices with 100,000 MWCO (Millipore) or 
similar device
8. 5% (w/v) sodium deoxycholate (DOC; Merck) in demineralized water
9. 1.24 g/ml, 1.33 g/ml and 1.4 g/ml cesium chloride (CsCl; Merck) solutions in Tris-
HCl pH 7.5 with 5% glycerol
10. 10 mg/ml DNaseI (grade II; Roche Applied Science)
11. 20G needles (BD microlance 3) and 5-ml syringes (BD plastipak)
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Methods
In brief, the AdV particles are first released from producer cells by a mild detergent treatment. 
Next, they are concentrated and purified by two consecutive ultracentrifugation steps 
entailing CsCl block and continuous isopycnic density gradients. Banded genome-containing 
AdV particles (Fig. 2B) are subsequently subjected to a de-salting buffer exchange protocol 
based on ultrafiltration.
1- Add to 20-ml suspensions of producer cells in PBS the detergent DOC at a final concentration 
of 0.5% and incubate the mixtures at 37ºC for 30 minutes. Gently invert the cell lysates 
every 5-10 minutes for a thorough homogenization of the resulting viscous solution.
2- Add MgCl2 and DNaseI at final concentrations of 40 mM and 8.7 µg/ml, respectively. 
Subsequently, incubate the mixtures at 37ºC for 30 minutes while gently inverting the cell 
lysates every 5-10 minutes for a thorough homogenization.
3- Centrifuge the producer cell lysates for 10 minutes at 2000 ×g. Next, recover the 
supernatants and centrifuge them for 10 minutes at 3000 ×g. The resulting clarified cell 
lysates are subsequently subjected to ultracentrifugation through block and continuous CsCl 
density gradients as follows.
4- Add, in a gentle manner, 20-22 ml of clarified supernatant material on top of block 
gradients consisting of 5 ml and 10 ml CsCl tires with densities of 1.4 g/ml and 1.24 g/ml, 
respectively. Open-top polyallomer centrifuge tubes with a 38-ml capacity can be used for 
this purpose.
5- Place the loaded centrifuge tubes in a SW28 swing-out rotor (or similar) and centrifuge 
them at 80,000 ×g for 2 hours at 10ºC. Of note, for proper counterbalancing during 
ultracentrifugation, the weight differences between tubes placed at opposite rotor positions 
should not exceed 0.02 grams.
6- Recover the AdV particles concentrated at the border between the two CsCl densities by 
pricking the centrifuge tubes with a 20G needle coupled to 5-ml syringe.
7- Transfer the recovered AdV material into 13.5-ml polyallomer Quick-Seal® tubes and 
fill them up completely with 1.33 g/ml CsCl solution. Next, heat-seal the tubes by using a 
pre-heated Tube Sealer 342420 (or similar device). In alternative to heat-sealing, use Opti-
Seal® polyallomer centrifuge tubes instead. Of note, for proper counterbalancing during 
ultracentrifugation, the weight differences between tubes placed at opposite rotor positions 
should not exceed 0.02 grams after sealing.
8- Place the loaded and sealed centrifuge tubes in a VTi 65.1 vertical-tube titanium rotor (or 
similar) and centrifuge them at 300,000 ×g for 16 hours at 10ºC to subject the AdV particles 
to a self-generating continuous buoyant density gradient. Of note, disable the break option 
of the ultracentrifuge prior to stopping these runs.
9- Use a needle to create a hole at the top of the sealed centrifuge tubes after which retrieve 
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Figure 2. Analysis of recombinant genomes packaged in purified AdV particles. (A) DNA structures 
of second-generation (AdVΔ2) fiber-modified (F50) adenoviral vectors AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.
TALEN-RS1.F50 drawn in relation to those of their respective molecular clones pAdVΔ2P.TALEN-LS1.F50 
and pAdVΔ2P.TALEN-RS1.F50. The thick and thin lines correspond to the AdV and plasmid backbone 
sequences, respectively. F5/50, ORF coding for a chimeric fiber consisting of basal shaft domains from 
HAdV serotype 5 fused to apical shaft and knob motifs from HAdV serotype 50. For an explanation of 
the other elements see the legend of Fig. 1. These recombinants contain an expression unit coding 
for the AAVS1-specific designer nucleases TALEN-LS1 or TALEN-RS1. The regulatory elements consist 
of the PGK promoter and the SV40 polyadenylation signal. The central portions of these TALEN ORFs 
encode an array of 17.5 repeats responsible for targeting the non-specific FokI nuclease domains to 
AAVS1 to form an operative TALEN pair. (B) Aspect of concentrated genome-containing AdVΔ2P.TALEN-
LS1.F50 and AdVΔ2P.TALEN-RS1.F50 particles after isopycnic CsCl density-gradient ultracentrifugation. 
(C) Characterization of DNA isolated from CsCl-purified AdV particles by restriction fragment length 
analysis. Agarose gel electrophoresis of AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-RS1.F50 genomes (left 
and right panels, respectively) digested with BamHI, BcuI, Bsp1407I or EcoRI. Marker, GeneRuler DNA 
Ladder Mix molecular weight marker (Fermentas). (D) Restriction patterns of AdVΔ2P.TALEN-LS1.F50 
and AdVΔ2P.TALEN-RS1.F50 DNA generated in silico with the aid of Gene Construction Kit (version 2.5) 
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10- Transfer the recovered AdV material into Amicon Ultra-15 Centrifugal Filter Devices with 
a nominal molecular weight cut-off of 100 kDa previously rinsed with storage buffer.
11- Fill-up the filter devices with storage buffer to their maximum 15 ml capacity and 
exchange the CsCl solution for the physiological storage buffer by carrying out a minimum 
of five consecutive cycles of centrifugation and addition of large volumes of fresh storage 
buffer. Of note, avoid drying the filter membrane by overextending the centrifugation 
step(s). As a guideline for the first centrifugation round, apply a centrifugal force of 2,000 
×g for 45 seconds at room temperature. For subsequent rounds adapt the centrifugation 
time depending on the retentate and flow-through volumes corresponding to each AdV 
preparation. 
12- After the last cycle, recover the retentate (1.5-2.0 ml) into sterilized Eppendorf tubes or 
5 ml polystyrene round-bottom tubes and rinse well the filter membranes 2-3 times with 
200 µl of storage buffer. Pool this material into the bulk material, mix and make aliquots. 
Store the aliquots at -80ºC until their use.
CHARACTERIZATION OF ADV PREPARATIONS
The characterization of purified stocks of TALEN-encoding AdVs includes determining 
the integrity and amounts of packaged recombinant genomes (sections 5.1 and 5.2, 
respectively) as well as validating the functionality of their expression units and encoded 
products (section 5.3). After being extracted from AdV particles, the integrity of the vector 
genomes can be routinely examined by conventional restriction enzyme fragment length 
analyses (Fig. 2C and Fig. 2D). If necessary, these data can be complemented by more 
detailed analyses based on DNA sequencing of selected AdV DNA portions (e.g. TALEN 
ORFs). In addition, recombinant AdV genomes in purified preparations can be quantified 
by qPCR or, alternatively, by a quicker procedure based on disrupting AdV capsids with an 
ionic detergent and directly measuring the released vector DNA content with the aid of a 
dsDNA-specific fluorescent dye. Here we deploy such a method, adapted from Murakami 
and McCaman (43), to determine AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-RS1.F50 titers in 
terms of genome-containing viral particles per ml (VP/ml). This method allows for accurate 
and rapid titer measurements by exploiting the sensitivity and wide dynamic range of the 
dsDNA-specific dye PicoGreen (Fig. 3). Finally, the functionality of AdV-delivered TALEN 
transcriptional units can be established by exploiting heterologous protein tags and standard 
western blot techniques (Fig. 4A) as well as surrogate NHEJ detecting assays (Fig. 4B) based 
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Figure 3. Fluorometric assay 
based on the double-stranded 
DNA dye PicoGreen for 
measuring AdV titers in terms 
of genome-containing viral 
particles per milliliter (VP/ml). 
Representative linear regression 
curves corresponding to a 
λ DNA standard curve and to 
DNA from CsCl-purified AdV 
stocks (i.e. AdVΔ2P.TALEN-LS1.
F50 and AdVΔ2P.TALEN-RS1.F50) 
are depicted. The resulting AdV 
physical particle titers for each 








































108  |  Chapter 4
Figure 4. Transgene expression and targeted mutagenesis assays for the validation of TALEN-encoding 
AdV preparations. (A) Influenza hemagglutinin tag-specific Western blot analyses on protein lysates 
of human myoblasts co-transduced with 1:1 mixtures of AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-RS1.F5 
at total MOIs of 15×103, 10×103, 5×103, 2.5×103 and 1×103 VP/cell (lanes 1 through 5, respectively) or 
mock-transduced (lane 6). A parallel Western blot deploying an anti-actin mouse monoclonal antibody 
(clone: C4) provided for a loading control. (B) T7 endonuclease I genotyping assay to detect site-specific 
DSBs in target cells exposed for three days to TALEN-encoding AdVs. Human myoblasts were co-
transduced with 1:1 mixtures of AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-RS1.F5 at total MOIs of 15×103, 
10×103, 5×103, 2.5×103 and 1×103 VP/cell (lanes 4 through 8, respectively). Controls were provided by 
mock-transduced human myoblasts (lane 3) or by human myoblasts exposed exclusively to 7.5×103 
VP/cell of AdVΔ2P.TALEN-LS1.F50 (lane 1) or to 7.5×103 VP/cell of AdVΔ2P.TALEN-RS1.F50, (lane 2). Lanes M, 
GeneRuler DNA Ladder Mix molecular weight marker (Fermentas). PCR products spanning the AAVS1 
target site of control human myoblasts or of human myoblasts transduced with different doses of 
AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-RS1.F50 are denatured and re-annealed. Heteroduplexes with 
indels resulting from NHEJ repair of DSBs at AAVS1 bear mismatched base pairs that can be recognized 
and cleaved by T7 endonuclease I yielding low-molecular-weight DNA fragments whose positions are 
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Structural analysis of packaged AdV genomes
Materials
1. 10× DNaseI buffer (130 mM Tris-HCl pH 7.5; 1.2 mM CaCl2 and 50 mM MgCl2)
2. 10 mg/ml DNaseI (Roche)
3. 0.5 mM EDTA pH 8
4. 20 mg/ml Proteinase K (Thermo Scientific)
5. 10% (w/v) SDS
6. Jetsorb Gel Extraction Kit (Genomed) or similar system
7. Selected restriction enzymes
8. Agarose gel electrophoresis reagents and apparatus
Methods
1- Add to a 50-µl aliquot of a CsCl-purified AdV preparation, 12 µl of 10× DNaseI buffer, 8 µl 
of 10 mg/ml DNaseI and 50 µl of demineralized water. Incubate the mixture for 30 minutes 
at 37ºC.
2- Inactivate the DNaseI by adding 2.4 µl of 0.5 mM EDTA pH 8, 6.0 µl of 10% SDS and 1.5 µl 
of 20 mg/ml proteinase K. Incubate the mixture for 1 hour at 55ºC. 
3- Add 390 µl of buffer A1 (Jetsorb Gel Extraction Kit) and 10 µl of silica beads (Jetsorb Gel 
Extraction Kit). Incubate for 20 minutes and homogenize every 3-5 minutes by inverting the 
samples several times.
4- Centrifuge for 30 seconds at 20,000 ×g, discard the supernatant and gently resuspend the 
bead pellets in 400 µl of buffer A1.
5- Centrifuge for 30 seconds at 20,000 ×g, discard the supernatant and gently resuspend the 
bead pellets in 400 µf of buffer A2 (Jetsorb Gel Extraction Kit). Repeat this washing step and 
remove the supernatants as thoroughly as possible.
6- Air-dry the bead pellets until they become white. Of note, avoid over-drying the pellets to 
prevent difficulties in eluting the bound DNA.
7- Elute the DNA by adding 30 µl of nuclease-free demineralized water and incubate for 
7 minutes at 55ºC. Increase the DNA elution by tapping the tubes approximately every 2 
minutes. 
8- Centrifuge the samples at 20,000 ×g for 30 seconds and carefully collect the supernatants 
containing the eluted AdV genomes. Of note, avoid carrying over silica beads as these can 
inhibit subsequent enzymatic reactions.
9- Perform restriction enzyme fragment length analysis to establish the integrity of the 
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Determination of AdV physical particle titers
Materials
1. Storage buffer (20 mM Tris-HCl pH 8.0; 25 mM NaCl and 5% glycerol)
2. Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies)
3. White 96-well microplate OptiPlate-96 (Perkin Elmer)
4. TE buffer (10mM Tris-HCl and 1 mM EDTA pH 7.5)
5. Spectrofluorometer plate reader (here Wallace 1420 VICTOR 3 multilabel plate 
reader, Perkin Elmer)
Methods
1- Dilute 5 µl of each AdV stock in 45 µl of storage buffer supplemented with 0.05% SDS. 
Next, prepare four 3-fold serial dilutions by mixing 15 µl of the vector material with 30 µl of 
storage buffer containing 0.05% SDS.
2- Incubate the dilution series for 5 minutes at 65ºC, after which pipet 20 µl of each of these 
samples into wells of white 96-well microplates.
3- Prepare a working solution of the fluorescent dye by diluting the stock of Quant-iT 
PicoGreen dsDNA 360 fold in TE buffer. Next, add 180 µl of this working solution to each of 
the dilutions. Incubate for 5 minutes in the dark at room temperature.
4- In parallel, set-up a calibration curve by serially diluting a stock of bacteriophage λ DNA 
(100 µg/ml) in storage buffer containing 0.05 % SDS to the final concentrations: 50, 16.7, 
5.6, 1.9 and 0.6 ng/µl. 
5- Measure the various DNA concentrations by deploying a Wallace 1420 VICTOR 3 multilabel 
plate reader (or similar device) set to excitation and emission wavelengths of 485 nm and 
535 nm, respectively.
6- Generate linear regression curves for each of the measured data sets confirming that 
the corresponding coefficients of determination (R2) lie between 0.98 and 1.0 (Fig. 3). Next, 
through the λ DNA standard curve correlating fluorescence signals to ng of DNA, determine 
for each AdV stock the amount of DNA (in ng) per µl of sample.
7- Calculate the molecular mass corresponding to each AdV DNA molecule by applying the 
relationship: Genome size (bp) × 660 (Da/bp) = Da (gmol-1).
e.g. AdVΔ2P.TALEN-LS1.F50 DNA = 34,155 bp × 660 Da/bp = 2.25×107 gmol-1.
8- Divide the resulting values by the Avogadro’s number (i.e. 6.022×1023) to obtain the 
weight of each AdV DNA molecule in grams and subsequently convert these values to ng; 
e.g. 2.25×107 gmol-1/6.022×1023 mol = 3.74×10-17 g à 3.74×10-8 ng
9- Determine the number of AdV genomes per ng; e.g. 1/3.74×10-8 ng = 2.67×107 genomes
10- Use the values obtained in step 6 to calculate the total number of genomes per µl; e.g. 
2.67×107 genomes/ng × 22.1 ng/µl = 5.91×108 genomes/µl à 5.91×1011 genomes/ml or 
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Functional validation of AdV-delivered TALENs 
Materials
1. Cell lysis solution for genomic DNA extraction (100 mM Tris-HCl pH 8.5; 5 mM 
EDTA; 0.2% SDS and 200 mM NaCl)
2. TE-saturated phenol:chloroform:isoamylalcohol (25:24:1) solution (J.T. Baker)
3. Chloroform (Merck)
4. 7.5 M ammonium acetate (Merck)
5. Absolute ethanol (J.T. Baker)
6. 10 mM TE buffer pH 8.0
7. 10 mg/ml RNase A (Thermo Scientific)
8. 5U/µl GoTaq DNA polymerase (Promega)
9. 5× Colorless GoTaq Flexi buffer (Promega)
10. 40 mM deoxynucleotide (dNTP) solution mix (New England Biolabs) and 10 µM 
selected primer pair (Eurofin)
11. PCR thermocycler (here DNA Engine Tetrad 2 Peltier Thermal Cycler [Bio-Rad])
12. Agarose gel electrophoresis reagents and apparatus
13. 5× loading buffer
14. 10 U/µl T7 endonuclease I and 10× NEBuffer 2 (both from New England Biolabs)
15. DNA molecular-weight marker e.g. Gene Ruler DNA Ladder Mix (Thermo Scientific)
16. Bio-Rad Image Lab 4.1 (Bio-Rad) or ImageJ (National Institutes of Health, USA) 
software
Methods
The below-specified transduction experiments serve simply as an example to provide general 
guidelines for validating TALEN-encoding AdVs. Obviously, types and amounts of human 
target cells as well as vector genotypes and doses are at the discretion of the investigator.
1- One day prior transduction, seed 2.0×105 human myoblasts in wells of a 24-well plate and 
incubate the cells overnight at 37ºC in a 5% CO2 atmosphere.
2- Co-transduce the target cells with 1:1 mixtures of AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-
RS1.F50. Preferably, to determine limiting doses and TALEN activity plateauing levels, apply a 
broad vector dose range onto the target cells. Negative controls can be provided by mock-
transduced cells as well as by cells exposed at high doses to each AdV individually. 
3- At 3 days post-infection, harvest the control and the co-transduced cell cultures and divide 
them in samples for protein expression and target site genotyping analysis. The assay for the 
former analyses has been detailed elsewhere (32), whereas that for the latter is as follows.
4- Initiate the total cellular DNA extraction procedure by incubating the target cells overnight 








































112  |  Chapter 4
of 100 ng/ml. Next, subject the DNA to two rounds of phenol:chloroform:isoamylalcohol 
(25:24:1) extraction and to one round of chloroform extraction to remove traces of phenol. 
Next, add half volume of 7.5 M ammonium acetate and 2.5 volumes of ice-cold ethanol and 
precipitate the DNA by centrifugation at 20,000 ×g for 30 minutes at 4ºC. Wash the DNA 
pellets with 70% ethanol, after which air-dry and resuspend the DNA in 100 µl TE buffer pH 
8.0 containing 100 µg/ml of DNase-free RNaseI. 
6- Add 2 µl of the purified DNA to 50-µl PCR mixtures containing 0.4 µM of AAVS1-specific 
primers (5’-TTCGGGTCACCTCTCACTCC-3’ and 5’-GGCTCCATCGTAAGCAAACC-3’), 0.1 mM of 
each dNTP, 1× Colorless GoTaq Flexi buffer, 1 mM MgCl2 and 2.5 U GoTaq DNA polymerase. 
7- Apply the following PCR cycling conditions: Initial denaturation for 5 minutes for 95ºC, 
followed by 40 cycles of 30 seconds at 95ºC, 30 seconds at 61ºC and 30 seconds at 72ºC. 
Terminate the reactions by an elongation period of 5 minutes at 72ºC.
8- Denature and re-anneal 20-µl amplicon samples by using a regular thermocycler machine 
and the following program: 
9- Incubate the resulting DNA species in 25-µl reactions containing 5 U of T7 endonuclease 
I and 1× NEBuffer 2 for 20 minutes at 37ºC. 
10- Stop the reactions by adding loading sample buffer containing SDS and immediately 
subject the DNA to electrophoresis through a 1.5% agarose gel in 1× Tris-Acetate-EDTA 
buffer.
11- Visualize by in-gel staining with a DNA dye (e.g. ethidium bromide) intact and digested 
amplicons resulting from NHEJ-mediated formation of small insertions and deletions (indels) 
at the TALEN target sequences.
12- Estimate the frequency of indel formation by densitometry of electrophoresis-resolved 
DNA molecules. To this end, commercially and publicly available software packages such as 
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ABSTRACT
CRISPR/Cas9-derived RNA-guided nucleases (RGNs) are DNA targeting systems, which are 
rapidly being harnessed for gene regulation and gene editing purposes in model organisms 
and cell lines. As bona fine gene delivery vehicles, viral vectors may be particularly fit to 
broaden the applicability of RGNs to other cell types including dividing and quiescent primary 
cells. Here, the suitability of adenoviral vectors (AdVs) for delivering RGN components into 
various cell types is investigated. We demonstrate that AdVs namely, second-generation 
fiber-modified AdVs encoding Cas9 or single guide RNA (gRNA) molecules addressing the 
Cas9 nuclease to the AAVS1 “safe harbor” locus or to a recombinant model allele can be 
produced to high-titers (up to 20×1010 transducing units/ml). Importantly, AdV-mediated 
transduction of gRNA:Cas9 ribonucleoprotein complexes into transformed and non-
transformed cells yields rates of targeted mutagenesis similar to or approaching those 
achieved by isogenic AdVs encoding TALENs targeting the same AAVS1 chromosomal region. 
RGN-induced gene disruption frequencies ranged from 18% to 31% in a cell type-dependent 
manner. We conclude that AdVs constitute a valuable platform for introducing RGNs into 
human somatic cells regardless of their transformation status. This approach should aid 
investigating the potential and limitations of RGNs in numerous experimental settings.
Key words: CRISPR/Cas9; RNA-guided nucleases; Adenoviral vectors; Primary cells; Targeted 
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INTRODUCTION
Genome engineering strategies based on designer nucleases can be harnessed to edit and 
to interrogate the function of genomic sequences in cells of higher eukaryotes. In common, 
these approaches entail the activation of cellular DNA repair pathways in target cells upon 
the induction of double-stranded DNA breaks (DSBs) at predefined chromosomal positions1,2. 
The engagement of non-homologous end-joining (NHEJ) and homologous recombination 
(HR) machineries at these artificially created DSBs can result in targeted gene knockout and 
addition, respectively. The potential of genome engineering is considerable for fundamental 
and applied research. For instance, in the form of new molecular medicine modalities such 
“genome surgery” approaches might constitute a watershed departure from canonical gene 
therapy in which chromosomal insertion of the therapeutic DNA is unpredictable3.
Programmable nuclease technologies are developing at a rapid pace1,2. These include 
zinc-finger nucleases (ZFNs), engineered homing endonucleases, transcription activator-
like effector nucleases (TALENs) and, more recently, RNA-guided nucleases (RGNs). RGNs 
are RNA-dependent DNA nucleases built on components from type II clustered regularly 
interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) systems. These 
systems have been evolving in bacteria and archaea as adaptive immune mechanisms 
against invading nucleic acids of foreign agents such as plasmids and phages4,5. CRISPR loci 
contain an array of short palindromic repeats separated by protospacer DNA snippets of 
around 20 bp that have been acquired from invading agents. Following expression, the short 
palindromic repeats in precursor CRISPR transcripts (pre-crRNA) hybridize to a portion of a 
trans-activating CRISPR RNA (tracrRNA). The bound tracrRNA, in concert with RNase III and 
Cas9, lead to the processing of the pre-crRNA into small CRISPR RNAs (crRNAs) each of which 
encompasses a sequence complementary to a specific protospacer. Finally, crRNAs base-
paired to tracrRNAs loaded with Cas9 nucleases direct site-specific DNA cleavage following 
crRNA:target DNA hybridization. Of note, the fact that foreign DNA harbors a so-called 
protospacer adjacent motif (PAM) next to the protospacer sequence whereas crRNAs lack 
this motif, ensures that crRNA:tracrRNA:Cas9 complexes recognize exclusively the incoming 
exogenous DNA as opposed to the chromosomal CRISPR-incorporated protospacers4,5. 
The above-described fundamental insights combined with enticing work done in vitro and 
in bacteria6,7 led the type II CRISPR/Cas9 system from Streptococcus pyogenes to be rapidly 
adapted as a gene editing toolbox for mammalian cells8-10. These studies comprised the 
transfection of cell lines with plasmids expressing from RNA polymerase II (Pol-II) and Pol-III 
promoters, respectively, Cas9 proteins and chimeric single guide RNAs (gRNAs) engineered 
by fusing sequence-tailored crRNAs to tracrRNA scaffolds. Thus, gRNAs are bifunctional 
molecules7 consisting of crRNA targeting and tracrRNA scaffolding moieties. Owing to the 
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to protein-DNA interactions, make CRISPR/Cas-based systems unique among customizable 
nucleases. Importantly, this feature allows for facile nuclease retargeting and multiplexing 
by simply replacing the RNA component of each ribonucleoprotein complex1,11. However, 
independent studies carried out in cell lines indicate that RGNs display high levels of off-
target DNA cleaving activities especially when compared to protein-based platforms such as 
TALENs with a tradeoff existing between activity and specificity12-16. The off-target cleaving 
profile of programmable nucleases is, clearly, a parameter to take into consideration in the 
context of both therapeutic and basic-research protocols.
To expand the range of experimental systems in which RGNs can be tested and optimized, 
it is crucial to introduce these rather large macromolecular complexes not only into 
established cell lines but also into non-transformed diploid cell types (i.e. Cas9: 1,368 aa; 
158 kDa; Cas9 ORF: 4.1 kb). In this regard, adenoviral vectors (AdVs) constitute interesting 
RGN delivery candidates especially owing to their episomal nature, large cloning capacity, 
high-titers and ability to transduced dividing as well as non-dividing cells17. 
In the present work, we sought to investigate the capacity of AdVs for packaging 
and delivering functional gRNA and human codon-optimized Cas9 transcriptional units 
into human cells. To this end, we selected previously validated gRNA molecules whose 
sequences target Cas9 to the so-called AAVS1 “safe harbor” locus located on the long arm of 
the human chromosome 19 (19q13.42-qter) or to a recombinant model allele consisting of 
a chromosomally integrated eGFP expression unit10. In parallel, to serve as a reference, we 
took along in these transduction experiments isogenic AdVs encoding TALENs, which have 
also been previously validated and target the same AAVS1 region18. By deploying targeted 
mutagenesis assays as well as live-cell readouts based on fluorescence microscopy and flow 
cytometry, we demonstrate that AdVs can efficiently transfer functional RGN components 
into human cells regardless of their transformation status. 
RESULTS
Adenoviral vectors encoding RGN components can be produced at high-titers
We started by investigating the feasibility of producing AdVs containing Cas9 and gRNA 
transcriptional units. For this purpose, we selected E1- and E2A-deleted AdVs displaying 
fiber motifs recognizing the ubiquitous cellular receptor CD46 (Fig. 1A). This retargeted 
second-generation AdV system offers several advantages when compared to its conventional 
E1-deleted AdV counterpart including higher genetic capacity, lower levels of “leaky” viral 
gene expression and efficient transduction of cells lacking, or with low amounts of, the 
coxsackievirus-adenovirus receptor CAR on their surface. Among these are human cell types 
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skeletal muscle progenitor cells (hereinafter referred to as myoblasts), and bone marrow-
derived mesenchymal stromal cells (hMSCs)19-22.
In the current work, we selected the previously validated gRNA_AAVS1-T2 unit10, herein 
named gRNAS1, to edit endogenous chromosomal sequences via AdV delivery of CRISPR/
Cas9-derived RGNs. The nucleotide sequence of this gRNA targets the Cas9 nuclease to the 
human AAVS1 locus (Fig. 1B). To serve as a reference, we took along the optimized designer 
nuclease pair TALEN-LS1/TALEN-RS1 specific for the same AAVS1 region18 (Fig. 1B) and placed 
their ORFs under the control of the same transcriptional elements as those regulating Cas9 
expression. To this end, AdV shuttle plasmids expressing Cas9, TALEN-LS1 or TALEN-RS1 from 
the Pol-II PGK promoter and short gRNAS1 molecules from the Pol-III U6 promoter were 
constructed. The choice for the former promoter was motivated by its ubiquitous expression 
in a diverse array of human cell types and, owing to its human origin, higher resistance to 
silencing phenomena than that offered by commonly-used viral transcriptional elements. 
Transient transfection experiments using as readout a surrogate DSB formation assay 
dependent on the NHEJ DNA repair pathway, showed that co-transfecting test cells with 
gRNAS1- and Cas9-encoding AdV shuttle plasmids resulted in AAVS1 targeted mutagenesis 
(Fig. 2). The functionality of the AdV shuttle plasmids encoding the AAVS1-specific TALENs 
was also confirmed through similar transient transfection experiments (not shown). Next, 
we used these validated reagents to assemble full-length AdV molecular clones for rescuing 
and propagating the E1- and E2A-deleted (AdVΔ2) fiber-modified (F50) vectors AdVΔ2P.Cas9.
F50, AdVΔ2U6.gRNAS1.F50, AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-RS1.F50. Following the rescue, 
propagation and purification of AdV particles, we determined that the AdV functional titers 
in the resulting preparations were within the typical range expected for these research-
scale production rounds (i.e. 23.7×1010, 13.3×1010, 2.4×1010 and 4.2×1010 TU/ml for AdVΔ2P.
Cas9.F50, AdVΔ2U6.gRNAS1.F50, AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-RS1.F50, respectively). 
In addition, as previously shown for AdVs harboring TALEN expression units18, structural 
analysis of packaged AdV genomes isolated from purified particles of AdVΔ2P.Cas9.F50 and 
AdVΔ2U6.gRNAS1.F50 revealed restriction patterns diagnostic for AdV backbones containing 








































124  |  Chapter 5
Figure 1. Schematic representation of the genome-modifying AdVs deployed in this study and 
corresponding target sequences. (A) The AdVs encode the Cas9 nuclease or TALEN proteins specific 
for the human “safe harbor” locus AAVS1 within PPP1R12C or gRNA molecules addressing Cas9 to 
AAVS1 or to eGFP sequences. All vectors were assembled on the basis of a second-generation (i.e. 
E1- plus E2A-deleted) AdV backbone (AdVΔ2) coding for chimeric fibers composed of basal domains 
from prototypic human adenovirus serotype 5 fused to the apical shaft and knob motifs from human 
adenovirus serotype 50 (F5/50). The Cas9 and TALEN ORFs are under the transcriptional control of the 
human PGK-1 gene promoter (PGK) and the simian virus 40 (SV40) polyadenylation signal whilst the 
gRNAs are regulated by a RNA Pol-III promoter (U6) and terminator sequences. Ψ, human adenovirus 
serotype 5 packaging signal; Ad L-ITR and Ad R-ITR, “left” and “right” adenoviral inverted terminal 
repeat, respectively. The structure of the single guide RNA molecules gRNAS1 and gRNAGFP, composed 
of Cas9 targeting and scaffolding portions, are depicted base-paired to their respective AAVS1 and 
eGFP target sequences. TALE-L and TALE-R, AAVS1-binding transcription activator-like effector repeats 
of designer nucleases TALEN-L and TALEN-R, respectively (TALE portions coding for repeat variable 
di-residues [RVDs] recognizing A, T, C and G are color-coded); FokI, nuclease domain of the type IIS 
restriction enzyme FokI; PAM, protospacer adjacent motif. (B) Location of the AAVS1 target sites for 
the RNA- and TALE-guided nuclease complexes gRNAS1:Cas9 and TALEN-LS1:TALEN-RS1, respectively, in 
relation to the whole PPP1R12C gene. The target sequences for the TALEN-LS1 and TALEN-RS1 proteins 
are in upper case, whereas that for the gRNAS1 is boxed (i.e. G[N]19NGG). PAM, protospacer adjacent 
motif. Solid and open vertical arrowheads indicate the positions at which DNA nicking takes place 
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Figure 2. Transient transfection experiments for validating AdV shuttle plasmids pAdSh.PGK.Cas9 
and pAdSh.U6.gRNAS1. AAVS1-specific PCR products amplified from E1-transformed PER.C6 cells co-
transfected with hCas9 (9.6 kb) and gRNA_AAVS1-T2 (4 kb), pAdSh.PGK.Cas9 (11.6 kb) and pAdSh.
U6.gRNAS1 (7.3 kb), hCas9 and “empty gRNA” construct gRNA_Cloning Vector (3.9 kb), hCas9_D10A 
(9.6 kb) and gRNA_AAVS1-T2 or mock-transfected. Marker, Gene Ruler DNA Ladder (Fermentas). 
Plasmids hCas9 and hCas9_D10A express Cas9 nucleases which induce a DSB and a nick at AAVS1, 
respectively. After amplicon denaturation and reannealing, the presence of mismatches derived from 
NHEJ-mediated repair of site-specific DSBs in cellula was probed by T7 endonuclease I (T7EI) digestions 
(upper panel). Negative controls were provided by amplicons not exposed to T7EI (-T7EI) as well as 
T7EI-treated amplicons (+T7EI) corresponding to mock-transfected cells, to cells co-transfected with 
hCas9 and gRNA_Cloning Vector and to cells co-transfected with hCas9_D10A and gRNA_AAVS1-T2 
encoding the “nickase” mutant version of Cas9 (i.e. Cas9D10A) and gRNAS1, respectively. Solid and open 
arrowheads indicate the positions of, respectively, undigested and T7EI-digested DNA fragments 
whose sizes are consistent with DSB formation at the AAVS1 target site. % KO and UN, knockout 
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Figure 3. Structural analysis of AdV genomes. (A) Genome-containing AdV particles after 
ultracentrifugation banding through continuous CsCl density gradients (B) Characterization by 
restriction fragment length analysis of DNA isolated from CsCl-purified AdV particles. Left panels, in-gel 
and in silico restriction patterns of AdVΔ2P.Cas9.F50 genomes (lanes 1) and respective pAdVΔ2PGK.Cas9.
F50 parental plasmid (lanes 2) treated with BglII. Right panel, in-gel and in silico restriction patterns of 
AdVΔ2U6.gRNAS1.F50 DNA (lanes 3) and corresponding pAdVΔ2U6.sgRNAS1.F50 parental plasmid (lanes 4) 
digested with Bsp1407I. Lanes M, Gene Ruler DNA Ladder marker. 
AdVs deliver functional RGN complexes into human cells inducing robust site-specific 
mutagenesis at native and recombinant target chromosomal loci
Subsequently, we sought to test via transduction experiments followed by gene knockout 
assays, the functionality of the gRNAS1- and Cas9-encoding AdVs in a panel of human cell 
types. These target cells comprised cervix carcinoma HeLa cells, osteosarcoma U2OS cells, 
hMSCs and myoblasts. In addition, we took advantage of the fine-tuned adenoviral infection 
mechanism to introduce into target cell nuclei a range of well-defined dosages of DNA 
templates encoding each RGN component. Related to this, it is noteworthy mentioning that, 
as of yet, bipartite CRISPR/Cas nuclease complexes have been introduced into target cells by 
transfection-based protocols mostly deploying fixed amounts of the two RGN components. 
In this regard it is relevant pointing out that in contrast to ZFNs and TALENs, in which the 
deployment of equimolar amounts of similarly sized monomers directly follows from their 
modus operandi (i.e assembly of catalytically active dimers at the target site), RGN activities 
might improve by optimizing total and relative quantities of gRNA and Cas templates. 
Therefore, for the experiments deploying AdVΔ2P.Cas9.F50 and AdVΔ2U6.gRNAS1.F50 we set-up 
“co-transduction grids” to determine gene disruption levels resulting from different combined 
dosages as well as ratios of the two RGN elements. Transduction experiments in the HeLa 
and U2OS cell lines led to dose-dependent AAVS1 disruption following AdV-mediated gene 
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the target site (Fig. 4, Fig. 5A and Fig. 5B). Importantly, control transduction experiments in 
which only one of the two vectors was used did not result in detectable indel formation (Fig. 
4). Moreover, co-transduction experiments in U2OS cells deploying side-by-side vector pairs 
AdVΔ2P.Cas9.F50/AdVΔ2U6.gRNAS1.F50 and AdVΔ2P.TALEN-LS1.F50/AdVΔ2P.TALEN-RS1.F50 showed 
that, in addition to a clear AdV dose dependency, the gene knockout frequencies achieved 
by gRNAS1:Cas9 and TALEN-LS1:TALEN-RS1 complexes were similar (compare Fig. 5B with the 
lower panel in Fig. 5C). 
Figure 4. Transduction experiments in HeLa cells for the functional validation of AdVΔ2P.Cas9.
F50 and AdVΔ2.U6.gRNAS1.F50. (A) Genotyping assays based on the detection of indels generated by 
NHEJ-mediated DSB repair at the chromosomal target site. The AAVS1-specific amplicons derived 
from genomic DNA of HeLa cells co-transduced with AdVΔ2P.Cas9.F50 and AdVΔ2.U6.gRNAS1.F50 at the 
indicated MOIs (in TU/cell) were denaturated and re-annealed, treated with T7EI and resolved through 
agarose gel electrophoresis. As negative controls, it was used genomic DNA isolated from HeLa cells 
exposed to 100 TU/cell of AdVΔ2P.Cas9.F50 (lane 1), 100 TU/cell of AdVΔ2.U6.gRNAS1.F50 (lane 2) or to 
no vector (lane 3). Solid and open arrowheads indicate the positions of undigested and T7EI-digested 
DNA molecules, respectively. Lane M, Gene Ruler DNA Ladder marker. (B) Target gene knockout 
frequencies in HeLa cells co-transduced with AdVΔ2P.Cas9.F50 and AdVΔ2.U6.gRNAS1.F50 as measured by 








































Viral vector-mediated delivery of RGNs  |  129
5
Figure 5. Analysis of site-specific DSB formation in U2OS cells following AdV-mediated delivery 
of transgenes encoding RGN and TALEN complexes. (A) Targeted mutagenesis experiments with 
AdVΔ2P.Cas9.F50 and AdVΔ2.U6.gRNAS1.F50. Agarose gel electrophoresis of AAVS1-specific PCR products 
amplified from chromosomal DNA of U2OS cells co-transduced with the indicated MOIs of AdVΔ2P.
Cas9.F50 and AdVΔ2.U6.gRNAS1.F50 (in TU/cell). Prior to loading the PCR products were denaturated, re-
annealed and treated with the mismatch-sensitive enzyme T7EI. Solid and open arrowheads point to 
the positions of undigested and T7EI-digested DNA molecules, respectively. Lane M, Gene Ruler DNA 
Ladder marker. (B) Target gene knockout frequencies in U2OS cells co-transduced with AdVΔ2P.Cas9.
F50 and AdVΔ2.U6.gRNAS1.F50 as measured by densitometry of the DNA species shown in Fig. 5A. (C) 
Targeted mutagenesis experiments with AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-RS1.F50. Upper panel, 
T7EI-based assays on AAVS1-specific amplicons corresponding to genomic DNA of mock-transduced 
U2OS cells (-) or of U2OS cells co-transduced with the specified MOIs of AdVΔ2P.TALEN-LS1.F50 and 
AdVΔ2P.TALEN-RS1.F50 (in TU/cell). Solid and open arrowheads indicate the positions of undigested and 
T7EI-digested DNA molecules, respectively. Lanes M, Gene Ruler DNA Ladder marker. Lower panel, 
target gene knockout frequencies in U2OS cells co-transduced with AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.
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Follow-up transduction experiments in myoblasts generally yielded results similar to 
those obtained in HeLa and U2OS cells. Crucially, at matched MOIs, the levels of RGN-induced 
targeted mutagenesis were higher in myoblasts than in the two cancer-derived cell lines 
(Fig. 6A and Fig. 6B). For instance, 1:1 mixtures of AdVΔ2P.Cas9.F50 and AdVΔ2U6.gRNAS1.F50 
corresponding to a combined MOI of 60 TU/cell led to gene disruption frequencies in HeLa, 
U2OS and myoblasts of 12%, 12% and 27%, respectively (compare Fig. 4B and Fig. 5B with 
Fig. 6B). Importantly, myoblasts exposed to only one of the two RGN or TALEN pair members 
did not contain detectable indels at AAVS1. Finally, it is also noteworthy pointing out that 
at the high-end of the MOI scale tested in myoblasts (i.e. double dose of 30 TU/cell) the 
AdVΔ2P.TALEN-LS1.F50/AdVΔ2P.TALEN-RS1.F50 set yielded roughly a 2-fold higher gene knockout 
activity when compared to equivalent MOIs of the AdVΔ2P.Cas9.F50/AdVΔ2U6.gRNAS1.F50 pair 
(compare Fig. 6B with the lower panel in Fig. 6C). To establish the AdV transduction levels 
achieved in the CRISPR/Cas9-mediated targeted mutagenesis experiments corresponding 
to Figs. 4, 5 and 6, the various target cell types were exposed to particles of AdVΔ2U6.
gRNAS1.F50 and reporter vector AdVΔ2P.eGFP.F50 under the same conditions as those used 
in transduction experiments with AdVΔ2U6.gRNAS1.F50 and AdVΔ2P.Cas9.F50. Of note, the 
transgene regulatory elements in AdVΔ2P.eGFP.F50 are identical to those in AdVΔ2P.Cas9.F50. 
Flow cytometric analyses clearly showed that the panel of MOIs selected for transducing 
each of the target cell types led to a wide range of gene delivery activities. Among these 
were MOIs yielding transduction levels of 100% (Supplementary Fig. 1).
In order to gather more information on target gene disruption activities attainable with 
the AAVS1-specific TALENs and RGN complexes within specific cell types and, simultaneously, 
probe for possible cell type-dependent effects on these activities following AdV-mediated 
gene transfer, we carried out parallel co-transduction experiments with both AdV sets 
on myoblast and hMSC cultures. In addition, to evaluate the impact of different relative 
concentrations of gRNAS1 and Cas9 molecules on gene knockout levels, we exposed these 
target cells to a constant total vector dose of 80 TU/cell spanning different ratios between 
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Figure 6. Analysis of targeted mutagenesis in human myoblasts following AdV-mediated transfer of 
DNA coding for RGN and TALEN complexes. (A) Targeted mutagenesis experiments with AdVΔ2P.Cas9.
F50 and AdVΔ2.U6.gRNAS1.F50. Upper panel, AAVS1-specific PCR products corresponding to genomic 
DNA of myoblasts co-transduced with the indicated MOIs of AdVΔ2P.Cas9.F50 and AdVΔ2.U6.gRNAS1.
F50 (in TU/cell) subjected to T7EI-based assays. Lower panel, negative controls corresponding to 
human myoblasts that were singly transduced with AdVΔ2P.Cas9.F50 (lane 1), AdVΔ2.U6.gRNAS1.F50 
(lane 2) and AdVΔ2P.TALEN-LS1.F50 (lane 3) or that were mock-transduced (lane 4). (B) Target gene 
knockout frequencies in human myoblasts co-transduced with AdVΔ2P.Cas9.F50 and AdVΔ2.U6.gRNAS1.
F50 as measured by densitometry of the DNA species depicted in Fig. 6A. (C) Targeted mutagenesis 
experiments with AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-RS1.F50. Upper panel, T7EI-based assays on 
AAVS1-specific amplicons obtained from genomic DNA of myoblasts co-transduced with the indicated 
MOIs of AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-RS1.F50 (in TU/cell). Solid and open arrowheads indicate 
the positions of undigested and T7EI-digested DNA molecules, respectively. Lanes M, Gene Ruler DNA 
Ladder marker. Lower panel, target gene disruption frequencies in myoblasts co-transduced with 
AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-RS1.F50 as determined by densitometry of the DNA fragments 
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The results depicted in Fig. 7A and in Fig. 7B corroborated the data on the higher TALEN 
pair activity in myoblasts presented in Fig. 6C and extended it to hMSCs. Indeed, gene 
knockout frequencies in myoblasts and hMSCs exposed to vector mixtures consisting of 
different ratios between AdVΔ2P.Cas9.F50 and AdVΔ2U6.gRNAS1.F50 were consistently lower 
than those resulting from co-transductions with 1:1 mixtures of AdVΔ2P.TALEN-LS1.F50 and 
AdVΔ2P.TALEN-RS1.F50. Of note, T7EI-digested DNA species corresponding to genomic DNA 
from cells transduced with the two nuclease systems displayed different migration profiles 
upon electrophoresis (Fig. 7A). These molecular weight differences are consistent with 
the predicted target site cleaving positions for the TALEN and RGN complexes i.e. within 
the spacer and three nucleotides “upstream” of the PAM, respectively (Fig. 1B). AdV 
transduction levels corresponding to these targeted mutagenesis experiments in myoblasts 
and hMSCs were determined by applying AdVΔ2U6.gRNAS1.F50 and AdVΔ2P.eGFP.F50 (Fig. 7C) 
under the same experimental conditions as those used with AdVΔ2U6.gRNAS1.F50 and AdVΔ2P.
Cas9.F50 (Fig. 7B). Collectively, these experiments also demonstrated that, at equivalent 
MOIs, AdV-mediated delivery of the AAVS1-specific RGNs resulted in higher gene disruption 
levels in myoblasts than in hMSCs regardless of the proportions of each vector type in the 
co-transducing AdVΔ2P.Cas9.F50/AdVΔ2U6.gRNAS1.F50 mixtures (Fig. 7D).
To further test the AdV system as a delivery platform for CRISPR/Cas9-derived RGNs, 
AdVΔ2U6.gRNAGFP.F50 was generated. This vector has the genetic make-up of AdVΔ2U6.gRNAS1.
F50 except that it encodes the eGFP-specific gRNAGFP in place of gRNAS1 (Fig. 1A). As with the 
other genome-modifying AdVs, AdVΔ2U6.gRNAGFP.F50 could also be produced to high titers of 
functional vector particles (i.e. 10.4 × 1010 TU/ml). Next, AdVΔ2U6.gRNAGFP.F50 was deployed 
together with AdVΔ2P.Cas9.F50 in transduction experiments in indicator H27 cells23. These 
cells contain a single-copy constitutionally active eGFP transcriptional unit providing, as 
a result, a convenient model system to evaluate target gene knockout strategies by live-
cell tracing and quantification of gene-modified populations. Thus, as in experiments using 
AdVΔ2P.Cas9.F50 and AdVΔ2U6.gRNAS1.F50, we set-up a ‘‘co-transduction grid’’ to determine 
targeted mutagenesis frequencies resulting from different combined dosages of AdVΔ2P.
Cas9.F50 and AdVΔ2U6.gRNAGFP.F50. Direct fluorescence microscopy (Fig. 8A) as well as flow 
cytometry (Figs. 8B and 8C), revealed a clear dose-dependent increase in eGFP disruption 
levels varying from a minimum of 0.8% to a maximum of 65%. Controls consisting of H27 
cells transduced either with AdVΔ2P.Cas9.F50 or with AdVΔ2U6.gRNAGFP.F50, each applied at 
an MOI of 100 TU/cell, did not yield frequencies of eGFP-negative cells above background 
levels (Fig. 8B).
Taken our data together, we conclude that AdVs encoding RGN components can be 
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Figure 7. Analysis of target gene knockout frequencies following AdV-mediated introduction of 
gRNAS1:Cas9 and TALEN-LS1:TALEN-RS1 complexes into hMSCs versus human myoblasts. (A) Target 
site genotyping assays. Upper and lower panels, agarose gel electrophoresis of AAVS1-specific PCR 
products amplified from chromosomal DNA of myoblasts and hMSCs, respectively, co-transduced 
with the indicated MOIs of AdVΔ2P.Cas9.F50 and AdVΔ2.U6.gRNAS1.F50 (in TU/cell). Before loading the 
amplicons were denaturated, re-annealed and treated with the mismatch-sensitive enzyme T7EI. The 
cells were co-transduced at a combined MOI of 80 TU/cell with different ratios of AdVΔ2P.Cas9.F50 
and AdVΔ2.U6.gRNAS1.F50 or with 1:1 mixtures of AdVΔ2P.TALEN-LS1.F50 and AdVΔ2P.TALEN-RS1.F50. Mock-
transduced cells or cells exposed to 80 TU/cell of AdVΔ2P.Cas9.F50, AdVΔ2.U6.gRNAS1.F50 or AdVΔ2P.TALEN-
LS1.F50 served as negative controls. Solid and open arrowheads indicate the positions of undigested 
and T7EI-digested amplicons, respectively. Lanes M, Gene Ruler DNA Ladder marker. (B) Target gene 
knockout activities in hMSCs and myoblasts transduced with AdVs. Target gene disruption frequencies 
in cells co-transduced with AdV pairs AdVΔ2P.Cas9.F50/AdVΔ2U6.gRNAS1.F50 and AdVΔ2P.TALEN-LS1.F50/
AdVΔ2P.TALEN-RS1.F50 as determined by densitometry of DNA fragments depicted in Fig. 7A. (C) Gene 
delivery activities in hMSCs and myoblasts transduced with AdVs. Percentages of transduced cells 
incubated with different mixtures of reporter vector AdVΔ2P.eGFP.F50 and AdVΔ2U6.gRNAS1.F50, applied 
at a combined MOI of 80 TU/cell. Cells exposed only to AdVΔ2U6.gRNAS1.F50 at an MOI of 80 TU/cell 
served as negative controls. The frequency of eGFP-positive cells was determined by flow cytometry 
at three days post-transduction. (D) Cumulative data corresponding to the gene knockout frequencies 
in hMSCs versus human myoblasts following AdV-mediated delivery of gRNAS1:Cas9 complexes into 
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Figure 8. Analyses of target gene editing frequencies in human H27 cells transduced with AdVs 
encoding eGFP-directed RGN complexes. (A) Fluorescence microscopy on cultures of eGFP-expressing 
H27 cells co-transduced with AdVΔ2P.Cas9.F50 and AdVΔ2.U6.gRNAGFP.F50 applied at an MOI of XX TU/
cell each. Negative controls consisted of mock-transduced H27 cells and of H27 cells transduced 
either with AdVΔ2P.Cas9.F50 or with AdVΔ2.U6.gRNAGFP.F50 at an MOI of 100 TU/cell. Cell nuclei and 
eGFP-expressing cells in each microscopic field were identified via Hoechst 33342- and eGFP-directed 
fluorescence microcopy, respectively. Note the presence of eGFP-negative cells in cultures transduced 
with both vector types. (B) Flow cytometry-based quantification of target gene knockout levels in 
H27 cell cultures co-transduced with AdVΔ2P.Cas9.F50 and AdVΔ2.U6.gRNAGFP.F50 at the indicated MOIs 
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DISCUSSION
One can postulate that AdV technologies, in addition to their utility in well-established 
biomedical research fields such as oncology and vaccinology24-26, will start having an 
increasing role in experimental and applied genome engineering as well. An initial effort in 
this direction is provided by an AIDS therapeutic strategy based on knocking out the HIV-1 
co-receptor gene CCR5 following AdV-mediated ZFN transfer into CD4+ T cells cultured ex 
vivo27. Related to this, we have recently shown that AdVs can also serve as delivery vehicles 
for introducing functional TALENs into human cells18, whereas Ebina and colleagues have 
provided a proof-of-concept for using RGNs to disrupt HIV-1 proviral DNA28. In the current 
work, we have extended the utility of the AdV technology to genome engineering strategies 
based on RNA-dependent DNA nucleases derived from a type II CRISPR/Cas system.
Assuming that designer nuclease gene expression should ideally occur at high levels29,30 
and be short-term, AdVs may ultimately be preferable expression platforms when compared 
to other episomal viral vector systems such as silencing-prone integrase-defective lentiviral 
vectors (IDLVs)30,31 and ssDNA adeno-associated viral vectors (AAVs)32. Moreover, the 
relatively large size of Cas ORFs may, to some extent, compromise the production of viral 
vectors whose optimal nucleic acid packaging capacities are significantly lower than those 
offered by AdV backbones and capsids. Still related to this payload capacity issue, our 
results further suggest that efficient chromosomal DSB formation seems to display a higher 
dependency on the overall RGN concentrations in target cell nuclei rather than on the use 
of a specific ratio between the Pol-II and Pol-III expression units. Thus, integrated vector 
designs in which both Cas9 and gRNA expression units are co-delivered within single vector 
particles may turn out to be advantageous in certain experimental settings.
By carrying out transduction experiments with AdVs encoding validated gRNAS1:Cas9 
complexes and optimized TALEN-LS1:TALEN-RS1 heterodimers, we found that the latter 
sequence-specific nuclease system yielded gene disruption levels that were similar to or 
higher than those achieved by the former. This outcome is different from that reported 
recently by Ding and colleagues33. Through co-transfection experiments in human 
pluripotent stem cell lines comparing gRNA:Cas9 sets with TALEN pairs based on a specific 
architecture, these authors showed that, for each targeted locus, the RGNs consistently and 
substantially outperformed the TALENs. At this stage it is difficult to pinpoint any culprit(s) 
for these different outcomes since the variables are numerous and include the nature of the 
scaffolds for each platform, the delivery methods as well as the cell types and chromosomal 
target sequences tested. Nonetheless, our results do support the view that the TALEN 
platform is not per se inferior to that of RGNs in what site-specific chromosomal cleaving 
activity is concerned. Finally, we have shown that, at matched doses, AdV-mediated transfer 
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Whether these data are a consequence of different epigenetic signatures at AAVS1 or some 
other cell type-specific variable(s) remains to be investigated. 
In conclusion, our findings demonstrate that AdVs constitute a valuable delivery option 
for introducing type II CRISPR/Cas-derived RGN complexes into human cells regardless of 
their transformation status and open as a result the perspective for RGN deployment and 
optimization in human primary cells. This research might include, in addition to on-target 
versus off-target assessments and gene knockout approaches, the testing of genome editing 
strategies based on donor DNA templates and AdV-mediated delivery of RGNs into target 
cell nuclei.
METHODS
Cells. The U2OS human osteosarcoma and the HeLa cervix carcinoma cells (American Type 
Culture Collection) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 
10% and 5% fetal bovine serum (FBS), respectively, at 37ºC in a 10% CO2 atmosphere. The E1- 
and E2A-complementing AdV packaging cell line PER.E2A34, was kept in DMEM supplemented 
with 10% FBS, 10 mM MgCl2 and 250 µg/ml of Geneticin (Invitrogen). PER.E2A cells were 
regularly sub-cultured at 39ºC and were shifted to 34ºC during AdV production for the 
proper folding of their E2A-encoded thermo-sensitive DNA-binding protein. The origin of 
and culture conditions for the HeLa cell-derived clone H27, constitutively expressing eGFP, 
as well as those of myoblasts and hMSCs have been detailed elsewhere23,35,36. PER.C6 cells37 
were cultured at 37ºC in DMEM with 10% FBS and 10 mM MgCl2.
Recombinant DNA. Standard recombinant DNA techniques were applied for the construction 
of the various AdV shuttle plasmids38. The TALEN-encoding plasmids pAdSh.PGK.TALEN-LS1 
39 and pAdSh.PGK.TALEN-RS1 39 harbor the TALEN ORFs derived from 1383.pVAX.AAVS1.
TALEN.L-9418 and 1384.pVAX.AAVS1.TALEN.R-9518, respectively. These constructs contain 
as transcription regulatory elements the human house-keeping phosphoglycerate kinase 1 
gene (PGK) promoter and the simian virus 40 polyadenylation signal (SV40)39. The pAdSh.
PGK.Cas9 and pSh.AAVS1.eGFP40 constructs have these PGK and SV40 regulatory elements 
controlling the human codon-optimized ORF encoding hCas910 (herein referred to as Cas9) 
and the reporter eGFP, respectively. The Cas9 ORF was isolated from Addgene plasmid 
41815. The expression units gRNA_AAVS1-T210 and gRNA_GFP-T210 based on the U6 RNA 
Pol III promoter (herein dubbed gRNAS1 and gRNAGFP, respectively) were retrieved from 
Addgene plasmid 41818 and 41820 and were inserted into the MCS of pAdSh.MCS.SV40, 








































Viral vector-mediated delivery of RGNs  |  137
5
The E1- and E2A-deleted (i.e. second-generation) fiber-modified AdV molecular clones 
pAdVΔ2P.TALEN-LS1.F50, pAdVΔ2P.TALEN-RS1.F50, pAdVΔ2P.Cas9.F50, pAdVΔ2U6.gRNAS1.F50, 
pAdVΔ2U6.gRNAGFP.F50 and pAdVΔ2P.eGFP.F50 were assembled via homologous recombination 
after transformation of BJ5183pAdEasy-2.50 E. coli cells41 with MssI-treated AdV shuttle plasmids 
pAdSh.PGK.TALEN-LS1, pAdSh.PGK.TALEN-RS1, pAdSh.PGK.Cas9, pAdSh.U6.gRNAS1, pAdSh.
U6.gRNAGFP and pSh.AAVS1.eGFP40, respectively. 
Validation of Cas9- and gRNAS1-encoding AdV shuttle plasmids. PER.C6 cells were plated 
at a density of 1.5×106 cells per well of 6-well plates (Greiner Bio-One). The next day, a 
total amount of 6 µg of DNA corresponding to 1:1 mixtures of hCas9 (Addgene plasmid 
41815) and gRNA_AAVS1-T2 (Addgene plasmid 41818), pAdSh.PGK.Cas9 and pAdSh.
U6.gRNAS1, hCas9 and gRNA_Cloning Vector (Addgene plasmid 41824) or hCas9_D10A 
(Addgene plasmid 41816) and gRNA_AAVS1-T2, were transfected by deploying a 1 mg/ml 
polyethyleneimine (PEI) solution (Polysciences) essentially as described elsewhere41 except 
for the use of 6 µg of DNA and 19.7 µl of PEI instead of 6.25 µg of DNA and 18.8 µl of PEI. At 
3 days post-transfection genomic DNA from mock-transfected cells and from co-transfected 
cells, was isolated according to a previously described method42. Targeted gene disruption 
was assessed by using the T7 endonuclease I (T7EI)-based assay as described below.
Viral vector production, purification and titration. The production of viral vectors AdVΔ2P.
TALEN-LS1.F50, AdVΔ2P.TALEN-RS1.F50, AdVΔ2P.Cas9.F50, AdVΔ2U6.gRNAS1.F50, AdVΔ2U6.gRNAGFP.
F50 and AdVΔ2P.eGFP.F50, was carried out essentially as described elsewhere41. In brief, the 
rescue of AdV particles was initiated by transfecting 1.25×106 PER.E2A cells seeded in 
medium without Geneticin in wells of 6-well plates (Greiner Bio-One). The next day, the cells 
were transfected by using 18.8 µl of a 1 mg/ml PEI solution and 6.25 µg of PacI-linearized 
plasmids pAdVΔ2P.TALEN-LS1.F50, pAdVΔ2P.TALEN-RS1.F50, pAdVΔ2P.Cas9.F50, pAdVΔ2U6.gRNAS1.
F50, pAdVΔ2U6.gRNAGFP.F50 and pAdVΔ2P.eGFP.F50. Following an overnight incubation period at 
39ºC, the transfection media was replaced and the cells were transferred to the permissive 
temperature of 34ºC. After the emergence of complete cytophatic effect (CPE), the producer 
cells were harvested and subjected to three cycles of freezing and thawing in liquid N2 and a 
37ºC water bath, respectively. Rescued AdVs present in clarified producer cell supernatants, 
were subsequently amplified through propagation on newly seeded PER.E2A cells. Large-
scale AdV stocks were prepared by infecting producer cells at 70-80% confluence in 16 
175-cm2 cell cultures flasks (Greiner Bio-One). The details on the isopycnic CsCl density-
gradient ultracentrifugation and ultrafiltration used to purify and de-salt AdV preparations, 
respectively, have been described before41. The titers of purified AdV stocks were determined 
by TCID50 assays as follows. One hundred microliters of a PER.E2A cell suspension containing 
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96-well plates (Greiner Bio-One). After an overnight incubation period at 39ºC in a 10% CO2 
atmosphere, the cells were exposed in octuplicate to 100 µl of 10-fold dilutions (range: 10-5 
through 10-12) of the various viral vector preparations. Next, the cells were incubated for 2.5 
weeks at 34ºC in a 10% CO2 atmosphere having 100 µl of DMEM containing 2% FBS and 10 
mM MgCl2 being added at 1 week post-infection. After this incubation period, wells with 
cultures containing viral plaques or at full CPE were scored to calculate the titers in terms of 
transducing units per ml (TU/ml) as specified elsewhere41.
Isolation of viral vector DNA for structural analysis. The isolation of AdV genomes from 
purified particles was carried out as specified elsewhere41. The in silico restriction patterns 
were made with the aid of Gene Construction kit (version 2.5) software (Textco BioSoftware, 
Inc.). 
Transduction experiments. Myoblasts, hMSCs and U2OS cells were seeded in their 
respective media at a density of 1×105 cells per well of 24-well plates (Greiner Bio-One), 
whereas HeLa cells were plated in the same vessel format at a density of 5×104 cells. 
Approximately 24 hours after seeding, the cells were exposed in 500-µl volumes to the two 
different AdV pair combinations (i.e. AdVΔ2P.TALEN-LS1.F50/AdVΔ2P.TALEN-RS1.F50 or AdVΔ2P.
Cas9.F50/AdVΔ2U6.gRNAS1.F50) at the indicated multiplicities of infection (MOI). Mock-
transduced cells or, whenever indicated, cells transduced exclusively with one element of 
each vector pair, served as negative controls. Three days post-infection, total cellular DNA 
was isolated by using the DNeasy Blood & Tissue kit (Qiagen) following the manufacturer’s 
recommendations.
Transduction experiments on indicator H27 cells. One day before transduction, 1.0×105 
H27 cells were seeded in wells of 24-well plates. After the removal of the culture medium, 
the H27 cell monolayers were incubated in 500-µl volumes consisting of various total and 
relative amounts of AdVΔ2P.Cas9.F50 and AdVΔ2U6.gRNAGFP.F50. Mock-transduced H27 cells 
and H27 cells exposed exclusively to AdVΔ2P.Cas9.F50 or to AdVΔ2U6.gRNAGFP.F50 each applied 
at an MOI of 100 TU/cell, provided for negative controls. Subsequently, after extensive sub-
culturing to remove reporter protein from cells with disrupted eGFP ORFs, the presence of 
eGFP-negative cells was assessed by direct fluorescence microscopy and flow cytometry at 
15 days post-transduction.
Direct fluorescence microscopy. Targeted eGFP knockout in H27 cell cultures was monitored 
by direct fluorescence microscopy. The H27 cell nuclei were stained by adding Hoechst 
33342 (Molecular Probes) at 10 µg/ml for 10 min. Next, the cell cultures were washed twice 
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signals were detected by using an Olympus IX51 inverse fluorescence microscope (Olympus). 
Micrographs were captured and archived by deploying a XC30 Peltier CCD camera and the 
CellF software (both from Olympus). 
Flow cytometry. The frequencies of eGFP-positive cells in cultures transduced with AdVΔ2P.
eGFP.F50 and of eGFP-negative cells in H27 cell cultures were determined by using a BD LSR II 
flow cytometer (BD Biosciences). Data were analyzed with the aid of FlowJo 7.2.2 software 
(Tree Star). Mock-transduced H27 cells served to establish the background fluorescence. 
Samples of at least 10,000 viable single cells were analyzed per experimental condition.
T7 endonuclease I-based genotyping assays. Target gene disruption levels were assessed by 
using mismatch-sensitive T7EI endonuclease I. To this end, genomic DNA samples from target 
cells were subjected to PCR for the amplification of a 469-bp DNA segment encompassing 
the target sites for the gRNAS1:Cas9 and TALEN-LS1:TALEN-RS1 complexes. The primers, PCR 
reagents and cycling conditions used have been described in detail before18. Next, the 
resulting amplicons were denaturated and reannealed in a thermocycler by applying the 
program specified in Supplementary Table S1. One fifth of each PCR mixture was incubated 
in 15-µl reactions with 1× NEBuffer 2 and 5 U of T7EI (both from New England Biolabs). 
Control reactions lacked T7EI. After 15 minutes at 37ºC, the samples were subjected to 
electrophoresis through 2% (w/v) agarose in 1×Tris-Acetate-EDTA buffer. Finally, ethidium 
bromide-stained DNA species were measured in a Molecular Imager Gel-Doc™ XR+ with the 
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ABSTRACT
Engineered sequence-specific nucleases and donor DNA templates can be customized to 
edit mammalian genomes via the homologous recombination (HR) pathway. Here we report 
that the nature of the donor DNA greatly affects the specificity and accuracy of the editing 
process following site-specific genomic cleavage by transcription activator–like effector 
nucleases (TALENs) and clustered, regularly interspaced, short palindromic repeats (CRISPR)-
Cas9 nucleases. By applying these designer nucleases together with donor DNA delivered 
as protein-capped adenoviral vector (AdV), free-ended integrase-defective lentiviral vector 
or nonviral vector templates, we found that the vast majority of AdV-modified human cells 
underwent scarless homology-directed genome editing. In contrast, a significant proportion 
of cells exposed to free-ended or to covalently closed HR substrates were subjected to 
random and illegitimate recombination events. These findings are particularly relevant for 
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INTRODUCTION
The exchange of genetic information between native acceptor loci and exogenous donor DNA 
through error-free HR is an established strategy to manipulate prokaryote and eukaryote 
genomes with nucleotide-level precision1. However, in mammalian somatic cells, typical 
frequencies of spontaneous HR-mediated gene-targeting range from 10−8 to 10−6 events per 
transfected cell, with most exogenous DNA being found randomly integrated throughout 
host-cell chromosomes2–4. Importantly, the deployment of sequence-specific nucleases 
greatly increases the odds of retrieving cells with specific allelic alterations5. Generation 
of double-stranded DNA breaks (DSBs) at predefined chromosomal positions together 
with the introduction of donor DNA containing sequences identical to those bracketing the 
genomic lesion can increase gene targeting by several orders of magnitude. In gene therapy, 
for instance, inserting transcriptional units into specific genomic positions (i.e., so-called 
safe harbors) or directly repairing faulty genes within their native chromosomal context is a 
highly desirable goal6
Viral vectors constitute attractive gene delivery vehicles owing to their efficient 
transduction of a wide range of cell types. In addition, in contrast to bulk nucleic acid 
transfections7, viral transductions permit fine control over the number of DNA copies 
that reach the nucleus. We have investigated the role of the donor-delivering vectors on 
the specificity and accuracy of the DNA editing process. Specificity refers to the relative 
frequencies of on-target versus off-target insertions; accuracy refers to the structure or 
arrangement of site-specifically integrated exogenous DNA. Low-fidelity gene targeting 
includes the chromosomal integration of exogenous DNA copies in tandem (i.e., concatemers) 
as well as the incorporation of virus-derived sequences at the target site. These events may 
result from the generation of vector-vector or vector-host DNA junctions through error-
prone nonhomologous end joining. Clearly, accurate site-specific gene addition and repair 
should yield, respectively, homogenous transgene activities and restored open reading 
frames (ORFs) in target cell populations.
In this study, we compared the specificity and the accuracy of nuclease-induced gene 
targeting upon the delivery of various types of HR substrates (i.e., protein-capped, free-
ended and covalently closed DNA) and found that the nature of the donor DNA greatly 
affects these key parameters. We demonstrate that donor DNA transferred by protein-
capped AdVs is amenable to homology-directed gene targeting after sequence-specific 
genomic cleavage by TALENs and CRISPR-Cas9 nucleases. Further, donor delivery by AdVs 
results in diminished off-target chromosomal insertion, concatemeric ‘footprint’ formation 
and prokaryotic DNA incorporation. In consequence, genetically modified cell populations 
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RESULTS
Designer nuclease–induced IDLV DNA targeting is inaccurate
Integrase-defective lentiviral vectors (IDLVs)8 are one of the most commonly used viral 
vectors for the delivery of HR substrates into human cells9–14. Because TALENs display a 
particularly favorable specificity profile15, we started by investigating the specificity and 
fidelity of TALEN-induced chromosomal insertion of IDLV donor DNA. We introduced TALENs 
specific for the safe harbor AAVS1 locus into human myoblasts through the early region 
1 (E1)-deleted adenoviral vectors AdV.TALEN-LS1 and AdV.TALEN-RS1 (ref. 16) together with 
the target site-matched HR substrate delivered by IDLV.donorS1 particles (Fig. 1a). The AdV-
delivered TALEN pair TALEN-LS1 and TALEN-RS1 forms a dimeric nuclease complex by binding, 
respectively, at the ‘left’ (L) and ‘right’ (R) end of the AAVS1 target sequence (S1). The 
IDLV.donorS1, generated on the basis of plasmid AQ25_pLV.donorS1 (Supplementary Note), 
contains a transgene encoding the fluorescent reporter EGFP flanked by sequences sharing 
identity to DNA bracketing the TALEN target site. Cells exposed to the latter vector alone 
or mixed with AdV.TALEN-LS1 served as negative controls. After subculturing to eliminate 
episomal vector DNA, flow cytometry (Fig. 1b) and live-cell fluorescence microscopy 
(Supplementary Fig. 1a) showed a significant (P < 0.0001) nuclease-dependent increase in 
the frequencies of stably transduced cells.
Next, to gauge the relative frequencies of on-target versus off-target IDLV donor DNA 
integration, we randomly selected EGFP+ myoblast clones (n = 104) from cultures exposed 
to the AAVS1-specific TALENs. We observed, using PCR screening with primers designed to 
yield amplicons diagnostic for HR-derived junctions between foreign and native target DNA 
(Fig. 1a and Supplementary Fig. 1b), that 86.6% of the EGFP+ cells underwent homology-
directed chromosomal integration of the exogenous DNA (Fig. 1c and Supplementary Fig. 
1b). The resulting AAVS1-donor DNA junctions represented events involving the telomeric 
(6.7%), centromeric (3.9%) or both ends of the targeting template (76.0%) (Fig. 1c). 
Further characterization of IDLV integrants revealed high frequencies of head-to-tail (H-T) 
concatemeric forms not only in the nontargeted but also in the three AAVS1-targeted clonal 
fractions (38.5%) (Fig. 1c and Supplementary Fig. 1b). Of note, PCR analysis of EGFP+ cells 
sorted from cultures that were not exposed to TALENs did not yield amplicons diagnostic 
for homology-directed gene addition (Supplementary Fig. 1c). These data indicate that a 
substantial fraction of incoming IDLV donor templates integrates randomly into host cell 
chromosomes, presumably at spontaneous DSBs through a noncanonical, i.e., integrase-
independent, process17,18. Moreover, owing to their concatemeric structure, a sizable 
proportion of IDLV-exposed cells harbors unwanted HIV-derived cis-acting elements (Fig. 1c 
and Supplementary Figs. 1b and 2). These tandem repeats are expected to neither restore 
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gene repair and gene addition strategies, respectively. These results are in line with those of 
other experiments carried out by us (Supplementary Results and Supplementary Fig. 3) as 
well as by others11,12,14 deploying IDLV donor DNA and zinc-finger nuclease (ZFN) technology.
Figure 1. Gene targeting with IDLV donor DNA and TALEN-induced DSBs. (a) The schematic shows 
TALENs drawn in relation to their target sites in the AAVS1 locus. These bipartite target sites frame 
spacer sequences, which are cleaved upon local nuclease pair dimerization. IDLV.donorS1 vector 
genomes contain HR substrates consisting of a reporter expression unit flanked by sequences 
identical to those bracketing the TALEN target sequences. The transgene in IDLV.donorS1 comprises 
the human PGK1 promoter, the EGFP ORF and the bovine GH1 polyadenylation signal. The structure 
of the integrated exogenous DNA resulting from error-free HR events, forming ‘telomeric’ and 
‘centromeric’ junctions (jT and jC), is depicted. Ψ, HIV-1 packaging signal; white and gray boxes, 5′ 
and 3′ long terminal repeat, respectively. (b) Flow cytometric analysis on myoblasts cotransduced 
with the indicated viral vector constructs. Flow cytometry was performed at 27 d post transduction; 
10,000 events, each corresponding to a single viable cell, were measured per sample. Error bars, s.d. P 
value (by two-tailed t-test) and the number of independent experiments (n) are shown. DSB, double-
stranded DNA break. (c) Cumulative molecular characterization of EGFP+ myoblast clones generated 
by TALEN-LS1:TALEN-RS1 and IDLV.donorS1 DNA delivery (Supplementary Fig. 1b). The frequencies of 
EGFP+ myoblast clones with random insertions (jT−/jC−), HR-derived telomeric junctions (jT+/jC−), HR-
derived centromeric junctions (jT−/jC+) and HR-derived telomeric and centromeric junctions (jT+/jC+) 
are plotted. The percentages of myoblast clones without (−) or with (+) head-to-tail IDLV concatemers 
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Designer nuclease–induced AdV DNA targeting is accurate
Together with IDLVs, adeno-associated viral vectors (rAAVs) constitute the most commonly 
used viral vectors for the delivery of HR substrates into mammalian cells4,19–22. Like IDLVs, 
rAAV genomes have free ends and can become inserted at sporadic genomic DSBs after 
being co-opted by illegitimate recombination pathways involved in chromosomal DNA 
break repair11,23. In contrast, linear double-stranded AdV DNA has a terminal protein (TP) 
covalently attached at its 5′ ends. This led us to postulate that this capped DNA structure 
reduces the chance for interactions between the donor and off-target DSBs, such that pairing 
between acceptor and donor DNA through shared sequences would favor HR-dependent 
insertions at cleaved target sites. We therefore asked whether delivering donor DNA in 
the context of protein-capped AdV genomes24 displays a less promiscuous chromosomal 
integration pattern and a more precise insertion profile than that resulting from using free-
ended DNA. We generated the E1- and early region 2A (E2A)-deleted AdV.Δ2.donorS1 to 
introduce the AAVS1-matched HR substrate into myoblasts exposed to the AAVS1-specific 
TALENs, as well as to unexposed cells. This AdV-delivered donor DNA harbors the same 
EGFP-encoding transcriptional unit present in the aforementioned IDLV.donorS1 (Fig. 1a). 
Flow cytometry of the resulting long-term cultures showed a clear nuclease-dependent 
increase in the frequencies of stably transduced cells (Fig. 2a) with not only TALEN-induced 
but also residual DNA integration rates being lower than those measured in their IDLV.
donorS1-transduced counterparts (Fig. 1b). The degree of the TALEN-dependent stimulatory 
effect was nonetheless similar to that observed in IDLV.donorS1-transduced myoblasts (Fig. 
1b). Interestingly, cotransducing myoblasts with the AdV.Δ2.donorS1 and TALEN-encoding 
AdVs resulted in EGFP+ populations with a distribution of transgene expression levels almost 
as narrow as those of clones harboring AAVS1-targeted donorS1 DNA and much narrower 
than those of IDLV.donorS1-modified populations (Fig. 2b). We observed similar results at 
the clonal level by comparing the mean fluorescence intensity (MFI) of EGFP+ myoblasts 
randomly selected from TALEN-treated cultures transduced either with IDLV.donorS1 or with 
AdV.Δ2.donorS1 (Fig. 2c). Collectively, these data indicate scarce chromosomal positional 
effects on transgene activity in AdV.Δ2.donorS1-modified populations, possibly resulting 
from a preponderance of site-specific over random genomic DNA insertions. Indeed, all of 
the EGFP+ myoblast clones isolated from cultures cotransduced with AdV.Δ2.donorS1 and 
TALEN-encoding AdVs (n = 110) had AAVS1–foreign DNA junctions resulting from HR events 
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Figure 2. Gene targeting with AdV donor DNA and TALEN-induced DSBs. (a) Flow cytometric analysis 
on myoblasts cotransduced with the indicated viral vector constructs. The AdV.Δ2.donorS1 was applied 
at multiplicity of infection values of 5 transducing units (TU)/cell (+) and 10 TU/cell (++). Cultures 
exposed to AdV.Δ2.donorS1 at 5 TU/cell alone (+, −) or mixed with AdV.TALEN-LS1 (+, L) or with AdV.
TALEN-RS1 (+, R) served as negative controls. Flow cytometry was performed at 45 d post transduction; 
10,000 events corresponding to single viable cells were measured per sample. Error bars, s.e.m. P 
value (by two-tailed t-test) and the number of independent experiments (n) are shown. DSB, doubled-
stranded DNA break. (b) Coefficient of variation (CV) of EGFP+ populations exposed to AAVS1-specific 
TALENs and HR substrates delivered via the indicated donors. Clones containing an AAVS1-targeted 
donorS1 DNA copy (n = 10 clones) and EGFP+ populations with randomly inserted IDLV.donorS1 DNA 
served as controls (gray and orange bars, respectively). (c) Mean fluorescence intensity (MFI) values 
of EGFP+ myoblast clones targeted with TALENs and either IDLV.donorS1 (red bars) or AdV.Δ2.donorS1 
(black bars). Inset, box plot of the cumulative MFI values corresponding to both series of myoblast 
clones analyzed; n indicates number of clones. Whiskers, minimum and maximum. P was calculated by 
two-tailed t-test. (d) Cumulative data on randomly selected EGFP+ myoblast clones (n = 110) isolated 
from cultures cotransduced with AdV.Δ2.donorS1, AdV.TALEN-LS1 and AdV.TALEN-RS1 (Supplementary 
Fig. 4a). The frequencies of EGFP+ myoblast clones representing the different integrant classes are 
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To further probe the precision of AdV gene targeting, we set up a PCR assay to detect 
head-to-tail exogenous DNA concatemers. This assay failed to produce any discernible head-
to-tail–specific PCR species from genomic DNA of EGFP+ myoblasts sorted from cultures 
cotransduced with AdV.Δ2.donorS1 and TALEN-encoding AdVs (Supplementary Fig. 4b). 
Southern blot analysis of AdV.Δ2.donorS1-modified clones confirmed target-site specificity. 
We note that we did identify a clone that, in addition to the typical AAVS1-targeted donor 
DNA, contained an integrant whose origin is consistent with HR-independent integration 
(Supplementary Fig. 5a). Nonetheless, in line with its low prevalence, we did not detect the 
latter type of integrant in the parental EGFP+ myoblast population (Supplementary Fig. 5b). 
Southern blot analysis also identified a clone that underwent biallelic targeting.
Next we performed AdV gene-targeting experiments in HeLa cells. These cells display 
a high degree of genetic instability (Supplementary Fig. 6), providing, as a result, a more 
stringent model system in which to evaluate HR-mediated genome editing amidst a 
presumably high frequency of spontaneous chromosomal DSBs. Consistent with the 
experiments carried out in myoblasts (Fig. 2a), we observed a significant (P < 0.0001) TALEN-
dependent increase in the frequency of stably transduced cells (Fig. 3a,b). We did not detect 
head-to-tail AdV DNA concatemers in the EGFP+ populations resulting from TALEN-induced 
chromosomal insertion of Adv.Δ1.donorS1 DNA (Fig. 3c). Notably, all randomly selected 
EGFP+ HeLa cell clones (n = 83) were genetically modified through homology-directed gene 
targeting at AAVS1, confirming a high level of target-site specificity following AdV-mediated 
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Figure 3. Nuclease-mediated gene targeting of AdV donor DNA in genetically unstable HeLa cells. (a) 
Flow cytometric analysis of HeLa cells 24 d after transduction with the indicated viral vector constructs. 
Error bars, s.d. P value (by two-tailed t-test) and the number of independent experiments (n) are 
shown. (b) Representative flow cytometry dot plots corresponding to HeLa cell cultures exposed 
to the indicated viral vector constructs at 24 d post transduction. Owing to a bicistronic expression 
unit, cells transduced with TALEN-encoding AdVs become tagged with DsRedEx2.1. (c) PCR analysis 
probing for head-to-tail AdV DNA concatemers in transduced EGFP+ HeLa cells. Top, schematics of 
in vitro–assembled head-to-tail AdV DNA junctions (jH-T). L-ITR and R-ITR, ‘left’ and ‘right’ AdV ITR, 
respectively; half arrows, primers; horizontal bar, amplicon diagnostic for the presence of head-to-
tail AdV DNA concatemers. Bottom, PCR analysis of genomic DNA from EGFP+ HeLa cells exposed to 
AAVS1-specific TALENs and AdV.Δ1.donorS1 (gDNA EGFP+). DNA from parental HeLa cells (gDNA HeLa 
cells) and nuclease-free water are negative controls; in vitro–generated head-to-tail AdV DNA (H-T 
AdV DNA) is the positive control. (d) Cumulative data on randomly selected EGFP+ HeLa cells isolated 
from cultures co-transduced with AdV.Δ1.donorS1, AdV.TALEN-LS1 and AdV.TALEN-RS1 (Supplementary 
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AdV-based gene targeting with CRISPR-Cas9
We investigated the compatibility of nuclease-induced AdV gene targeting with the versatile 
CRISPR-Cas9 RNA-guided nuclease system25. We deployed the vector pair AdV.Cas9 and AdV.
gRNAS1, which encode Cas9 and a single guide RNA (gRNAS1) addressing the Cas9 nuclease to 
a genomic position overlapping with the target site for the AAVS1-specific TALENs (Fig. 4a). 
Exposing HeLa cells to AdV.Cas9 and AdV.gRNAS1 resulted in robust and dose-dependent DSB 
formation at AAVS1 (Supplementary Fig. 8).
We initiated gene-targeting experiments by cotransducing HeLa cells with AdV.
Δ2.donorS1, AdV.Cas9 and AdV.gRNAS1. HeLa cells cotransduced exclusively with AdV.
Δ2.donorS1 and AdV.Cas9 served as negative controls. In these experiments, we also tested 
conventional nonviral plasmid donors with both circular and linear topologies deploying, 
in this case, TALENs as the designer nuclease system. Thus, HeLa cells were cotransfected 
with constructs encoding the AAVS1-specific TALENs mixed with supercoiled pAdV.donorS1, 
PacI-linearized pAdV.donorS1 or TALEN-cleavable pAdV.donorS1/T-TS (Supplementary Fig. 9). 
The free-ended plasmid donor templates were generated in vitro and in cellula by restriction 
enzyme– and TALEN–induced DNA cleavage, respectively. Of note, the nonprokaryotic DNA 
portions of these plasmids are isogenic to those present in protein-capped AdV.Δ2.donorS1 
genomes. HeLa cells transfected with the TALEN-LS1-expressing construct plus each donor 
plasmid type served as negative controls.
The percentages of EGFP+ cells in cultures exposed to Cas9:gRNAS1 complexes and AdV.
Δ2.donorS1 (Supplementary Fig. 9) were comparable to those measured in populations 
treated with TALEN-LS1:TALEN-RS1 dimers and AdV.Δ2.donorS1 (Fig. 3a,b). Moreover, the 
frequencies of genetically modified cells were clearly higher in cultures that had been 
subjected to site-specific DSBs. Crucially, stably transduced HeLa cells generated by co-
delivering CRISPR-Cas9 complexes and AdV.Δ2.donorS1 DNA displayed a remarkably narrow 
range of transgene activities, as determined by flow cytometric screening of randomly 
selected EGFP+ clones (Fig. 4b,c), reminiscent of data in myoblasts modified with TALENs 
and AdV donor DNA (Fig. 2c). 
Figure 4. Nuclease-induced gene targeting with AdV- versus plasmid-mediated delivery of HR 
substrates. (a) AAVS1 recognition sequences for the TALEN and Cas9:gRNA complexes are drawn in 
relation to the PPP1R12C locus in which they are embedded. The target sites of the TALEN pair and the 
RNA-guided CRISPR-Cas9 nuclease are shown in upper case and boxed, respectively. The protospacer-
adjacent motif (PAM) is shaded. Open vertical arrowheads indicate the Cas9 cleavage site. (b) MFI 
distribution of randomly selected EGFP+ HeLa cell clones genetically modified by Cas9:gRNAS1 and 
AdV.Δ2.donorS1 (TP capped) or by TALEN-LS1:TALEN-RS1 (L/R) and either pAdV.donorS1 (supercoiled), 
PacI linearized pAdV.donorS1 (in vitro linearized) or pAdV.donorS1/T-TS (in vivo linearized). (c) Box plot of 
cumulative MFI values corresponding to panel b. Whiskers, minimum and maximum; ns, not significant 
(two-tailed t-test), n indicates number of clones. (d) Frequencies of EGFP+ clones lacking the AAVS1-
donor DNA ‘telomeric’ junction, as identified by PCR screening of HeLa cell clones (Supplementary 
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In contrast, cells exposed to TALENs and plasmid donors led to EGFP+ clones displaying 
significantly (P < 0.0001) broader distributions of transgene expression levels, independently 
of the topology of the donor DNA (Fig. 4b,c). The higher homogeneity of transgene expression 
among AdV-modified cells is also apparent in the correlation between the coefficient of 
variation (CV) and MFI values for each individual clone (Supplementary Fig. 10a), as well 
as by comparing the range of transgene expression levels in EGFP+ populations resulting 
from CRISPR-Cas9–induced AdV gene targeting to those obtained using plasmid donors as 
templates (Supplementary Fig. 10b).
PCR analysis of donor DNA-AAVS1 junctions demonstrated higher target-site specificity 
of AdV over plasmid HR substrates even when using the presumably more promiscuous26–28, 
yet more versatile, CRISPR-Cas9 system25 (Fig. 4d and Supplementary Fig. 11). Furthermore, 
as previously observed for IDLV donor DNA, plasmid donor DNA resulted in intermolecular 
illegitimate recombination events (Supplementary Fig. 11a). Of note, these data represent, 
to the best of our knowledge, the first demonstration of the utility of the CRISPR-Cas9 
system for viral vector–mediated exogenous DNA targeting in human cells.
There are precedents for the delivery and persistence of bacterial DNA in mammalian 
cells exposed to both nonviral and viral vectors29,30. Besides their unpredictable structures, 
these prokaryotic DNA footprints are also undesirable owing to their immunostimulatory 
and methylation-prone nucleotide patterns (for example, CpG motifs). We probed for 
bacterial DNA in cell populations genetically modified by AdV- and plasmid-based gene 
targeting, and we detected KanR DNA exclusively in the latter case (Supplementary Fig. 12).
Capped AdV donor DNA reduces illegitimate recombination
Finally, we tested whether the protein cap of AdV genomes is a determinant of the specificity 
and fidelity of the AdV gene-targeting process. To this end, we generated AdV.Δ2.donorS1/T-TS 
and used it together with AdV.Δ2.TALEN-LS1 and AdV.Δ2.TALEN-RS1 to transduce HeLa cells. 
The AdV.Δ2.donorS1/T-TS has the same genetic makeup as the AdV.Δ2.donorS1 except that its 
donor DNA payload is flanked by recognition sequences for the AAVS1-specific TALENs (T-
TS) (Fig. 5a). The AdV.Δ2.TALEN-LS1 and AdV.Δ2.TALEN-RS1 differ from AdV.TALEN-LS1 and AdV.
TALEN-RS1, respectively, in that they are deleted simultaneously in E1 and E2A. In striking 
difference with the results obtained with the T-TS–negative AdV (Fig. 3d and Supplementary 
Fig. 7), PCR screening of thirty EGFP+ HeLa cell clones expanded from cultures exposed to 
TALENs and AdV.Δ2.donorS1/T-TS revealed that seven of these lines lacked HR-derived AAVS1–
exogenous DNA centromeric junctions (Fig. 5a). Control experiments established the release 
of donorS1/T-TS DNA from the AdV.Δ2.donorS1/T-TS genome in transduced cells (Supplementary 
Fig. 13). These results confirm that HR substrates delivered in the context of protein-
capped AdV genomes lead to more precise gene targeting when compared to HR substrates 
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AdV transduction experiments in reporter cells (Supplementary Results and Supplementary 
Fig. 14) and differentiating myoblasts (Supplementary Results and Supplementary Fig. 15).
Figure 5. The protein cap of AdVs contributes to gene-targeting specificity and accuracy. (a) The effect 
of donor DNA excision from the protein-capped AdV genomes on gene targeting frequency. Top, 
experimental strategy for the TALEN-mediated excision of HR templates from AdV DNA in transduced 
cells. AdV.Δ2.donorS1/T-TS, AdV carrying donorS1 DNA framed by target sequences for the AAVS1-specific 
TALENs (solid vertical arrowheads); Open oval, terminal protein (TP) covalently attached to the 5′ 
termini of AdV DNA; Ψ, AdV packaging signal; Exo., exogenous DNA. Bottom, PCR screening of EGFP+ 
HeLa cell clones to detect DNA junctions formed by HR events between AdV.Δ2.donorS1/T-TS DNA and 
the ‘centromeric’ side of the AAVS1 locus. Open arrowheads, clones harboring integrants lacking HR-
derived centromeric junctions. (b) Model for high-fidelity genome editing based on site-specific DSBs 
and AdV-delivered donor DNA. Left, donor DNA with free ends are sensed as broken DNA and rerouted 
to off-target or sporadic DSBs. Precision can be further compounded by the chromosomal insertion 
of concatemeric vector DNA forms. Right, protein-capped AdV genomes make interactions between 








































158  |  Chapter 6
DISCUSSION
The overall performance of genome-editing technology depends on its efficiency as well 
as on its specificity and accuracy. On-target specificity is being actively investigated, with 
significant efforts devoted to not only examining but also reducing off-target DNA cleaving 
activities of artificial nucleases5,26–28,31–34. The contribution of the donor DNA component to 
the specificity and accuracy with which different exogenous HR substrates are inserted at a 
target site has, comparatively, received scarcer scrutiny. It is known, however, that commonly 
used viral vector–borne donor templates lead to off-targeted events, presumably owing 
to their capture by random chromosomal DSBs11,23,29. In fact, IDLV and rAAV genomes are 
being exploited as tags for mapping the distribution of DSBs at a genome-wide scale11,35,36. 
Experimental evidence indicates that linear DNA molecules, by resembling DSB repair 
intermediates, are targets for illegitimate recombination mechanisms regardless of their viral 
or nonviral origin37,38. The ensuing processing of these molecules by DNA repair factors can 
result in their off-target chromosomal insertion as single or multiple copies. These outcomes 
reduce the predictability of transgene expression and gene repair in target cell populations. 
In principle, viral vector–mediated genome editing might be refined by adding, ‘outside’ 
the targeting HR module, a heterologous cassette conferring negative selection against cells 
with insertions at off-target sites. However, purging cells with targeted insertions formed by 
a combination of nonhomologous end joining and HR and/or with irregular concatemeric 
footprints would be less certain. Besides being complex and measurably ‘leaky’, negative 
selection strategies also reduce the effective packaging capacity of vector particles. 
The overall fidelity of the IDLV-based genome-editing process may also suffer from the 
intrinsic genetic ‘plasticity’ of lentiviruses. For instance, the error rates of retroviral reverse 
transcriptases are orders of magnitude higher than those of dsDNA viral polymerases39.
The frequencies of genetic modification achieved by DSB-induced AdV gene targeting 
were lower than those obtained with the IDLV platform but were within the range of or 
above those reached with plasmid donors co-delivered with nucleases or reported for single-
stranded rAAV templates40. Regardless, the high packaging capacity of AdV particles coupled 
to the availability of robust positive selection strategies can, if necessary, be exploited to 
rapidly enrich for the AdV-modified population. Notably, the precision of the AdV gene-
targeting procedure is expected to reduce the dependency on time-consuming screening of 
genetically modified populations to identify properly targeted cells.
On the basis of our findings, we put forward the view that the numerous efforts 
devoted to minimizing off-target activity of sequence-specific nucleases5,31–34 should be 
complemented with those aiming at identifying HR substrates whose features maximize 
on-target and accurate insertion of foreign DNA. The development of these optimized HR 
templates is expected to promote fundamental and applied research activities dependent 
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METHODS
Cells. The HeLa cells (American Type Culture Collection) and EGFP-positive H27 clone 
derivative41 were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) 
supplemented with 5% fetal bovine serum (FBS; Invitrogen). The HEK 293T lentiviral vector 
producer cells were maintained in DMEM containing 10% FBS, whereas the AdV packaging 
cell lines PER.C6 (ref. 42) and PER.E2A43 were cultured in DMEM supplemented with 10% 
FBS and 10 mM MgCl2 (Sigma-Aldrich) in the absence and in the presence of 250 μg/ml of 
Geneticin (Invitrogen), respectively. These cell types were kept in a humidified atmosphere 
containing 10% CO2. The origin of and the culture conditions for the human myoblasts have 
been detailed elsewhere44,45. The cell batches used to generate the viral vector preparations 
and to carry out the experiments were mycoplasma free.
Recombinant DNA. The complete and annotated DNA sequences of lentiviral vector 
shuttle plasmids AP45_pLV.donorEGFP and AQ25_pLV.donorS1 can be retrieved via GenBank 
accession numbers KF419293 and KF419294, respectively. The AdV shuttle plasmid AQ60_
pAdV.donorEGFP contains as foreign DNA the same targeting module as that in AP45_pLV.
donorEGFP. The AdV shuttle plasmid pAdV.donorS1/T-TS was constructed by inserting ‘upstream’ 
and ‘downstream’ of the donorS1 DNA module in pSh.AAVS1.eGFP14 (herein named pAdV.
donorS1) two annealed oligodeoxyribonucleotides containing bipartite target sequences 
for the AAVS1-specific TALENs (T-TS). A similar approach based on inserting into pAdV.
donorS1 a direct repeat of FRT sites in place of the T-TS sequences was pursued in parallel. 
These maneuvers resulted in pAdV.donorS1/FRT. The AdV molecular clones AL25_pAdV.ΔE1.
donorS1.F50 and AL27_pAdV.ΔE1ΔE2A.donorS1.F50 were assembled by HR in Escherichia 
coli strains46 BJ5183pAdEasy-1.50 and BJ5183pAdEasy-2.50, respectively, transformed with MssI-
treated pAdV.donorS1. The AdV molecular clones pAdV.ΔE1ΔE2A.donorS1/T-TS.F50 and pAdV.
ΔE1ΔE2A.donorS1/FRT.F50 were built by HR following the transformation of the latter cells 
with MssI-digested plasmids pAdV.donorS1/T-TS and pAdV.donorS1/FRT, respectively. The FP635-
encoding AdV molecular clone AR02_pAdV.ΔE1.ΔE2A.donorEGFP.F50 was generated by HR in 
BJ5183pAdEasy-2.50 cells46 transformed with MssI-digested AQ60_pAdV.donorEGFP. The AdV shuttle 
plasmid AG03_pAdV.CMV.TALEN-LEGFP and AF59_pAdV.CMV.TALEN-REGFP were constructed 
by inserting into the multiple cloning site of AQ17_pAdV.MCS.SV40pA the CMV promoter 
linked to the ORFs of TALEN-LEGFP and TALEN-REGFP, respectively. The TALEN-LEGFP and TALEN-
REGFP proteins (Supplementary Fig. 14a) were custom designed (GeneArt) to recognize the 
EGFP half target sites 5′-TGAACTTCAAGATCCGCCA-3′ and 5′-TCGGCGAGCTGCACGCTGC-3′, 
respectively, and cleave within their 14-bp intervening spacer sequence (Supplementary 
Fig. 14a). Next, the full-length AdV molecular clones AF50_pAdV.ΔE1.TALEN-LEGFP.F50 and 
AF52_pAdV.ΔE1.TALEN-REGFP.F50 were assembled by HR in E. coli by transforming strain 
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The AdV shuttle plasmid pAdSh.PGK.Cas9 contains a humanized ORF encoding the 
Streptococcus pyogenes nuclease Cas9 under the transcriptional control of the PGK1 
promoter and the SV40 polyadenylation signal, whereas the AdV shuttle plasmid pAdSh.
U6.gRNAS1 encodes a U6 promoter–driven single guide RNA targeting the Cas9 protein 
to the human AAVS1 locus47. The human codon-optimized cas9 ORF and the RNA Pol III-
dependent gRNAS1 expression unit have been published elsewhere48 and were isolated from 
constructs hCas9 (Addgene plasmid 41815) and gRNA_AAVS1-T2 (Addgene plasmid 41818), 
respectively. Next, the AdV molecular clones pAdVΔ2P.Cas9.F50 and pAdVΔ2U6.gRNAS1.F50 
were generated by HR in BJ5183pAdEasy-2.50 cells46 following their transformation with MssI-
treated pAdSh.PGK.Cas9 and pAdSh.U6.gRNAS1, respectively47. Further details about DNA 
constructs generated for this study can be found in the Supplementary Note.
Production and titration of AdV vectors. The generation of the fiber-modified E1-
deleted AdVs Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 (herein referred to as AdV.
TALEN-LS1 and AdV.TALEN-RS1, respectively) has been detailed elsewhere46. The same applies 
to the fiber-modified E1- and E2A-deleted AdVs Ad.ΔE1ΔE2A.TALEN-LS1.F50 and Ad.ΔE1ΔE2A.
TALEN-RS1.F50 (herein named AdV.Δ2.TALEN-LS1 and AdV.Δ2.TALEN-RS1, respectively)16. The 
productions of the fiber-modified E1-deleted AdV AdV.Δ1.donorS1 and of its E1- plus E2A-
deleted derivative AdV.Δ2.donorS1, were initiated by transfecting PER.C6 and PER.E2A 
cells with PacI-linearized AL25_pAdV.ΔE1.donorS1.F50 and AL27_pAdV.ΔE1ΔE2A.donorS1.
F50, respectively. The productions of the fiber-modified, EGFP-encoding, donor AdVs AdV.
Δ2.donorS1/T-TS and AdV.Δ2.donorS1/FRT as well as that of the fiber-modified, E1- and E2A-
deleted, FP635-encoding, donor AdV AdV.Δ2.donorEGFP were started by transfecting PER.
E2A cells with PacI-treated pAdV.ΔE1ΔE2A.donorS1/T-TS.F50, pAdV.ΔE1ΔE2A.donorS1/FRT.F50 and 
AR02_pAdV.ΔE1.ΔE2A.donorEGFP.F50, respectively. The E1- plus E2A-complementing PER.E2A 
cells were also used for rescuing and propagating the fiber-modified AdVs AdV.Cas9 and AdV.
gRNAS1 following their transfection with the PacI-linearized molecular clones pAdVΔ2P.Cas9.
F50 and pAdVΔ2U6.gRNAS1.F50, respectively. Finally, the generation of the first-generation 
and fiber-modified AdVs AdV.TALEN-LEGFP and AdV.TALEN-REGFP, was carried out in E1-only 
complementing cells transfected with PacI-digested AF50_pAdV.ΔE1.TALEN-LEGFP.F50 and 
AF52_pAdV.ΔE1.TALEN-REGFP.F50, respectively.
The DNA transfection–mediated rescue of AdV particles in packaging cell lines and 
their subsequent propagation and purification were performed essentially as described 
previously46,49. The isolation and restriction fragment length analysis of AdV.Δ2.donorS1/T-
TS and AdV.Δ2.donorS1/FRT DNA was carried out as detailed elsewhere46,49. The titers of the 
various reporter-encoding AdV stocks, expressed in terms of transducing units (TU) per ml, 
were determined through limiting dilutions on HeLa indicator cells seeded at a density of 
8 × 104 cells per well of 24-well plates. At 3 d post transduction, frequencies of reporter-
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negative AdV preparations were established by TCID50 assays in complementing cells and 
by fluorometric quantification of genome-containing vector particles (VP) per milliliter as 
described elsewhere46,49.
Production and titration of lentiviral vectors. The generation of the vesicular stomatitis 
virus glycoprotein G (VSV-G)-pseudotyped lentiviral vectors LV.ZFN-1EGFP and LV.ZFN-2EGFP has 
been described before50. The generation of the VSV-G-pseudotyped vectors IDLV.donorEGFP 
and IDLV.donorS1 was carried out by transient transfections of 293T cells with shuttle 
plasmids AP45_pLV.donorEGFP and AQ25_pLV.donorS1, respectively, together with packaging 
construct51 AM16_psPAX2.IND116N and pseudotyping construct pLP/VSVG (Invitrogen) as 
detailed elsewhere51,52. The physical particle titers of lentiviral vector preparations were 
determined by using the RETRO-TEK HIV-1 p24 ELISA kit as specified by the manufacturer 
(Gentaur Molecular Products). Titers of these vector stocks expressed in terms of TU/ml 
were derived by using a conversion factor of 2,500 TU/ng of HIV-1 p24gag protein.
Transduction experiments. The IDLV.donorEGFP transductions on cultures of EGFP+ H27 
indicator cells were carried out as follows. Eighty-thousand cells were seeded in wells of 
24-well plates (Greiner Bio-One). The next day, IDLV.donorEGFP was added at a multiplicity 
of infection (MOI) of 45 TU/cell together with the LV.ZFN-1EGFP and LV.ZFN-2EGFP vectors each 
applied at an MOI of 8 TU/cell. Parallel H27 cultures that were either untreated or were 
incubated exclusively with IDLV.donorEGFP at an MOI of 45 TU/cell, served as controls. Next, 
after an extensive 5-week subculturing period, the frequencies of reporter-positive and 
reporter-negative H27 cell populations were monitored and quantified, respectively, by 
two-color fluorescence microscopy and flow cytometry.
Long-term transduction experiments on human myoblasts were initiated by seeding 2 × 
105 cells per well in 24-well plates. The next day, the cells were incubated with AdV.TALEN-
LS1 (2.5 TU/cell) and AdV.TALEN-RS1 (2.5 TU/cell) mixed with IDLV.donorS1 (10 TU/cell) or with 
AdV.Δ2.donorS1 (10 TU/cell). The frequencies of IDLV.donorS1- and AdV.Δ2.donorS1-modified 
myoblasts were determined at 27 and 45 d post transduction, respectively.
Long-term transduction experiments on HeLa cells were started by seeding 8 × 104 cells 
per well in 24-well plates. After an overnight incubation period, the cells were exposed to 
AdV.TALEN-LS1 (3 TU/cell) and AdV.TALEN-RS1 (3 TU/cell) together with AdV.Δ1.donorS1 (6 TU/
cell). The frequencies of stably transduced cells were measured by flow cytometry at 24 d 
post transduction.
To investigate the effect of TALEN-mediated donor DNA excision on the rate of gene 
targeting, 8 × 104 HeLa cells, seeded 1 d before, were transduced with AdV.Δ2.TALEN-LS1 (1.5 
TU/cell) and AdV.Δ2.TALEN-RS1 (1.5 TU/cell) together with AdV.Δ2.donorS1/T-TS (3 TU/cell). The 
frequencies of stably transduced cells were established at 24 d post transduction by flow 
cytometry. The EGFP+ populations present in the various long-term cultures were sorted, 
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The gene-targeting experiments on EGFP+ H27 cells with the FP635-encoding vector AdV.
Δ2.donorEGFP were carried out as follows. Two-hundred thousand cells were seeded in wells 
of 24-well plates. The next day, AdV.Δ2.donorEGFP was added at an MOI of 4 TU/cell together 
with 1:1 mixtures of AdV.TALEN-LEGFP and AdV.TALEN-REGFP applied at total doses of 6.0 × 103, 
2.4 × 103 and 9.6 × 102 VP/cell. Controls consisted of H27 cells, HeLa cells exposed for 3 days 
to AdV.Δ2.donorEGFP (0.5 TU/cell) and H27 cells transduced with AdV.Δ2.donorEGFP (4 TU/cell) 
plus AdV.TALEN-LEGFP at 6.0 × 103, 2.4 × 103 and 9.6 × 102 VP/cell. At 48 h post transduction, 
the various H27 cultures received fresh regular medium, and 1 d later they started to be 
subcultured at a rate of about twice per week in order to remove the episomal vector DNA. 
The frequencies of the various types of H27 cell populations were determined by two-color 
flow cytometry at 37 d post transduction.
Flow cytometry and light microcopy. The measurement of transgene expression 
parameters (i.e., frequencies of reporter-positive and reporter-negative target cells, mean 
fluorescence intensities and coefficients of variation) were determined by using a BD LSR 
II flow cytometer (BD Biosciences). Data were analyzed with the aid of BD FACSDiva 6.1.3 
software (BD Biosciences) or FlowJo 7.2.2 (Tree Star). Mock-transduced target cells were used 
to set background fluorescence levels. At least 10,000 viable single cells were analyzed per 
sample. The light microscopic analyses were carried out with an IX51 inverse fluorescence 
microscope equipped with a XC30 Peltier-cooled digital color camera (Olympus). The images 
were processed with the aid of CellF 3.4 imaging software (Olympus).
Functional validation of CRISPR-Cas9 complexes delivered into target cells by AdVs. 
Fifty-thousand HeLa cells were transduced with AdV.Cas9 alone (300 TCID50/cell) or with 
1:1 mixtures of AdV.Cas9 and AdV.gRNAS1 applied at total vector doses of 60, 120, 180, 240 
and 300 TCID50/cell. At 3 d post transduction, chromosomal DNA was extracted from the 
target cells by using the DNeasy Blood & Tissue Kit (Qiagen) following the manufacturer’s 
instructions. Next, AAVS1-specific PCR amplifications and T7 endonuclease I–based 
genotyping assays were carried out essentially as previously described49.
Designer nuclease–mediated gene targeting of linear and supercoiled plasmid donor 
DNA. HeLa cells were seeded at a density of 6.5 × 104 cells per well of 24-well plates. The 
next day, the cells were transfected with DNA mixtures consisting of 100 ng of 1383.pVAX.
AAVS1.TALEN.L-94 (ref. 16), 100 ng of 1384.pVAX.AAVS1.TALEN.R-95 (ref. 16) and 200 ng 
of AAVS1-targeting AdV donor DNA plasmids. The targeting constructs were pAdV.donorS1, 
PacI-linearized pAdV.donorS1 and pAdV.donorS1/T-TS. Controls were provided by transfecting 
HeLa cells with 200 ng of 1383.pVAX.AAVS1.TALEN.L-94 mixed together with 200 ng of 
pAdV.donorS1, PacI-linearized pAdV.donorS1 or pAdV.donorS1/T-TS. The completion of the PacI 
digestions was confirmed by agarose gel electrophoreses and ethidium bromide staining. 
Each of the plasmid mixtures were diluted in 50 μl of 150 mM NaCl and received 1.32 μl 
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min incubation period at room temperature, the resulting polycation-DNA complexes were 
directly added into the culture medium. After 7 h, the transfection mixtures were removed 
and fresh culture medium was added. The resulting cell populations were subsequently 
subjected to subculturing for 3 weeks, after which cells stably expressing EGFP in these 
populations were individually sorted by flow cytometry into wells of 96-well plates. Viable 
single cell-derived clones corresponding to the various experimental settings were randomly 
selected for transgene expression and integration status analysis. 
Gene targeting of AdV donor DNA by using the RNA-guided nuclease Cas9. HeLa cells 
were seeded at a density of 8.0 × 104 cells per well in 24-well plates. The following day, 
the cells were transduced with AdV.Cas9 (150 TCID50/cell), AdV.gRNAS1 (50 TCID50/cell) and 
AdV.Δ2.donorS1 (10 TU/cell). To serve as negative controls, HeLa cells were either mock-
transduced or were transduced with AdV.Cas9 (150 TCID50/cell) and AdV.Δ2.donorS1 (10 
TU/cell). At 3 d post transduction, mock- and vector-transduced HeLa cells started to be 
subcultured. At 17 d post transduction, EGFP stably expressing cells were individually sorted 
by flow cytometry into wells of 96-well plates. Viable single cell-derived clones isolated 
from cultures initially exposed to AdV.Cas9, AdV.gRNAS1 and AdV.Δ2.donorS1 were randomly 
selected for transgene expression and integration status analysis.
Cell sorting and clonal expansion. Flow cytometry–assisted cell sorting was done after 
the removal of donor DNA-containing episomes from long-term HeLa and human myoblast 
cultures. The EGFP+ cells were collected in 1:1 mixtures of regular medium containing 
2× penicillin-streptomycin (Invitrogen) and FBS. Next, the sorted cells were individually 
seeded in wells of 96-well plates (Greiner Bio-One) at a density of 0.3 cells per well in their 
respective medium supplemented with 50 μM of α-thioglycerol (Sigma-Aldrich) and 20 nM 
of bathocuprione disulphonate (Sigma-Aldrich) to increase cloning efficiency53. Finally, over 
250 individual clones were randomly selected for expansion and molecular analyses.
Genomic DNA extraction. Genomic DNA was extracted from cell populations and clones 
essentially as described before54. In brief, the cells were collected and incubated overnight 
at 55 °C in 500 μl of lysis buffer (100 mM Tris-HCl, pH 8.5, 5 mM EDTA, 0.2% sodium dodecyl 
sulfate and 200 mM NaCl) supplemented with freshly added proteinase K (Thermo Scientific) 
at a final concentration of 100 ng/ml. The cell lysates were extracted twice with a buffer-
saturated phenol:chloroform:isoamyl alcohol mixture (25:24:1) and once with chloroform. 
Next, the genomic DNA was precipitated by the addition of 2.5 volumes of absolute ethanol 
and 0.5 volumes of 7.5 M ammonium acetate (pH 5.5). After washing with 70% ethanol, the 
DNA pellets were air dried and dissolved in 100 μl of Tris-EDTA buffer (10 mM Tris, pH 8.0, 
and 1 mM EDTA) supplemented with RNase A (Thermo Scientific) at a final concentration 
of 100 μg/ml. The genomic DNA of EGFP+ clones derived from cultures transfected with 
plasmid DNA as well as that derived from cultures cotransduced with AdV.Cas9, AdV.gRNAS1 
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protocol provided by the manufacturer. The genomic DNA samples of FP635+ H27 clones 
were also isolated by deploying the DNeasy Blood & Tissue Kit.
PCR analyses of gene-targeting experiments with plasmid, IDLV and AdV donor DNA. 
The composition of the PCR mixtures and cycling parameters used for the analyses of 
genome-modification events are specified in the Supplementary Tables 1 and 2, respectively.
Statistics. Data sets were analyzed by using the GraphPad Prism 5 software package 
and evaluated for significance by applying unpaired two-tailed Student’s t-tests (P < 0.05 
considered significant).
Southern blot analyses. Genomic DNA was isolated from individual human myoblast 
clones and from parental human myoblast populations according to aforementioned organic 
solvent-based protocol. Next, DNA samples (10 μg or 20 μg) were digested overnight with 
NcoI (Thermo Scientific) and were resolved through a 0.8% agarose gel in 1× Tris-acetate-
EDTA buffer. The DNA was transferred by capillary action onto an Amersham Hybond-XL 
membrane (GE Healthcare Life Sciences) using standard Southern blot techniques. The 635- 
and 790-bp DNA probes specific for the centromeric AAVS1 arm and for the transgene in 
donor DNA templates, respectively, were isolated from source plasmids following standard 
restriction enzymes digestions and agarose gel electrophoreses. The purified DNA probes 
were subsequently radiolabeled with [α-32P]dATP (GE Healthcare Life Sciences) by using the 
DecaLabel DNA labeling Kit following the manufacturer’s instructions (Thermo Scientific). 
Prior to its deployment, the radiolabeled probe were separated from unincorporated 
dNTPs through size-exclusion chromatography in Sephadex-50 columns (GE Healthcare Life 
Sciences). A Storm 820 Phosphoimager (Amersham Biosciences) was used for the detection 
of the probe-hybridized DNA. The images were acquired by using the Storm Scanner Control 
5.03 software and were processed with the aid of ImageQuant Tools 3.0 software (both from 
Amersham Biosciences).
COBRA-FISH karyotyping. The COBRA-FISH karyotyping of HeLa target cells was done 
according to a published protocol55.
Analysis of in vivo excision of AdV donor DNA. The experiments designed to assess TALEN-
mediated excision of donorS1 DNA from AdV backbones were performed as follows. Eighty-
thousand HeLa cells were seeded in wells of 24-well plates, and the following day they were 
cotransduced with AdV.Δ2.TALEN-LS1 (1.5 TU/cell), AdV.Δ2.TALEN-RS1 (1.5 TU/cell) and AdV.
Δ2.donorS1/T-TS (3 TU/cell) or were cotransduced with 2 gene switch–activating units per cell 
of hcAd.FLPe.F50 (ref. 56) and AdV.Δ2.donorS1/FRT (3 TU/cell). Control samples were provided 
by parallel HeLa cell cultures exposed exclusively to AdV.Δ2.donorS1/T-TS (3 TU/cell) or to AdV.
Δ2.donorS1/FRT (3 TU/cell). At 72 h post transduction, extrachromosomal DNA was isolated 
essentially as described previously57, after which 2-μl DNA samples were subjected to PCR. 
The PCR mixtures consisted of 0.4 μM of primer #997 (5′-GCACTGAAACCCTCAGTCCTAGG-3′), 
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1 mM MgCl2 (Promega), 1× Colorless GoTaq Flexi Buffer (Promega) and 2.5 U of GoTaq Flexi 
DNA polymerase (Promega). Next, 50-μl PCR mixtures were subjected to an initial 2-min 
denaturation period at 95 °C, followed by 30 cycles of 30 s at 95 °C, 30 s at 62 °C and 45 
s at 72 °C. The reactions were terminated by a final extension period of 5 min at 72 °C. 
The detection of the resulting PCR products was performed by conventional agarose gel 
electrophoresis.
Investigation of vector-vector illegitimate recombination in a myoblast-to-myotube 
cellular differentiation model. Two-hundred thousand human myoblasts were seeded in 
wells of 24-well plates. Two days later, the cells were transduced with 10 TU/cell of AdV.
Δ2.donorS1 or with 10 TU/cell of IDLV.donorS1 mixed with AdV.TALEN-LS1 plus AdV.TALEN-RS1 
at MOIs of 2.5 TU/cell each or mixed with AdV.TALEN-RS1 alone at an MOI of 5 TU/cell. Mock-
transduced myoblasts served as negative controls. At 3 d post transduction, the growth 
medium44 was removed, the cells were washed twice with 2 ml of PBS, and mitogen-free 
differentiation medium44 was added onto the different myoblast cultures. Five days later, 
cellular DNA was extracted from the various cultures containing post-mitotic syncytial 
myotubes. Next, PCR analysis of the cellular DNA was carried out for detecting head-to-tail 
vector DNA forms using as negative controls nuclease-free water and DNA extracted from 
the mock-transduced myotube cultures. Positive controls were obtained by using in vitro–
assembled head-to-tail AdV DNA templates (Fig. 3c and Supplementary Fig. 4b) and DNA 
isolated from IDLV.donorS1-transduced myoblast clone 10. The integrity of the various DNA 
templates was controlled for by parallel DMD-specific PCR amplifications.
Accession codes. GenBank/EMBL/DDBJ: AP45_pLV.donorEGFP, KF419293; AQ25_pLV.
donorS1, KF419294. Plasmids available at Addgene: hCas9, 41815; gRNA_AAVS1-T2, 41818.
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INTRODUCTION
Providing a cure for monogenetic diseases, not by means of administering protein 
replacement therapies, but by gene complementation or even gene repair instead, is a 
long sought goal of gene therapy. Some of these expectations were met for specific genetic 
disorders by providing corrective expression units into hematopoietic stem cells which, 
once transduced ex vivo and re-infused into the patient, could repopulate the bone marrow 
providing the blood system with corrected cells [1-3]. The success of these trials were 
clouded with the onset of leukemia in some patients initiated by the insertion of the viral 
vectors used pushing scientists back to the drawing board in order to redesign their genetic 
carriers [4]. After many years of optimization, involving trial and error experimentation and 
extensive laboratory work, has led to, nowadays, vector systems with an highly improved 
safety profile. These developments combined with extensive screening of patients enrolled 
in clinical trials, is opening the perspective for tackling many genetic diseases through gene 
therapy. [5, 6]. Despite this trust in the field of gene therapy, the research is set to continue 
gathering momentum. For the time being, the gene complementation strategy on itself gives 
clinicians a tool to tackle genetic defects, but the ultimate goal of gene therapy is to directly 
repair the genetic defect by changing the endogenous mutated DNA into a functional gene. 
Currently, very large efforts are ongoing to achieve this DNA repair by activating the cellular 
DNA damage response pathways following the generation of sequence-specific lesions in the 
chromosomal DNA of human cells. These targeted DNA breaks can subsequently processed 
by the non-homologous end-joining DNA repair pathway resulting in small insertions and 
deletions (indels). Alternatively, in the presence of exogenous donor DNA templates, the 
targeted DNA breaks can be processed by the homologous recombination (HR) pathway 
and can lead to precise chromosomal DNA changes by the removal of a disease-causing 
mutation [7, 8]. 
Of note, these genome manipulation processes can be initiated by the formation of a single- 
or double-stranded DNA break in the target region of choice [9 - 11]. Work done during 
the last two decades of the previous century showed that by inducing a double-stranded 
DNA break, the restoration of an expression unit by homology-directed gene repair (or 
HR) could be enhanced from about 10-6 events to up to 10% of the targeted population. 
Designer nucleases like zinc-finger nucleases (ZFNs) [12], transcription activator-like effector 
nucleases (TALENs) [13] and clustered regularly interspaced short palindromic repeats 
(CRISPR)-associated proteins (Cas) [14-16] are capable of generating these site-specific 
DNA lesions. These various technologies have their own sets of pros and cons in terms of 
specificity, complexity and the amenability for multiplexing, yet the general principle is to 
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to the use of designer nucleases, is to investigate whether specific DNA structures can, by 
themselves, serve as triggers of the DNA damage response and, in doing so, elicit targeted 
gene repair. Such an approach would simplify genome editing protocols, such as, by reducing 
the number of reagents needed to be introduced into target cells. The discovery of GEN1 
and SLX4 complexes involved in the resolution of Holliday-like secondary DNA structures [17, 
18], led us to investigating whether such high-order DNA structures can serve as stimuli for 
HR. Specifically, we hypothesized that recognition and processing of secondary DNA forms 
associated with an expression unit by cellular gene products like the aforementioned GEN1 
and SLX4 would lead to their resolution by DNA cleaving and ensuing targeted gene repair. 
In chapter 2 of this thesis, evidence is provided for the capacity of relatively small, non-
spaced, inverted repeats located within an open reading frame to provoke HR-mediated 
DNA repair. By using a complementary donor-template, restoration of the coding region 
could be demonstrated by measuring transgene expression and DNA sequence analysis. 
In this chapter, an extrachromosomal functional read-out system, based on pairs of 
complementary DNA templates carrying defective reporter gene sequences, was devised, 
that can serve as substrates for testing intermolecular HR-dependent gene repair. This 
experimental system allowed us to investigate in a quantitative manner the effect of various 
types of single DNA repeats on the HR process in mammalian cells as well as the role of DNA 
replication on the recombinogenic potential of these motifs. We found that, in contrast to 
direct and spaced inverted repeats, both simple palindromes and composite inverted DNA 
repeats constitute targets for the HR pathway in mammalian cells. Induction of homology-
directed gene repair was dependent on the arrangement and spacing of the repetitive DNA 
unit rather than on its nucleotide sequence. We also found that the presence of inverted 
DNA repeat sequences in target molecules rendered them susceptible to coordinated 
nicking by T7 endonuclease I, a bona fide four-way DNA branch resolving enzyme [19]. These 
results are consistent with other in vitro data showing that lineform-to-cruciform transition 
in double-stranded DNA molecules relies on the presence of an inverted repeat and is 
negatively affected by intervening spacer sequences in a length-dependent manner [20-22]. 
Furthermore, as aforementioned, by endowing acceptor DNA molecules with an eukaryotic 
origin of replication, we could probe in a strict manner the role of template DNA synthesis on 
repeat-induced homology-directed gene repair. Thus, in this chapter, it was demonstrated 
that non-spaced inverted DNA repeats can per se stimulate homology-directed gene repair 
in mammalian cells presumably due to their capacity to form secondary structures in vivo 
that can subsequently serve as direct targets for cellular structure-specific nucleases. 
These findings form a basis to further investigate the usefulness of secondary DNA structures 
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loci is scarce and reduces the use of this technique for the engagement of the DNA-repair 
pathways. Being able to induce the DNA repair in a site-specific manner As mentioned earlier, 
the efficient HR-mediated chromosomal insertion of donor DNA templates is dependent on 
inducing DNA lesions at specific target sequences. To this end, designer nucleases like ZFNs, 
TALENs and CRISPR/Cas-based nucleases must be introduced into target cells. Therefore, in 
this Thesis, different methodologies of providing target cells with expression units encoding 
these molecular scissors, were investigated. The starting of this research, described in 
chapter 3, consisted of investigating the feasibility in producing lentiviral vectors (LVs) and 
adenoviral vectors (AdVs) encoding TALENs. It was found that HIV-1-based LV genomes 
bearing TALEN sequences are predisposed to rearrangements in target cells. The structural 
analyses of these genomes in HeLa cell populations and in individual HeLa cell clones by 
PCR, Southern blotting and DNA sequencing showed that most of the rearrangements 
occurred through recombination events involving the TALE repeat array, ultimately leading 
to deletions with various sizes. The DNA sequence analyses in particular revealed that 
these rearrangements of the TALE array, albeit variable in number, consisted of precise as 
opposed to randomly truncated deletions of individual TALE repeats. Presumably, these 
deletions/truncations occur during the conversion of the lentiviral vector RNA genomes into 
complementary DNA by the viral reverse transcriptase (RT). The low template processivity 
of RT, combined with its low template affinity caused by RNaseH-mediated removal of the 
RNA template, leads to template switching events and ensuing deletions of TALE repeat 
sequences. Indeed, subsequent independent experiments performed by others provided 
additional evidence for this interpretation which can be reduced by different means. It has 
been recently demonstrated that the genetic instability of TALEN ORFs following lentiviral 
vector transductions can be overcome, either by mutating the RT, effectively converting the 
lentiviral RNA genomes in mRNA templates for protein production [23], or by re-coding 
the TALE repeats in order to minimizing as much as possible identical sequences and 
thereby reduce their “repetitiveness” character [24]. Conversely, data presented also in 
Chapter 3, demonstrates that TALEN sequences are stably maintained in first- and second-
generation adenoviral vectors following their serial propagation in producer cells. Indeed, 
the TALEN-encoding transgenes present in the adenoviral vector genomes suffered neither 
large rearrangements nor small-scale mutations as revealed by restriction fragment length 
analysis and DNA sequencing, respectively. Importantly, transduction experiments with 
the resulting TALEN-encoding adenoviral vector preparations led to DSB formation at the 
intended target chromosomal locus in transformed and non-transformed human cells at 
similarly high frequencies. A detailed protocol for the introduction of TALEN expression 
units into AdV backbones, and for the production, purification and characterization of the 
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In Chapter 5, the feasibility of using AdVs for the delivery of CRISPR/Cas9 components into 
human cells is investigated. To this end, AdV preparations containing either an expression 
unit for the S. pyogenes Cas9 nuclease or for an RNA Pol-III polymerase expression unit of an 
AAVS1-specific or eGFP-specific guide RNA, required to direct the Cas9 nuclease complex to 
its complementary DNA target sequence were produced and characterized. The capability 
for AdVs encoding RGN components, to achieve robust targeted mutagenesis in a diverse 
array of human cell types was clearly demonstrated. In all the cell types tested, the dose-
dependent CRISPR/Cas9 mediated disruption of the target sequence was demonstrated. 
In specific examples, there was a similar efficiency measured when compared to an, also 
AdV delivered, isogenic AAVS1-specific TALEN pair. In contrast, through co-transfection 
experiments in human pluripotent stem cell lines comparing gRNA:Cas9 sets with TALEN 
pairs based on specific architectures, Ding and colleagues showed that, for each targeted 
locus, the RGNs consistently and substantially outperformed the TALENs [25]. Nonetheless, 
these results do support the view that the TALEN platform is not per se inferior to that of 
RGNs in what site-specific chromosomal cleaving activity is concerned.
Taken together, the data presented in Chapters 3, 4 and 5 provide a concrete basis for the 
use of AdV-based technology for the delivery of artificial nucleases into human target cells. 
In gene editing protocols depending on NHEJ events, the introduction of these nucleases 
is enough. Nevertheless, for the repair of genes, the introduction of an exogenous DNA 
template provided at the same time as the nucleases is needed. In chapter 6, the impact 
of different types of donor DNA templates on the efficiency, specificity and accuracy of the 
genome editing process was determined. Next to the efficiency of donor DNA template 
usage, the accuracy and specificity can have a great impact on the outcome of the repaired 
sequences on an individual cell basis. For this assessment, a donor template, consisting of 
an eGFP expression cassette, was used. This unit was flanked by sequences homologous 
to the human AAVS1 locus in which the target site of TALENs or CRISPR/Cas9 was situated. 
Transducing DMD myoblasts with IDLV particles, carrying the AAVS1-targeting donor DNA, 
combined with AdV-mediated delivery of the AAVS1-specific TALEN pair, yielded a relatively 
large population of cells (i.e. 9%) stably expressing the transgene. This stably transduced 
population contained, however, several cells fractions whose donor DNA had inserted into 
the genome via “illegitimate”, recombination events. Moreover, although the majority 
of stably transduced cells contained exogenous DNA insertions formed by HR at termini 
precise homologous recombination (76,0%), 33,7% of this population contained two or 
more head-to-tail concatemeric copies of the donor DNA. These concatemeric forms are 
likely to contribute to heterogeneous expression levels in stably transduced cell populations 
and, especially in a gene repair settings, are expected to be deleterious for the success 
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AAVS1-specific TALENs but were instead transduced with an AdV delivering the AAVS1-
targeting donor DNA template, the percentage of stably transduced cells was lower that 
obtained following the use of IDLV donor DNA (i.e. 1,24% versus 9%). Nevertheless, detailed 
molecular analysis of individual single cell-derived clones revealed that AdV-modified cells 
underwent through a precise genome editing process. Specifically, in all randomly selected 
clones analyzed, the donor DNA templates were found to be properly inserted at the target 
site, that is, endogenous-exogenous DNA junctions were formed by HR events and there 
without evidence for concatemerization. Furthermore, different topologies of plasmid DNA 
were also used as source for donor-DNA templates. Finally, the designer nuclease-assisted 
genome editing specificity and accuracy attained by using plasmid donor DNA templates 
was also investigated. It was found that the topology of the plasmid template has a clear 
impact on the specificity and accuracy of the genome editing process. Indeed, supercoiled 
plasmids were less prone to non-homologous recombination events when compared with 
linearized free-ended plasmid templates. In any case, neither supercoiled nor linear donor 
DNA plasmids yielded the levels of genome editing specificity and accuracy attainable by 
using AdV donor DNA templates. The findings summarized in this thesis put forward the 
view that the numerous efforts devoted to minimizing off-target activity of sequence-specific 
nucleases, should be complemented with those aiming at identifying HR substrates whose 
features maximize on-target and accurate insertion of foreign DNA. The development of 
these optimized HR templates is expected to promote fundamental and applied research 
activities dependent on the precise manipulation of mammalian genomes.
FUTURE DIRECTIONS
In the future, patients suffering from a genetic disorder will go to their medical specialists, 
which can provide them with a patient-specific treatment designed to repair the mutated 
sequences in the affected cell population. This is, however, until now only science fiction. 
Decades of research in the field of gene therapy did bring this “fiction” closer to reality by 
being able to complement mutated sequences with correct genes packaged into integrating 
viral vector particles. Upon transduction of target cells, these genomes can integrate and 
express the wild-type protein, effectively curing the genetic disease. This large first step 
in gene therapy buys time to optimize the ultimate goal, being able to precisely repair the 
mutation, restoring the endogenous gene and allowing cellular control over the expression. 
How far are we from reaching this goal? In a laboratory setting, using specialized cell types 
and molecular techniques, researches are able to effectively transduce these cells with 
nucleases and donor-DNA templates resulting in gene repair in a rather small target cell 
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to allow translation into most clinical trial protocols. All of these elements on themselves 
have been proven to be efficient; nuclease systems such as ZFNs, TALENs or CRISPR/Cas-
based nucleases can all disrupt their target sites with very high frequency and donor-DNA 
templates can be adopted by the cells in frequencies close to 10% in immortalized cells. 
Nevertheless, bringing all these components together is one of the, if not the biggest, hurdle 
to take to bring gene repair into the clinic. 
The unsurpassed efficiency of viral vectors in transducing target cells, introducing the 
individual components for gene repair, makes them prime candidates to take this hurdle. 
In this thesis, the use of AdVs for the delivery of each of the modules needed for gene 
editing, i.e., the artificial nucleases and the donor-DNA templates, is demonstrated. In 
the future, research will focus on being able to package all of these components into a 
single viral vector particle. Furthermore, as the problem of efficient delivery starts to be 
satisfactorily tackled, enhancing the efficiency of homology-directed gene repair itself is 
required in order to reach clinical relevant levels. For instance, by blocking the error-prone 
non-homologous end-joining pathway to maximize HR-mediated repair of site-specific 
DSBs, might increase the rate of gene corrected cells. Nevertheless, as these DNA repair 
pathways share a number of proteins, the challenge will be to determine which signals to 
block in order to let the HR pathway to prevail. In a recent publication, it was shown that 
knocking down proteins involved in NHEJ, the rate of CRISPR mediated HR was elevated 
4 to 5-fold [26]. Interestingly, by expressing the adenoviral 4 proteins E1B55K and E4orf6 
improved the efficiency up to eightfold in human and mouse cell lines. However, being able 
to specifically transduce, in vitro, but even more challenging in vivo, clinically relevant cell 
types in an highly efficient manner, followed by proficient engagement of the DNA repair 
machinery, will take considerable amount of research. Yet, as the rapid progression in the 
search of efficient gene editing protocols demonstrates, the next step in gene therapy, gene 
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NEDERLANDSE SAMENVATTING
Sommige genetische aandoeningen, zoals bijvoorbeeld de ziekte van Pompe, kunnen 
bestreden worden door het aanbieden van medicijnen die de taak van het defecte of 
ontbrekende eiwit overnemen. Deze methode is kostbaar en belastend voor de patiënt. 
Gentherapie is een andere methode om dit soort genetische aandoeningen te behandelen. 
Hierbij wordt een correctie kopie van het defecte gen in de cel gebracht of wordt het defecte 
gen zelf gerepareerd in de aangedane cellen. In de jaren ’90 van de vorige eeuw hebben 
onderzoekers het principe van gen-complementatie succesvol toegepast bij patiënten die 
lijden aan een aandoening van het immuunsysteem. Een correcte kopie van het gen werd 
met behulp van een virale vector in bloedcellen gebracht waar het, na integratie, kon zorgen 
voor de aanmaak van functioneel eiwit. 
Het succes van deze klinische studies werd helaas overschaduwd door de ontwikkeling 
van leukemie in enkele van de patiënten. Na onderzoek bleek integratie van de virale vector 
op een verkeerde plaats de oorzaak van de ontsporing van de witte bloedcellen. Nieuwe 
ontwikkelingen op het gebied van vector-ontwerp en diepgaande moleculaire screening van 
de gemodificeerde cellen heeft ervoor gezorgd dat er hedendaags vectoren beschikbaar zijn 
met een verhoogde veiligheidsprofiel waardoor deze vorm van patiënt-specifieke medische 
zorg steeds vaker toegepast kan worden met acceptabele risico’s voor de patiënt. 
Naast deze vorm van gentherapie, de gen-complementatie, is het mogelijk om de 
sequentie van genen zodanig aan te passen dat mutaties gerepareerd kunnen worden. Deze 
vorm van gen-reparatie is complex en afhankelijk van de activatie van cellulaire eiwitten 
betrokken bij de reparatie van DNA schade. Door deze activatie kan de machinerie exogene 
donor-DNA fragmenten gebruiken om het genoom te repareren. De kans op spontane 
activatie van deze cascade op de exacte locatie van het gendefect is vrijwel nihil. Door 
onderzoek in gistcellen is duidelijk geworden dat deze activatie kan worden getriggerd door 
het aanbrengen van een enkel- of dubbelstrengs breuk in het DNA. Middelen om deze breuk 
te genereren zijn tegenwoordig voorhanden in de vorm van artificiële nucleasen waarbij 
DNA digestie domeinen van restrictie enzymen naar de locatie van keuze worden gebracht 
door zink-vingers (ZFNs) of zogenoemde “transcription activator-like effector nucleases”, 
TALENs. De nieuwste toevoeging aan dit pallet is het CRISPR/Cas systeem, wat staat voor 
“clustered regularly interspaced short palindromic repeats (CRISPR)-associated proteins 
(Cas)”. Deze nucleasen worden doormiddel van korte stukken RNA, “guide RNA” genoemd, 
naar de exacte locatie gebracht. In hoofdstuk 2 van deze thesis vroegen we ons af of deze 
breuken ook gegenereerd konden worden doormiddel van DNA sequenties zelf in plaats 
van het aanmaken van niet-humane eiwitten. Op basis van pas gepubliceerde resultaten 
waarbij onderzoekers lieten zien dat een eiwit genaamd GEN1 specifieke secundaire 








































186  |  Addendum
acceptor en een donor. De acceptor plasmide bevat een relatief korte haarspeldstructuur 
in een hrGFP expressie cassette. Pas na recombinatie met een andere plasmide die de 
homologe sequenties bevatte zonder deze haarspeldstructuur, is het hrGFP gen functioneel 
en kleuren getransduceerde cellen fluorescent groen. In hoofdstuk 2 toont aan dat deze 
haarspeldstructuren homologe recombinatie activeren tussen deze twee plasmiden en 
dat dezelfde sequentie, gekloneerd in een directe oriëntatie of een haarspeldstructuur 
met een DNA fragment ertussen, deze recombinatie niet activeerden. Uitgebreide 
moleculaire karakterisering van de gerecombineerde plasmiden alsmede de bepaling van 
het mechanisme toonden aan dat deze recombinatie sequentie-onafhankelijk was, en 
onafhankelijk van replicatie van de plasmiden, maar afhankelijk van de haarspeldstructuur. 
Hoewel deze resultaten aangaven dat haarspeldstructuren in het DNA gebruikt kunnen 
worden om exogene DNA fragmenten in te brengen bleek na literatuurstudie dat deze 
structuren zeldzaam zijn. Vrijwel alle recombinogene sequenties zijn, tijdens de evolutie, uit 
het genoom verdwenen. 
In hoofdstuk 3 geeft weer dat de keuze voor een type virale vector een grote invloed 
kan hebben op de stabiliteit van TALEN gen sequenties na transductie in doelcellen. In deze 
studie zijn twee expressie cassettes voor AAVS1-specifieke TALENs in HIV-1 gebaseerde 
lentivirale vectoren (LV) geplaatst en in vectoren gebaseerd op adenovirussen (AdV). 
Waar de eerstgenoemde een grote diversiteit in ingekorte genomen laat zien, geven AdV 
getransduceerde cellen een hoge mate van TALEN activiteit weer. De hypothese was dat het 
kopiëren van het lentivirale RNA genoom in DNA, doormiddel van het eigen relatief slordige 
reverse transcriptase, deleties van specifieke stukken van het repetitieve deel van de TALEN 
met zich meebracht. Het sequensen van integreerde virale genomen toonde grote deleties, 
verschillend per kloon. Deze deleties waren heel specifiek en omvatten veelal een meervoud 
van 102 baseparen, waarbij elke 102 nucleotiden voor 1 variabel TALE domain codeerde. 
AdV getransduceerde cellen gaven dit patroon niet, integendeel, het genoom van de AdV 
was volledig intact en ook de eiwitten zelf waren functioneel in zowel getransformeerde 
als primaire cellen. Hoofdstuk 4 beschrijft een uitvoerig protocol voor het kloneren van 
deze TALENs in AdV, en laat zien hoe de virale vectoren geproduceerd en gekarakteriseerd 
kunnen worden. 
In hoofdstuk 5 van deze thesis is dezelfde principe van het door AdV afleveren van 
nuclease componenten in doelcellen toegepast voor elementen van het CRISPR/Cas systeem. 
In afzonderlijke virale vectoren werden expressie cassettes voor Cas9 nuclease en de “guide 
RNA” geplaatst en gebruikt om doelcellen te transduceren. We hebben aangetoond dat de 
efficiëntie van CRISPR/Cas-gemedieerde digestie van de doelsequentie afhankelijk was van 
de dosis virale vector en dat per celtype de effectiviteit gelijk is aan of minder is dan TALEN-
gemedieerde digestie van de doelsequentie. Dit staat in contrast met wat Ding en collega’s 








































Nederlandse samenvatting  |  187
S
humane pluripotente stamcellen, het CRISPR/Cas altijd superieur was aan TALENs. Onze 
mening is dat de efficiëntie van artificiële nucleasen gemedieerde digestie van sequenties in 
doelcellen sterk afhankelijk is van de wijze waarop de genen coderend voor deze eiwitten in 
doelcellen gebracht wordt. 
In hoofdstuk 6 van deze thesis hebben we de meest gangbare methodes voor het 
aanleveren van donor-DNA in doelcellen met elkaar vergeleken en daarbij gekeken naar de 
effectiviteit van gebruik, maar ook naar de moleculaire compositie van het eindresultaat. 
De totale populatie gemodificeerde cellen kan meerdere subpopulaties bevatten, elk met 
hun eigen sequentie, wat gevolgen kan hebben voor de uiteindelijke expressie van het 
gecorrigeerde gen. Als eerste werden de twee meest gebruikte virale vectoren getest, die 
van de integratie deficiëntie lentivirale vectoren (IDLV) en AdV. Hoewel de eerstgenoemde 
een veel hogere efficiëntie van transgen insertie liet zien (9,1% tegenover 1,24% in 
myoblasten) liet de moleculaire karakterisatie duidelijk zien dat slechts 42,3% van deze 
populatie een enkele, correct ingebrachte, kopie van een eGFP expressie cassette bevatte. 
Dit in tegenstelling tot de cellen getransduceerd met AdV deeltjes waarbij alle klonen deze 
juiste insertie liet zien. Pas nadat er genomisch instabiele HeLa cellen in combinatie met het 
intrinsiek slordige CRISPR/Cas nuclease systeem werd gebruikt konden er cellen gevonden 
worden die niet een juiste insertie bevatten. Als laatste werden ook plasmiden, in diverse 
conformaties, getest. Deze bleken dezelfde gemengde populatie te bevatten waarbij de 
circulaire vormen minder van deze onzorgvuldige inserties lieten zien. 
Samengevat geven de hoofdstukken 3, 4, 5 en 6 van deze thesis weer hoe AdVs gebruikt 
kunnen worden om individuele componenten van gentherapie efficiënt in doelcellen 
te brengen. Daarbij geeft het een basis om, naast de intensieve zoektocht naar steeds 
specifiekere nuclease systemen met gereduceerde “off-target” effecten, donor-DNA 
fragmenten te onderzoeken die bijdragen aan deze specificiteit. De resultaten uit hoofdstuk 
2 kunnen daaraan bijdragen; specifieke DNA samenstellingen dragen bij aan de activatie van 
reparatie van deze structuren wat mogelijk een toegevoegde waarde heeft om, wellicht, de 
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